Synaptic vulnerability in spinal muscular atrophy by Murray, Lyndsay M.
 
Synaptic Vulnerability in Spinal 
Muscular Atrophy 
 
Lyndsay M Murray 
 
 
A thesis submitted for the degree of PhD at the 
University of Edinburgh 
 
2009 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 










Lyndsay M Murray 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 




I would like to thank a number of people for making the last three years really interesting and 
enjoyable.  
 
First and foremost, I’d like to thank my supervisor Tom Gillingwater.  I really appreciate the 
endless support, motivation and opportunities he has given me, along with his seemingly 
limitless knowledge and ideas. I would like to thank him for designing a great project, always 
finding time and continually encouraging me. 
 
I would also really like to thank my second supervisor Simon Parson and all the members of 
the Gillingwater lab for all their ideas, training and technical expertise and making this a 
fantastic place to work.  In particular, Tom Wishart for his exemplary time-management skills, 
Laura Comley for being exceedingly happy and letting me rant, and Derek Thomson for 
knowing everything!  
 
I would, of course, like to thank the Anatomical Society of Great Britain and Ireland for my 
studentship and all associated opportunities. 
 
I would also like to acknowledge the continual encouragement and enthusiasm from my 
parents and sister, Kirsty.  I would really like to thank David for his constant support, patience 
and making me dinner. Also thanks to my friends in Edinburgh and beyond, in particular 
Claire and Kevin for always listening.  
 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 




Mounting evidence suggests that synaptic connections are early pathological targets in 
many neurodegenerative diseases, including motor neuron disease. A better 
understanding of synaptic pathology is therefore likely to be critical in order to develop 
effective therapeutic strategies.  Spinal muscular atrophy (SMA) is a common autosomal 
recessive childhood form of motor neuron disease. Previous studies have highlighted 
nerve- and muscle-specific events in SMA, including atrophy of muscle fibres and post-
synaptic motor endplates, loss of lower motor neuron cell bodies and denervation of 
neuromuscular junctions caused by loss of pre-synaptic inputs. Here I have undertaken a 
detailed morphological investigation of neuromuscular synaptic pathology in the Smn-/-
;SMN2 and Smn-/-;SMN2;Δ7 mouse models of SMA. Results imply that synaptic 
degeneration is an early and significant event in SMA, with progressive denervation and 
neurofilament accumulation being present at early symptomatic time points.  I have 
identified selectively vulnerable motor units, which appear to conform to a distinct 
developmental subtype compared to more stable motor units.  I have also identified 
significant postsynaptic atrophy which does no correlate with pre-synaptic denervation, 
suggesting that there is a requirement for Smn in both muscle and nerve and 
pathological events can occur in both tissues independently.  Rigorous investigation of 
lower motor neuron development, connectivity and gene expression at pre-symptomatic 
time points revealed developmental abnormalities do not underlie neuromuscular 
vulnerability in SMA.  Equivalent gene expression analysis at end-stage time points has 
implicated growth factor signalling and extracellular matrix integrity in SMA pathology.  
Using an alternative model of early onset neurodegeneration, I  provide evidence that the 
processes regulating morphologically distinct types of synaptic degeneration are also 
mechanistically distinct.  In summary, in this work I highlight the importance and 
incidence of synaptic pathology in mouse models of spinal muscular atrophy and 
provide mechanistic insight into the processes regulating neurodegeneration. 
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Chapter 1: Introduction 
 
1.1 Synaptic vulnerability in neurodegenerative disease 
It is now widely recognised that uncovering pathogenic mechanisms occurring during 
the initial and early stages of disease progression will be key to understanding and 
treating a wide range of human neurodegenerative disorders affecting the central and/or 
peripheral nervous systems.  Amid the great diversity of neurodegenerative conditions 
known to exist, there is a growing body of evidence suggesting that synapses and distal 
axonal compartments are common, early and important sub-cellular pathological targets 
(Raff et al., 2002; Wishart et al., 2006). It is also clear that mechanisms triggering and 
regulating neurodegenerative pathways in neurons are very much compartmentalised, 
with distinct sub-cellular mechanisms regulating the breakdown of synapses, axons and 
cell bodies (Gillingwater and Ribchester, 2001). This is partly based upon the 
observation that the spontaneously occurring Wallerian degeneration slow (Wlds) 
mutation can modify the survival of distal axonal and synaptic compartments in the 
absence of the cell body (Mack et al., 2001; Gillingwater et al., 2006).  The therapeutic 
relevance of such compartmental degeneration is underlined by studies in which genetic 
or pharmacological manipulations have conferred significant protection on neuronal cell 
bodies but failed to provide any protection on synaptic or axonal compartments, 
resulting in no significant improvement in general outcome measures such as life 
expectancy (e.g. Sagot et al., 1995; Chiesa et al., 2005; Dewil et al., 2007; Gould et al., 
2006). 
 
The list of diseases with known synaptic and/or distal axonal involvement now includes 
hereditary and sporadic neurodegenerative diseases such as Alzheimer’s disease (Selkoe, 
2002), Huntington’s disease (Li et al., 2003), prion diseases (Cunningham et al., 2003), 
lysosomal storage disorders such as Batten disease (Kielar et al., 2009), auto-immune 
conditions such as Guillain-Barré syndrome (Willison, 2005), and also after hypoxic 
injury (Baxter et al., 2008) or exposure to toxins such as snake venom (Prasarnpun et al., 
2005). Thus, mechanisms underlying selective vulnerability of synaptic and distal 
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axonal compartments of neurons have become the focus of much interest from both 
basic research and clinical therapeutic perspectives.  
 
This phenomenon of synaptic vulnerability appears to extend to the peripheral nervous 
system, and may therefore have significant impact upon the pathogenesis in peripheral 
neuropathies, such as motor neuron disease. A growing number of studies have therefore 
focussed on the importance of peripheral synapses between lower motor neurons and 
muscle fibres, known as neuromuscular junctions (NMJ), in motor neuron disease 
pathogenesis. Additionally, the experimental accessibility of NMJs and availability of 
numerous different animal models of motor neuron disease provides excellent model 
systems in which to study synaptic and axonal biology and vulnerability in vivo.  
 
In this chapter I will review the current literature available detailing the structure and 
function of the NMJ during development and maturity, and discuss its potential 
involvement in motor neuron diseases, with particular focus on the childhood motor 
neuron disease, Spinal Muscular Atrophy (SMA).     
 
1.2 The neuromuscular junction 
1.2.1 Structure  
Early studies of the NMJ utilised gold and silver stains coupled with light microscopy to 
reveal the morphology of neuromuscular connections, while the subsequent 
development and refinement of electron microscopy techniques added detail about sub-
cellular organelles and organisation (Kuhne, 1888; Ranvier, 1889; Robertson, 1956). 
Such studies have generally stood the test of time, and even following the development 
of fluorescent labelling technology, ideas regarding the structure of the neuromuscular 
junction (NMJ) have remained relatively unchanged over the past century.  The NMJ is 
principally made up of 3 cell types: the motor neuron, the muscle and the terminal 
Schwann cell, although recent reports have identified the presence of a fourth cell type, 
the kranocyte (Grinnell, 1995; Court et al., 2008; Figure 1.1 A).  The motor neuron cell 
body is situated in the ventral horn of the spinal cord from where it projects axons 
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through the ventral root of the spinal column to its target muscle. The axon projecting 
from the spinal cord to the muscle fibre is tightly ensheathed by myelin to facilitate 
efficient signal transduction, contains structural proteins such as neurofilaments to 
maintain axonal integrity and microtubules to facilitate both retrograde and anterograde 
transport to and from the cell body and peripheral synapse.  Upon entering the muscle 
region, an individual axon will undergo a degree of intramuscular branching and will 
ultimately innervate anywhere between 10 and 2000 muscle fibres depending on the 
motor unit and muscle function (Bradley, 1987; Conwit et al., 1999).  At the muscle 
fibre, the neuron forms the pre-synaptic terminal, becoming highly specialised in both 
structure and function for neurotransmitter release and contains a large number of 
mitochondria and synaptic vesicles containing the neurotransmitter acetylcholine (ACh). 
ACh is an excitatory neurotransmitter which is released and binds to ACh receptors 
(AChRs) in the post-synaptic membrane of the muscle fibre which form the motor end-
plate.  The post-synaptic endplate is organised into a series of membrane invaginations, 
known as post-synaptic folds which function to increase the post-synaptic area and thus 
increase the area available for AChRs. AChRs are found at a high density within the 
upper half and crest of the post-synaptic folds, and are associated with the post-synaptic 
apparatus, a network of structural and signalling proteins specialised for efficient signal 
transduction (Grinnell et al., 1995; Sanes and Lichtman, 1999, Hughes et al., 2006).  
This synapse between the motor neuron and muscle is enveloped by terminal Schwann 
cells, which are thought to provide a protective ensheathment and trophic support at the 
NMJ, and modulate synaptic transmission (Feng et al., 2005).  More recently, an 
additional cell type, termed kranocytes have been identified at the NMJ, and are thought 




The development of the NMJ involves a series of complex interactions between muscle, 
nerve and glial cells resulting in structural and functional specialisation within all three 
cell types (For a detailed review, see Grinnell, 1995 and Sanes and Lichtman 1999).   
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During the process of embryogenesis, all three cell types originate in distinct locations.  
Myoblasts, deriving from the embryonic mesenchyme of the somites, fuse to form 
myotubes which constitute primordial muscle fibres (Grinnell, 1995). Nerve independent 
signalling events, thought to be primarily directed by muscle derived agrin, induce the 
formation of acetylcholine receptor clusters (Anderson & Cohen 1977, Frank & 
Fischbach 1979). Motor neurons arise from the progenitors within the ventral neural tube 
and after differentiation form axons which project to the muscle (Grinnell 1995, Jacob et 
al., 2001). Axon path-finding is then directed by a complex array of chemo attractant 
and repellent guidance cues at defined points along the pathway from the spinal cord to 
the target muscle (Jacob et al., 2001). Upon reaching the muscle fibre, nerve derived 
agrin induces further AChR clustering and a primary synaptic contact is established.  
Schwann cells also originate in the neural crest and follow axon tracts to reach the target 
muscle and although they do not appear to be necessary for axonal guidance during 
development, they are crucial for synaptic maintenance (Sanes and Lichtman 1999; 
Woldeyesus  et al., 1999, Wolpowitz et al., 2000).  Upon reaching the NMJ, Schwann 
cells differentiate into terminal Schwann cells, and during the first two post natal weeks, 
they will increase in number to around 3 or 4 (Feng et al., 2005).  At this point, the 
innervation pattern is highly complex with each muscle fibre innervated by a number of 
axons.  During subsequent weeks the process of developmental synapse elimination 
results in the pruning of excess inputs until the one-to-one pattern of adult innervation is 
established.  The mechanisms regulating synapse elimination are generally unclear 
although neuronal activity appears to be sufficient, if not necessary (Gillingwater and 
Ribchester, 2003; Wyatt and Balice-Gordon, 2003; Buffelli et al., 2004). 
 
Concurrent with synapse elimination, the post-synaptic motor endplate also becomes 
increasingly specialised (Marques et al., 2000).  On initial formation, AChRs are 
distributed uniformly within the endplate zone, forming a plaque like appearance.  
During synaptic maturation AChRs become increasingly dense in areas directly 
opposing pre-synaptic terminal, and increasingly diffuse in areas not directly opposing 
the pre-synaptic terminal.  This initially results in the formation of perforations in the 
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AChR clusters, and ultimately results in the formation of the adult, ‘pretzel’ like 
morphology.  Concurrent with this, there is a defined transcriptional switch in the 
subunit composition of the AChR as the embryonic γ subunit is replaced by the adult ε 
subunit (Martinou and Merlie, 1991).  The switch in subunit results in distinct 
electrophysiological properties and appears to be fundamental to the formation of post-
synaptic folds (Missias et al., 1997).  Again the processes regulating post-synaptic 
maturation are relatively undefined, although they appear to involve pre- and post- 
synaptic communication via synaptic activity and neurotrophic regulation (Fox and 
Umemori, 2006). The time course of the process of synaptic maturation differs between 
different species, occurring within the first two post natal weeks in mice and generally 
being complete by around mid-gestation in humans (Hesselmans et al., 1993; Sanes and 
Lichtman, 1999).   
 
Interestingly, it has been demonstrated in mice that there are subtypes of motor units 
which are distinct in regards to their embryonic developmental time course (Fast 
Synapsing; FaSyn, or Delayed Synapsing; DeSyn). Motor units which conform to a 
FaSyn subtype display AChR clustering and rudimentary synaptic formation at E14.5, 
while those categorised as DeSyn did not reach the equivalent stage until E16.5 (Pun et 
al., 2002).  These distinct developmental subtypes can be distinguished in adulthood by 
challenge with paralysis induced by botulinum toxin, which induces significant 
sprouting and ectopic endplate formation in DeSyn muscles but not in FaSyn muscles. 
These two subtypes thus retain differential properties in the adult but are 
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Figure 1: The neuromuscular junction. A – Schematic diagram illustrating the 
location of, and relationships between, cell types and organelles at the mammalian 
NMJ. The distal axon and pre-synaptic motor nerve terminal are shown in green. 
Note the presence of large numbers of mitochondria and synaptic vesicles in the 
motor nerve terminal. Also note how the termination of the myelin sheath proximal to 
the muscle forms the final hemi-node of Ranvier. The post-synaptic muscle fibre is 
shown in yellow, with characteristic postsynaptic folds and clustering of acetylcholine 
receptors (AChRs; red). Terminal Schwann cells (TSC) are shown in blue and two 
NMJ-capping cells (kranocytes) are shown in magenta. B – Schematic diagram 
illustrating the normal innervation pattern of three muscle fibres (yellow) in an adult 
mammalian muscle. Note how each muscle fibre is only innervated by a single axon 
(green; ensheathed by myelin shown in grey) at a single point of synaptic contact 
(red; AChRs). Also note how each pre-synaptic motor nerve terminal branches at the 
endplate resulting in a mirror image of the underlying AChRs. C,E – Schematic 
diagram (C) and representative confocal micrograph (E; taken from a late-
symptomatic wasted mouse muscle immunohistochemically labeled to reveal 150ka 
neurofilament proteins, green and AChRs, red) illustrating the morphological 
correlates of dying-back pathology at the NMJ. Note how there is a gradual 
retraction of pre-synaptic motor nerve terminals from post-synaptic endplates, 
rendering muscle fibres denervated in the absence of any major fragmentation of 
neuronal processes or a breakdown of the myelin sheath. Dying-back pathology 
occurs over a typical time-course of several days or weeks. D, F - Schematic 
diagram (D) and representative confocal micrograph (F; taken from a wild-type 
mouse 24 hours after axotomy immunohistochemically labeled to reveal 150ka 
neurofilament proteins, green and AChRs, red) illustrating the morphological 
correlates of Wallerian degeneration at the NMJ. Note how there is a gross, in situ 
fragmentation of pre-synaptic motor nerve terminals and distal axons as well as a 
loss of integrity of the myelin sheath. Wallerian degeneration occurs over a typical 
time-course of several hours. (Scale bars; 40µm (E), 50µm (F)). 
 
 
1.3 The NMJ in motor neuron disease 
 
Due to the observation that synapses appear specifically vulnerable in a range of 
neurodegenerative diseases, the neuromuscular junction phenotype in motor neuron 
disease is of great interest. The term motor neuron disease can be used to describe a 
wide range of heterogeneous disorders resulting from the degeneration of motor neurons 
and atrophy of associated skeletal musculature.  A range of subtypes are observed 
depending on the motor neuron subset affected, for example purely upper motor neuron 
involvement, projecting from the motor cortex to the spinal cord (primary lateral 
sclerosis; Singer et al., 2006), purely lower motor neuron involvement, projecting from 
the spinal cord to muscle (spinal muscular atrophy; Monani et al., 2005) or both upper 
and lower motor neuron involvement (amyotrophic lateral sclerosis; Cleveland and 
Rothstein, 2001). While a number of atypical subsets of this disease exist, amyotrophic 
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lateral sclerosis and spinal muscular atrophy remain the most common forms of motor 
neuron disease and thus the best characterised. In this, and the following section I will 
review the current literature about amyotrophic lateral sclerosis and spinal muscular 
atrophy with particular reference to what is known about the involvement of NMJ 
pathology. 
      
1.3.1 ALS: incidence and aetiology  
Amyotrophic lateral sclerosis (ALS) is the most common form of adult onset motor 
neuron disease, with a typical onset late in adult life (ca.50-60 years old) and a 
prevalence of 1 in 50,000 (for reviews see Rothstein, 2009). It is a fatal 
neurodegenerative disease characterised by progressive paralysis resulting from the 
selective death of both upper and lower motor neurons (Cleveland & Rothstein, 2001). 
The genetic background to ALS remains complex, with around 5-10% of cases being 
familial and the remaining 90-95% of sporadic cases having an unknown aetiology 
(Schymick et al., 2007). However, the underlying genetics of familial ALS cases have 
begun to shed light on the underlying cellular mechanisms, with numerous genetic 
mutations now identified as being causative for various different forms of ALS. For 
example, approximately 20% of familial ALS cases are caused by mutations in the 
SOD1 gene (Rosen et al., 1993). More recent discoveries have implicated other genes, 
including TDP-43 (a DNA/RNA binding protein; Sreedharan et al., 2008), FUS (a 
DNA/RNA binding protein; Vance et al., 2009; Kwiatkowski et al., 2009; Chio et al., 
2009) and VAPB (a membrane protein found in plasma and intracellular vesicle 
membranes; Nishimura et al., 2004; Kanekura et al., 2006). The identification of the 
underlying genetic components of ALS has allowed the development of animal models 
of the disease (such as mice, rats, zebrafish and Drosophila; Gurney et al., 1994; Nagai 
et al., 2001; Lemmens et al., 2007; Ratnaparkhi et al., 2008), which have been critical 
for uncovering morphological and molecular pathogenic events in vivo.  Such models 
have allowed investigations into the initiating events in disease pathogenesis and there is 
now mounting evidence that pathological changes at the neuromuscular junction can be 
detected early in the disease process.     
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1.3.2 The NMJ as an early pathological target in animal models and human ALS 
patients 
Early studies on human patient material suggested that histological and 
electrophysiological changes associated with the NMJ were present in ALS (Tsukihata 
et al., 1984; Maselli et al., 1993). However, it was only with the development and 
analysis of rodent models of ALS (e.g. the SOD1G93A mouse which displays numerous 
ALS-associated symptoms; Gurney et al., 1994) that researchers were able to 
accurately examine the contribution of NMJ breakdown during the early stages of 
ALS pathogenesis. High-resolution analysis of NMJs in SOD1G93A mice at early- and 
late-symptomatic stages revealed significant synaptic degeneration prior to the onset 
of clinical symptoms and motor neuron cell body loss (Fischer et al., 2004). In these 
mice 40% of motor endplates were devoid of pre-synaptic motor nerve terminals at 47 
days old although mice of the same age showed no loss of lower motor neuron cell 
bodies in the ventral horn of spinal cord and the mice didn’t become clinically weak 
until 80 days old. In addition, microglial and astrocytic activation around motor 
neurons were not identified until later stages of the disease. These findings, supported 
by other prior and subsequent studies using SOD1G93A mice; e.g. Frey et al., 2000; 
Schaefer et al., 2005, led Fischer and colleagues to classify ALS as a “distal 
axonopathy” (Fischer et al., 2004), with “dying-back” morphological characteristics 
distinguishing the process from ther neurodegenerative pathways known to be capable 
of bringing about the breakdown and loss of NMJs (e.g. Wallerian degeneration; see 
section 1.5). 
 
The early vulnerability of NMJs in mouse models of ALS is not restricted to the 
SOD1G93A mouse, thus providing strong evidence for the common involvement of NMJs 
in many forms of ALS. For example, other studies have identified NMJ pathology at 
early stages of disease progression in motoneuron degeneration (mnd) mice and 
progressive motoneuropathy (pmn) mice (Frey et al., 2000; Ferri et al., 2003). More 
recent work on non-rodent models of ALS has provided additional evidence supporting 
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the notion that NMJs represent important and early pathological targets. For example, 
analysis of NMJs in dogs with hereditary canine spinal muscular atrophy (HCSMA) has 
revealed functional deficits at pre-symptomatic ages (Rich et al., 2002). Expression of 
mutant SOD1G85R in Caenorhabditis elegans generates locomotor defects resulting from 
pathological changes at neuromuscular synapses, including dysfunction of the synaptic 
vesicle machinery (Wang et al., 2009a). Similarly, studies of VAPB in Drosophila have 
identified important roles in synaptic remodeling and synaptic function at the NMJ (Chai 
et al., 2008). Depletion of TDP-43 in Drosophila has also been shown to induce 
locomotor defects associated with pathological modifications at the NMJ (Feiguin et al., 
2009).  
 
The ability to validate the findings from these animal models in human patients is 
restricted by the availability of good quality muscle samples (containing NMJs) from 
human patients at pre- or early-symptomatic stages of the disease. Post-mortem material 
is almost always from end-stage patients, where it is virtually impossible to identify 
early and important pathological changes in the neuromuscular system with any 
accuracy or reliability. However, one case study has been reported from a 58-year-old 
male ALS patient with a 6-month history of weakness and muscle wasting who died 
unexpectedly during a minor surgical procedure (Fischer et al., 2004). In this patient, 
evidence of a “distal axonopathy” was present with denervation characteristics present in 
muscle alongside an absence of axonal degeneration in ventral roots or degenerative 
changes in the spinal cord (Fischer et al., 2004). 
 
Taken together, this body of evidence provides strong support for the hypothesis that 
NMJs are early and important pathological targets in many forms of ALS. However, it 
should be noted that NMJ vulnerability may not play a key role in all forms of ALS, as 
evidence has been presented from an ALS mouse model generated via consumption of 
cycad seed flour, where changes in lower motor neuron soma preceded denervation at 
the NMJ (Lee et al., 2009).  
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The clinical relevance of NMJ vulnerability in ALS has been highlighted by several 
recent in vivo studies where a complete therapeutic rescue of lower motor neuron soma 
or improvement in muscle strength, but failure to concomitantly protect NMJs, offered 
minimal improvements in overall outcome measures such as lifespan. Both 
pharmacological and genetic approaches have been used in these experiments, including 
genetic ablation of the apoptotic regulator bax (Gould et al., 2006), pharmacological 
inhibition of epigenetic chromatin remodelling (Rouaux et al., 2007), pharmacological 
inhibition of the stress responsive protein kinase p38MAPK (Dewil et al., 2007), 
delivery of neurotrophic factors such as GDNF (Suzuki et al., 2007), and treatment with 
a soluble activin type IIB receptor to prevent myostatin induced muscle growth 
inhibition (Morrison et al., 2009).  These studies underline the importance of treating the 
site at which pathology originates in order to deliver meaningful therapeutic intervention 
in ALS. They also offer strong additional support to the idea that NMJs are one of the 
major sites of early pathological changes in ALS.   
 
1.4 Spinal Muscular Atrophy 
1.4.1 Incidence and Aetiology 
Spinal muscular atrophy (SMA) is a childhood form of autosomal recessive motor 
neuron disease caused by mutations in the survival motor neuron (SMN) gene.  SMA is 
the most common genetic cause of mortality in children, affecting 1:6000-10,000 live 
births (Pearn et al., 1978; Wirth et al. 2006; Lunn & Wang, 2008).  SMA occurs in one 
of four types which are defined by the age of onset and motor mile stones reached 
(Monani, 2005; Wirth et al., 2006; Farrar et al., 2009).  SMA type I has an onset under 6 
months of age.  Affected individuals will never be able to sit unaided and death occurs 
prior to 2 years of age.  SMA type II has an onset of between 6 and 18 months and 
patients will sit unaided but not walk.  SMA type III patients have an onset of between 
18 months and early adolescence.  Patients are able to initially able stand and walk and 
although they have a normal lifespan, are likely to be wheelchair bound by adulthood. 
SMA type IV is characterised by an adult onset and although patients may experience 
significant muscle weakness later in life, this form of the disease is comparatively mild 
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and life span is generally normal.  A further severe type of SMA has been suggested 
(type 0), which has a prenatal onset (Russman, 2007). This form of the disease is 
thought to be rare and as such, has not been extensively described.  
 
In contrast to ALS, SMA is characterised by a specific loss of lower motor neurons 
(rather than upper and lower motor neurons) and atrophy of the associated skeletal 
musculature. Clinically, SMA is defined by progressive symmetrical weakness of 
skeletal musculature in the arms, legs and trunk.  Postural muscles in the body trunk are 
generally more severely affected, with a marked sparing of motor units in the diaphragm 
and extra-occular muscles (Farrar et al., 2009). Alongside locomotor defects, patients 
experience difficultly sucking and swallowing and respiratory difficulties (Russman, 
2007).   Cognitive function and sensory neural systems are thought to be spared (von 
Gontard et al., 2002; Farrar et al., 2009).  
 
1.4.2 SMA, SMN and animal models 
The classification and diagnosis of SMA has been greatly enhanced by the identification 
of the causative gene: SMN (Lefebvre et al, 1995).  Smn is a ubiquitously expressed 
protein and its best documented role is in assembly of the essential components of the 
spliceosomal machinery, required for the removal introns during protein translation 
(Chari et al., 2009).  It is currently unclear how reduction of a ubiquitous protein results 
in neuromuscular specific pathology, although it has been suggested that Smn may have 
additional axon/muscle specific roles that are critical for neuromuscular function 
(Burghes, 2008; Burghes and Beattie, 2009). Multiple copies of the SMN gene are 
present in the human genome: one SMN1 (telomeric copy) and several SMN2 
(centromeric copies). The two genes are almost identical (differing by only five 
nucleotides; Lefebvre et al., 1995). SMN1 encodes a 38kDa protein (Smn) that is widely 
expressed in tissues throughout the body and localises to the nucleus and cytoplasm of 
all cells (Francis et al., 1998). The vast majority (~95%) of human SMA cases are 
caused by a homozygous deletion in SMN1 (Lefebvre et al., 1995). As complete loss of 
Smn protein is incompatible with life, the presence of at least one copy of the SMN2 
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gene is required for patients to survive beyond birth. However, SMN2 is not capable of 
fully replacing the loss of SMN1 as it undergoes alternative splicing producing a 
truncated mRNA isoform, the transcript of which (mostly lacking exon 7) is rapidly 
degraded (for review see Burghes & Beattie, 2009). SMA is therefore the result of low 
levels of Smn protein and the copy number of SMN2 therefore determines disease 
severity. 
 
Our clear understanding of the molecular genetic basis of SMA has facilitated the 
development of a wide range of different animal models of SMA, including a diverse 
range of mouse models. A significant problem experienced during the generation of 
animals models is that all animals, other than humans and higher primates, have only 
one copy of Smn, with loss being incompatible with life.  To circumvent the embryonic 
lethality due to loss of Smn, two approaches have been commonly employed: 
conditional loss of Smn directed to specific tissues, or introduction of various Smn 
transgenes on the Smn knockout background (Table 1.1). Currently, the most commonly 
used are rodent models genetically engineered to express low levels of Smn protein from 
a human SMN2 transgene whilst silencing endogenous expression from the mouse SMN 
gene, with or without the presence of an additional ∆7 transgene (Smn-/-;SMN2 mice, 
Monani et al., 2000; Smn-/-;SMN2;∆7 mice, Le et al., 2005). These mice model a severe 
form of SMA, with disease onset occurring around postnatal day 2 (P2) and death by 
P5/P6 in Smn-/-;SMN2 mice (Monani et al., 2000). This time-course is extended by 
around a week in the presence of the ∆7 transgene (Le et al., 2005). Other mouse models 
have been generated, reducing Smn protein levels by a variety of different means (Table 
1.1).  More recently, SMA models have been reported in zebrafish (McWhorter et al., 
2003; Winkler et al., 2005; Boon et al., 2009), Drosophila (Chan et al., 2003; Rajendra 
et al., 2007; Chang et al., 2008) and Caenorhabditis elegans (Briese et al., 2009). 
 
Whilst the genetic basis of SMA is well established, the precise role(s) of SMN and its 
protein product (Smn) in bringing about the selective breakdown of the neuromuscular 
system remain unknown. The key role played by Smn in pre-mRNA splicing has led to 
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the suggestion that splicing defects lead to breakdown of the neuromuscular system in 
SMA (Zhang et al., 2008). However, detailed examination of the temporal 
characteristics of splicing changes in two mouse models of SMA suggest that splicing 
defects occur only during late stages of the disease, and are therefore unlikely to 
contribute to SMA pathogenesis (Baumer et al., under review).  Alternative hypotheses 
for a mechanism of action have also been proposed, some focused on the role of Smn in 
transport of mRNA in neurons (for review see Burghes & Beattie, 2009), others 
postulating that Smn has additional neural and/or muscle specific functions (Giavazzi et 
al., 2006; Rajendra et al., 2007; Setola et al., 2007). The variety of SMA models now 
available should help elucidate both the cellular function of Smn and the mechanisms by 
which its loss results in SMA.  For example, such models will facilitate studies aimed at 
identifying the initiating events in SMA pathogenesis and identifying the primary site of 
pathology.  For this reason, defining the involvement of neuromuscular junction 
pathology will likely be of great importance.  
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Table 1.1: Available mouse models of SMA 
Model Genetics Life Span Reference 
Reduced Smn levels 
Smn KO Disruption of mSmn exon 2 (Schrank et al.) 




Schrank et al., 
1997; Hseish-Li 
et al., 2000;  




Jablonka et al., 
2000 
Smn-/-;SMN2low KO mSmn; insertion of 2 copies of hSMN2 
 
4-6 days Monani et al., 
2000 




Monani et al., 
2000 
Smn-/-;SMN2;Δ7 KO mSmn; insertion of 2 copies of hSMN2; 
Insertion of mSmn lacking exon7 
 
14 days Le et al., 2005 
Smn-/-;SMN2;SmnA2G KO mSmn; insertion of 2 copies of hSMN2; 
Insertion of 11 copies of hSMNA2G 
 
227 days Monani et al., 
2003 
SmnΔ7/Δ7;SMN2 Disruption of mSmn exon 7 
Insertion of hSMN2  
Variable: 
10 days – 
normal 
survival 
Hseish-Li et al., 
2000 
Tissue specific Smn expression alteration 
Smnf7;HSACRE Cre-lox excision of Smn exon 7 targeted to 
muscle 
 
33 days Cifuentes et al., 
2001 
Smnf7;NSECRE Cre-lox excision of Smn exon 7 targeted to 
neurons 
 





Smn-/-;SMN2low  background with Smn 
expression restored exclusively in muscle 




Smn-/-;SMN2low  background with Smn 
expression restored predominantly in neural 
tissue 
210 days Gavrillina et al., 
2008 
Abbreviations: KO – knock out; mSmn – murine Smn gene; hSmn – human SMN gene; PRP- human 
prion protein gene, predominantly neural expression; HSA – Human Skeletal Actin – exclusively 
muscle expression; NSE - rat neural specific enolase gene.  
 
 
1.4.3 NMJ pathology in SMA 
As for ALS, many early studies on human SMA patient material identified 
electrophysiological changes consistent with a disruption of NMJ connectivity and 
denervation of skeletal muscle (Mishra et al., 2004; Swoboda et al., 2005).  Further 
research to examine the contribution of NMJs to SMA pathogenesis in human material 
has been hampered by the end-stage nature of post-mortem material as well as a limited 
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supply of material suitable for high-resolution analyses of NMJ structure and/or 
function.  For this reason, animal models have once again proven to be powerful tools 
for investigating the incidence and importance of NMJ pathology in SMA (Swoboda et 
al., 2005).  
 
Experimental evidence that a breakdown of connectivity at the NMJ may occur in SMA 
came from important initial studies using mouse models. A significant denervation of 
NMJs (evidenced by vacant post-synaptic endplates on skeletal muscle fibres) was 
reported in mice at the end-stage of disease, alongside significant accumulations of 
neurofilament proteins in distal axons and motor nerve terminals (Frugier et al., 2000; 
Cifuentes-Diaz et al., 2002). However, the ability to draw parallels between these 
findings and events likely to be occurring in human patients was compromised by the 
fact that this mouse model (SmnF7/Smn∆7, NSE-Cre+) carries a deletion of SMN exon 7 
directed to neurons using the Cre–loxP system, thereby having a genetic status distinct 
from that which causes human SMA. Interestingly however, the morphological 
correlates of motor nerve terminal loss reported in the SmnF7/Smn∆7, NSE-Cre+ mouse 
models of SMA appear very similar to those described in ALS mouse models (c.f. 
Cifuentes-Diaz et al., 2002; Fischer et al., 2004; Schaefer et al., 2005;). This suggests 
that both forms of motor neuron disease are distal axonopathies, potentially united by 
the presence of “dying-back” pathways. Despite this correlation, there is a clear lack of 
detailed studies regarding the incidence and importance of NMJ pathology in SMA. 
Additionally, there are a number of outstanding questions in SMA research, specifically, 
in which tissue does pathology originate - muscle or nerve, and to what extent does 
abnormal development of the neuromuscular system contribute to neuromuscular 
pathology.  Together these questions will be fundamental in increasing our 
understanding of SMA pathogenesis and in the development of viable and effective 
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1.4.4 Nerve or muscle? 
A fundamental and ongoing question in SMA research is which tissue is the primary 
target: muscle and/or nerve (Vrbová, 2008).  The development and survival of motor 
neurons and muscle are highly integrated, with each tissue being mutually dependant on 
the other for maintenance (for review see Navarrette  and  Vrbová, 1993).  This 
inevitably makes identifying the primary site of pathology in SMA a great challenge. 
A logical experiment is the creation of transgenic animals which selectively lose Smn 
expression in either muscle or nerve.  Initial attempts at this, employing cre-lox 
technology to selective ablate Smn expression in either muscle or nerve, indicated Smn 
was required in both tissues and deletion in either tissue led to a severe degenerative 
phenotype (Frugier 2000; Cifuentes 2001; Table 1.1).  However, due to the general 
house keeping functions of Smn and the embryonic lethality of Smn knockouts, it is 
perhaps not surprising that complete ablation of Smn expression in given tissue results in 
associated pathological changes. More recent attempts have been based upon restoring 
Smn function to specific tissues on the Smn-/-;SMN2 background (Gavrilina et al., 
2008).  The introduction of high levels of Smn in muscle had minimal phenotypic 
affects, suggesting a loss of Smn in muscle cannot be solely responsible for the 
neuromuscular degeneration in SMA.  Restoring Smn expression in neural tissue 
resulted in a significant improvement in life span, with mice which survived up to 210 
days. While this result demonstrates a clear requirement for Smn in motor neurons, a 
modest increase in Smn expression was also seen in muscle, meaning a simultaneous 
requirement for Smn in muscle and nerve cannot be eliminated (Table 1.1). 
 
Studies utilising drosophila models of SMA have indicated that Smn is found post-
synaptically at the NMJ and is also sarcomeric protein with a significant role in 
myofibril formation (Rajendra et al., 2007; Chang et al., 2008).  To study the intrinsic 
properties of SMA muscle, myoblasts from patients have been cultured in both the 
presence and absence of motor neurons.  Samples from type I patients display 
abnormalities which are consistent with abnormal muscle growth and development 
(Guettier-Sigrist et al.,  2001; Arnold et al., 2004; Martínez-Hernández et al., 2009; see 
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section 1.4.4).  Culture of myoblasts from SMA patients with rat embryonic motor 
neurons resulted in a significant reduction in survival compared with cultures from other 
peripheral neuropathies and controls subjects (Braun et al., 1995).  Interestingly they 
noted that cultures of SMA muscle induced apoptotic cell death of rat embryonic motor 
neurons, underlining the fact that defects in muscle could conceivable cause the SMA 
phenotype (Guettier-Sigrist et al., 2002).   The authors speculate that there may be some 
deficiency in nerve-muscle trophic signalling which prevents NMJ maintenance 
(Guettier-Sigrist et al., 2001). 
 
The experiments detailed above may perhaps imply that loss of Smn can cause 
pathology in both muscle and nerve.  Studies in drosophila SMA models have revealed 
significant NMJ defects when Smn is lost from either muscle or nerve (Chan et al., 
2008).  There is therefore a potential requirement for Smn in both tissues, but further 
work is required to directly address this question. 
 
1.4.5 Developmental or degenerative disorder? 
Given the early onset of SMA in its most severe form, developmental pathways could 
potentially play an important role in neuromuscular vulnerability.  It is possible that 
developmental abnormalities could precede pathological onset and lead to intrinsic 
abnormalities to the neuromuscular system structure and function which pre-disposes the 
system to post-natal degeneration.  Studies investigating the expression of Smn protein 
report high levels during cellular differentiation, thus suggesting Smn could have a role 
in  developmental pathways (Gabanella et al., 2005).  Using cultured neurospheres from 
Smn-/-;SMN2 mice, Shafey and colleagues demonstrated low Smn levels result in 
defects in neuronal differentiation and neuritogenesis (Shafey et al., 2008).  Additional 
work in vitro has shown Smn accumulates in growth cones (Fan and Simard, 2002) and 
that reduced levels decrease axon outgrowth and growth cone size, and have attributed 
this to defective B-actin transport (Rossoll et al., 2003).  Together this data suggests that 
reduced Smn levels could cause defects motor neuron outgrowth and path-finding 
making it possible that these defects underlie pathology in SMA.  Work in both 
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zebrafish and xenopus SMA models supports this theory, noting abnormalities such as 
truncations and increased axon branching (McWhorter et al., 2003, Ymlahi-Ouazzani et 
al., 2009).  
 
A more limited body of work has investigated muscle development in spinal muscular 
atrophy.  Work on cultured myoblasts from SMA patients has shown that myoblast 
fusion into myotubes is delayed in samples from SMA patients compared to samples 
from other peripheral neuropathies and normal controls, with a reduction in 
acetylcholine receptor clustering in response to agrin (Guettier-Sigrist et al., 2001; 
Arnold et al., 2004).  Furthermore, a recent study on human embryonic muscle reported 
a general decrease in myotube diameter in samples from SMA patients (Martínez-
Hernández et al., 2009).  Myotube growth and maturation did not follow the same 
patterns seen in control samples, indicating muscle development may be abnormal.  This 
work suggests that there may be intrinsic abnormalities in muscle development in SMA 
which may have post-natal implications for the stability of the neuromuscular system.   
 
Together these findings highlight the requirement for studies on pre-symptomatic 
neuromuscular development in mammalian systems, to ascertain whether low Smn 
levels can cause developmental defects which can, to some degree, account for the post 
natal degenerative phenotype observed. 
 
1.5 Complexity of different cellular pathways resulting in NMJ loss: dying-back 
pathology versus Wallerian degeneration   
To aid our understanding of the mechanisms of neurodegenerative disease, including 
motor neuron disease, there is a clear requirement to understand the mechanisms 
regulating and perturbing synaptic vulnerability.  Despite the fact that many different 
neurodegenerative diseases are united by synaptic vulnerability, there are a number of 
quite morphologically distinct processes by which a synapse can degenerate, i.e. 
Wallerian Degeneration and dying-back neuropathy (Figure 1.1 C-F). For example, 
several different motor neuron diseases and sensory neuropathies are thought to 
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primarily occur via dying-back pathways (Schmalbruch et al., 1991; Frey et al., 2000; 
Cifuentes-Diaz et al., 2002; Fischer et al., 2004; Keswani et al., 2006), whereas 
conditions such as multiple sclerosis and degeneration after traumatic nerve injury are 
more commonly associated with Wallerian degeneration (Ferguson et al., 1997; Perry 
and Anthony, 1999; Gillingwater and Ribchester, 2001).  Wallerian degeneration is 
characterised by rapid axonal and synaptic fragmentation associated with disruption and 
loss of organelles and plasma membranes, breakdown of the axonal myelin sheath, and 
phagocytosis of synaptic and axonal debris (Figure 1.1 D,F). In stark contrast, dying- 
back neuropathies are characterised by a wave of degeneration beginning at the distal 
extremities of the neuron and are devoid of the gross fragmentation associated with 
Wallerian degeneration (Figure 1.1 C,E).  
 
Despite obvious morphological discrepancies, it has been suggested that common 
mechanisms regulate morphologically distinct types of synaptic and axonal degeneration 
(Coleman, 2005).  This suggestion is based partly upon the fact that the spontaneous 
neuroprotective Wallerian Degeneration Slow (Wlds) mutation (see below) can be 
protective in a range of conditions, including both traumatic injury (a process which 
induces traditional Wallerian degeneration of distal axons and synapses) and in 
characteristic dying-back neuropathies (Mack et al.,  2001, Ferri et al., 2003; 
Gillingwater  et al., 2006b).  The degree of mechanistic commonality is fundamental 
when attempting to understand the processes regulating synaptic breakdown.  The ability 
to decipher such mechanisms could potentially allow functional categorisation of 
neuropathies and broaden the scope of pathogenic insight and therapeutic potential.    
 
1.6 The neuro-protective Wlds model 
Although most studies investigating the mechanisms of synaptic vulnerability are 
centred around neurodegenerative models, we can also gain great insight by utilising 
models of neuro-protection. One such neuro-protective model is the spontaneously 
arising Wallerian degeneration slow (Wlds) mutant. The Wlds mutation was identified in 
1989 after distal axonal compartments failed to undergo highly characteristic 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
21 
degeneration following a traumatic nerve injury (Lunn et al., 1989).  Subsequent work 
demonstrated that NMJs were also preserved and retained synaptic function up to 2 
weeks after nerve injury (Ribchester et al., 1995).  The mutation was ultimately found to 
be a spontaneous triplication resulting in the formation of a novel chimeric protein 
comprising the N-terminal fragment of ubiquitination factor E4B (Ube4b) fused to the 
whole coding region of nicotinamide mononucleotide adenylyltransferase (Nmnat) as 
well as eighteen amino acids normally contained in the 5’ untranslated region (Mack et 
al., 2001).  The resultant chimeric protein has been shown to be neuro-protective in both 
the central and peripheral nervous systems, in a range animals and culture based models 
and in response to a wide range of traumatic, toxic and genetic insults (Wang et al., 
2001; Ferri et al., 2003; Samsam et al., 2003; Fischer et al, 2004; Gillingwater et al., 
2006a; Hasbani and O’Malley 2006).  The mechanisms by which this nuclear protein 
can confer synaptic protection to distal axonal and synaptic compartments, even when 
physically separated from the cell body remain undefined and controversial.  For 
example, even though it is generally accepted that Wlds is acting through downstream 
modifications of subcellular pathways that are in some way affecting the persistence of 
axons and synapse, opinions vary in relation to which component of the Wlds mutation 
is specifically responsible i.e. the NMNAT1 portion of the mutation or the N70 UBE4b 
fragment.   Despite this controversy, the Wlds mutation is of interest for several reasons.  
Firstly, this mutation clearly demonstrates that synapses and distal axon compartment 
can control their own fate when physically removed from the cell body. Secondly, due to 
the diversity of insults it can protect against, it suggests that there is a degree of 
commonality in the pathways mediating synaptic and axonal degeneration. Finally, it is 
clearly of interest for its therapeutic potential as if it could be applied exogenously, 
either via virus or direct application of the protein, it could feasible inhibit 
neurodegenerative processes. The Wlds mutation is therefore a useful tool when 
attempting to understand the mechanisms regulating synaptic vulnerability.   
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1.7 Aims 
From the above introduction covering the current literature available it is clear that there 
is a rationale and requirement for studies on NMJ pathology in SMA.  In this study, I 
therefore aim to address the following aspects of SMA pathology using established 
mouse models.   
 
Hypothesis 1: Synaptic pathology is an early and significant event in SMA. 
AIM 1: Investigate the incidence and importance of NMJ pathology in mouse 
models of SMA 
a. Examine the occurrence of NMJ loss and NMJ morphology during disease 
progression in a selection of muscle groups reflecting different subtypes and 
body locations. 
b. Investigate potential selectively vulnerable populations of NMJs in different 
muscles/muscle areas 
c. Investigate and correlate the occurrence and relationship of pre- and post- 
synaptic pathology in nerve and muscle 
 
Hypothesis 2: Abnormal pre-symptomatic development of the lower motor neuron 
connectivity pre-disposes the neuromuscular system to subsequent degeneration in SMA. 
AIM 2: Determine the contribution of abnormal lower motor neuron development 
to subsequent degenerative events. 
a. Examine pre-symptomatic development of lower motor neuron connectivity 
with regards to axonal path-finding, branching and establishment of 
innervation patterns 
b. Examine pre-symptomatic gene expression by microarray analysis. 
 
 
Hypothesis 3: Pathological changes occurring in SMA result in altered gene expression  
AIM 3: Attempt to identify pathways contributing to the degeneration of lower 
motor neurons by microarray analysis of spinal cord at end-stage time points. 
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Hypothesis 4: Common molecular mechanisms regulate morphologically distinct types 
of  synaptic degeneration. 
AIM 4: Investigate the relationship between pathways controlling dying-back 
neuropathy and Wallerian degeneration 
a. Define NMJ phenotype in the wasted mouse model of early onset 
neurodegeneration. 
b. Investigate progression of Wallerian degeneration in response to nerve injury 
in wasted mice.  
 
Hypothesis 5: Wlds mice can give mechanistic insight into degenerative pathways in 
SMA 
AIM 5: Investigate potential correlates between the Wlds mouse model of neuro-
protection and a mouse model of SMA 
a. Investigate if proteomic changes identified in Wlds mice occur in an opposite 
direction in a mouse model of SMA. 
b. Investigate if proteins identified as being altered in Wlds to can be used  
toidentify potential biomarkers and gauge pathological progression in SMA? 
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Chapter 2: Materials and methods 
 
2.1 Colony management 
2.1.1 Mouse maintenance  
C57Bl/6 and YFP-H mice were maintained as breeding colonies in the animal care 
facilities in Edinburgh under standard SPF conditions. Smn+/-;SMN2 mice (Jackson labs 
strain no. 005024) were also maintained as heterozygote breeding pairs in animal care 
facilities in Edinburgh. Smn+/-;SMN2;Δ7 (Jackson labs strain no. 005025) breeding pairs 
were maintained in animal care facilities in Oxford. For this strain, basic dissection of 
muscle groups was performed by Nick Parkinson and Dirk Bäumer in Oxford and 
shipped to Edinburgh. All genotyping of this colony was performed in Oxford by Nick 
Parkinson.  Pairs of heterozygous wasted mice were kindly provided by Dr Cathy 
Abbott and a breeding colony was established. Breeding colonies of YFP-H mice (Feng 
et al., 2000) were already established in animal care facilities at the University of 
Edinburgh and were crossed with wasted mice in order to obtain homozygous and 
heterozygous wasted mice, as well as wild-type littermates, endogenously expressing 
yellow fluorescent protein (YFP) in a subset of neurons. Wlds mice were bought in from 
Harlan UK. All animal procedures and breeding were performed in accordance with 
Home Office and institutional guidelines. All mice were housed in a semi-barrier facility 
and were fed a standard chow diet. Mice older than P6 were sacrificed by intra-
peritoneal injection of sodium pentabarbitol or overdose of isofluorane.  Mice younger 
than P6 were chilled on ice and decapitated.  All animal procedures were performed in 
accordance with the licensed authority of the UK Home Office.  
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2.1.2 Genotyping 
Wasted and Smn-/-;SMN2 mice were genotyped using the following primers (product 
sizes in bases pairs are shown in brackets): 

























Product amplification was performed using the following thermocycler programme: 
Smn knockout, Smn wild-type, SMN2 Wasted knockout and wild-type 
Step Temperature 
(°C) 
Time (Seconds) Step Temperature 
(°C) 
Time (Seconds) 
1  94 120 1 94 300 
2  94 30 2 94 15 
3  61 30 3 55 30 
4 72 45  
(go to step 2 x 27) 
4 68 40 
(Go to step 2 x 34) 
5 72 120    
      
Products were separated by gel electrophoresis and genotype assigned by presence or 
absence of a band of appropriate size.   
 
YFP (yellow fluorescent protein) status was ascertained by examining ear punches for 
evidence of YFP-labelled neurons.   
  
Real time quantitative PCR was used to assess copy number of Wlds and SMN2. The 
following primers and probes were used for Wlds and SMN2 genes along with 
endogenous controls. 
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Endogenous mouse Smn (exon 1): Forward: CCAGAAGAAAACCTGCCAAGAA 
Reverse: GGTTAAATCAATCTATCACCTGTTTCAA 
Probe: 6FAM- AAGAATGCCACAACTC-MGB 
 
 
For Wlds copy number analysis, primers and probes specific to Wlds and Tubulin were 
combined within 1 well (Wishart et al., 2007a).  For SMN2 copy number analysis 
primers and probes specific to SMN2 and mouse endogenous Smn were amplified in 
neighbouring wells.  Amplification was performed using the following thermocycler 
programme.  
  
Stage Temperature (°C) Time (Seconds) 
1 50 120 
2 95 600 
3 95 15 
4 60 60 
  Go to step 3 x40 
   
Relative copy number was established by measuring the cycle number difference for 
equivalent fluorescence between the gene of interest and control gene during the linear 
phase of amplification (Wishart et al., 2007a).  
 
2.1.3 Nerve axotomy 
Mice were anesthetized by inhalation of isofluorane (2% in 1:1 N2O/O2).  A 2mm 
incision in the skin was made just above the heel to expose the tibial nerve.  Blunt 
dissection was used to tease away overlying muscle, taking care not to damage neighboring 
blood vessels.  A 1–2mm section of the tibial nerve was then removed which denervates the 
flexor digitorum brevis and deep lumbrical muscles. The incision was closed with a single 
suture.  Mice were allowed to recover from anesthetic before being returned to standard 
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cages. All surgical procedures were carried out with the licensed authority of the UK 
Home Office.  
 
2.1.4 Paralysis with Botulinum toxin type A 
Botulinum toxin type A (0.5µl/g of a 5ng/ml solution; Sigma) or vehicle control (non-
sprouting buffer) was repeatedly injected subcutaneously above each levator auris 
longus muscle (LAL) at postnatal days 15, 19, 22, 26 and 29 (as previously described; 
Pun et al., 2002). Technical assistance for these experiments was provided by Derek 
Thomson.  Mice were sacrificed and muscles analysed at P45. Muscles were quantified 
for presence/absence of collateral terminal sprouting and percentage of ectopic endplates 
(as described below).  
 
2.2 Muscle preparation and staining 
2.2.1 Whole mount muscle preparation 
The levator auris longus (LAL; from the dorsal surface of the neck), adductor auris 
longus (AAL; from the dorsal surface of the neck, deep to the LAL); auriculars superior 
(AS; from the dorsal surface of the neck, deep to the LAL); lumbricals (from the plantar 
surface of the hind-paw); flexor digitorum brevis (FDB; from the plantar surface of the 
hind-paw) and/or transversus abdominis (TVA; from the antero-lateral abdominal wall) 
muscles were dissected in oxygenated mammalian physiological saline (mM: NaCl 120, 
KCl 5, CaCl2 2, MgCl2 1, NaH2PO4 0.4, NaHCO3 23.8, D-glucose 5.6).  Muscles were 
exposed to α-bungarotoxin (BTX), conjugated to tetramethyl-rhodamine isothiocyanate 
(TRITC-α-bungarotoxin; 5mg/ml, Molecular Probes) or AlexaFluor-647 (5mg/ml, 
Molecular Probes), to label AChRs for 10 minutes and fixed in 0.1M PBS containing 
4% Paraformaldehyde (Electron microscopy science) for 15 minutes.  
 
2.2.2 Preparation of sectioned muscles 
For muscles sectioned in cross section, muscles were dissected and fixed as described 
above and embedded in 3% agarose gel. Muscles were then embedded in wax, sectioned 
on a wax microtome at 10um and mounted on poly-lysine coated slides. Sections were 
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dewaxed in xylene and rehydrated in ascending alcohol series before processing for 
immunofluorescence on slides. 
 
2.2.3 FM4-64FX labelling of neuromuscular synaptic function 
Freshly dissected LAL muscles were loaded with the styryl dye FM4-64FX (FM4-64FX, 
2mg/ml: Molecular Probes) using a high K+ stimulus (Baxter et al., 2008). Muscle 
preparations were exposed to a fixable form of the styryl dye FM4-64 in 95%:5% 
O2:CO2 sparged, high K+ Krebs’ Solution (102 mM Na+, 50 mM K+, 2 mM Ca2+ , 2 mM 
Mg2+ , 132 mM Cl-, 23.8 mM HCO3- , 0.4 mM H2PO42- , 5 mM D-glucose, 5.5mM 
HEPES: pH 7.2-7.4) for 10mins. Following rigorous washing, muscles were fixed in 4% 
formaldehyde/PBS solution (Electron Microscopy Science, Pennsylvania). 
 
2.2.4 Electrophysiology 
Electrophysiological records were conducted with the technical support of Derek 
Thomson.  FDB muscles were used to obtain intracellular recordings of evoked endplate 
potentials (EPPs) and spontaneous miniature endplate potentials (mEPPs). Isolated 
muscles were pinned out in a Sylgard (VWR International, Poole, UK) lined bath and 
perfused with oxygenated mammalian physiological saline. Muscle contractions were 
reduced or eliminated by bathing the muscles in 2.5µM µ-conotoxin (µ-CTX) GIIIB 
(Scientific Marketing Associates, UK) for 30–45 min. 10 muscle fibres per muscle were 
sampled using microelectrodes filled with 5M potassium acetate (impedance ≈ 40 MΩ), 
according to standard techniques. Spontaneous and evoked endplate potentials were 
recorded using Axoclamp 2B amplifiers (Axon Instruments) and stored and analysed on 
a PC using WinWCP v3.9.5 software (developed and distributed by Dr John Dempster, 
Strathclyde University).  
 
2.2.5  Immunocytochemistry  
Whole mount muscles were blocked in 4% bovine serum albumin (BSA) and 1% 
TritonX in 0.1M PBS for 30min before incubation in primary antibodies (150kDa 
neurofilament proteins - 1:350 dilution, Chemicon International) overnight. After 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
29 
washing for 30min in 0.1M PBS, muscles were incubated for 4h in a 1:40 dilution of 
secondary antibody (swine anti-rabbit FITC: swine anti-rabbit TRITC; Goat anti-mouse 
FITC; all 1:50, Dako). Muscles were then whole-mounted in Mowoil® (Calbiochem) on 
glass slides and cover-slipped for subsequent imaging.  
 
Sectioned muscles were processed as above but procedures were carried out on slides 
and incubation times were reduced to 2 hours (Myosin slow/fast – 1:50, AbCam) and 1 
hour (Rabbit anti-mouse FITC, 1:50, Dako). Slides were coverslipped using Mowoil® 
(Calbiochem) for subsequent imaging. 
 
2.3 Image analysis and quantification 
2.3.1 Imaging  
Muscle preparations were viewed using either a phase contrast microscope (for muscle 
measurements), a standard epi-fluorescence microscope equipped with a chilled CCD 
camera (x10 0.3NA, x40 0.6NA lens; Nikon IX71 microscope; Hammamatsu C4742-95), 
and/or a laser scanning confocal microscope (BioRad Radiance 2000, x40 1.3NA oil 
immersion lens; Zeiss Axioskop, x40 1.3NA, x63 1.4NA oil immersion lenses).   TRITC-
α-BTX-labeled preparations were imaged using 543nm excitation and 590nm emission 
optics and FITC-labeled preparations utilised 488nm excitation and 520nm emission 
optics. For confocal microscopy, 488nm, 543nm and 633 laser lines were used for 
excitation and confocal Z-series were merged using Lasersharp (Biorad) or Image J 
software. All images were then assembled using Adobe Photoshop. 
 
2.3.2 Montages and reconstructions 
Reconstructions of immunocytochemically labelled and YFP-H labelled muscle 
preparations were produced in Adobe Photoshop software by layering and combining 
multiple micrographs covering the entire muscle. Individual motor neurons were traced 
and pseudo-coloured manually in Adobe Photoshop software. 
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2.3.3 Quantification and statistics 
A minimum of 80 endplates from a minimum of 3 fields of view per muscle/muscle 
band were assessed. Muscles with poor staining and/or damage were excluded from 
further analysis. Wherever possible, all analysis was performed without the operator 
knowing the status of the material.  For basic occupancy counts, the occupancy of 
individual NMJs was evaluated by categorising endplates as either fully occupied 
(neurofilament entirely overlies endplate), partially occupied (neurofilament partially 
overlies endplate) or vacant (no neurofilament overlies endplate). For correlated pre- and 
post-synaptic measurements, calibrated individual images of NMJs were imported into 
ImageJ software (NIH, USA) and split into red (endplate) and green (axon and motor 
nerve terminal) channels. Each endplate and corresponding motor nerve terminal were 
manually outlined in ImageJ (see Figure 3.3 A-B) and the software used to calculate 
total areas. To evaluate the number of neural inputs, the number of axons converging on 
a single motor endplate were counted. Collateral terminal sprouts were identified by the 
presence of nerve terminal projections exceeding 2µm in length to exclude the 
possibility that sprouting was due to ongoing synaptic reorganisation. Ectopic endplates 
were identified by clusters of acetylcholine receptors under 5µm in diameter. Individual 
muscle fibre diameters were measured in ImageJ using regions of the muscle where 
teased fibres were present. Only isolated fibres with no overlapping fibres obscuring 
their profile were included in these analyses. The number of endplates per axon was 
quantified by evaluating axon number from deconvolved images.  Images were taken 
approximately 100µm from the endplate area of interest to minimise variability 
introduced from axon branching occurring adjacent to sites of innervation. All muscles 
in which the complete area of innervation could not be seen, or additional axons 
branches were present, were excluded from further analysis.   Axon numbers were 
counted by visualisation in the X-Y plane and scanning up and down through the z-
series.  This was done at three pre-defined points per image with images re-blinded 
between each measurement. The average of each three counts was divided by the total 
number of endplates innervated by the axon bundle to give the average number of axons 
per endplate.   To quantify sprouting, sprouts were categorised as ‘small sprouts’ (those 
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less than 150µm) or ‘super sprouts’ (those exceeding 150µm).  Sprouts were defined as 
a neurofilament positive process that did not project to a cluster of AChR receptors.  
Small sprouts were quantified by counting the number of sprouts in a given field of view 
expressed in relation to the number of endplates present.  A minimum of three fields of 
view were evaluated for each muscle (AAL/AS) or muscle band (LAL).  Super sprouts 
were quantified by counting the total number of sprouts in a muscle region and divided 
by the total number of endplates in the relevant region. Endplate maturation was 
evaluated by categorising endplates as either uniform (even distribution of AChRs), 
folded (bright bands within the AChR region) or perforated (holes within the AChR 
staining; see Figure 4.11).  Any endplate which was difficult to quantify due to 
orientation or proximity of other endplates was excluded from further analysis. All data 
were collected and analysed using GraphPad Prism software. 
 
2.4 Electron microscopy 
Muscle/nerve preparations were dissected and pinned out on dental wax before being 
immersion fixed in 0.1M phosphate buffer containing 4% formaldehyde (electron 
microscopy sciences) and 2.5% glutaraldehyde (sigma) for 4 hours before post-fixation 
in 1% osmium tetroxide (sigma) for 45 minutes. Preparations were dehydrated in 
ascending alcohol series (50%, 70%, 90%, 100%x2) and propylene oxide.  Preparations 
were embedded in Durcupan resin.  Ultra-thin sections (75-90nm) were cut and collected 
on formvar-coated grids (Agar Scientific, UK), stained with uranyl acetate and lead 
citrate in a LKB ‘Ultrostainer’ and then viewed in a Philips CM12 transmission electron 
microscope (TEM).  
 
2.5 Quantitative fluorescent (Li-COR) western blots 
Total protein was isolated from the spinal cord of late-symptomatic wasted mice and 
control littermates as well as spinal cord, skin and muscle of Smn-/-;SMN2 mice and 
control littermates.  Total protein was drawn through a decreasing size of needle (spinal 
cord) or homogenised with mortar and pestle (skin and muscle).  Protein levels were 
quantified by use of a BCA protein quantification kit according to manufacturers 
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instructions.   Protein was separated by SDS/Polyacrylamide gel electrophoresis on 4-
20% pre-cast NuPage 4-12% Bis Tris gradient gels (Invitrogen) and then transferred to 
PVDF membrane overnight. The membranes were blocked using Odyssey blocking 
buffer (Li-COR) and incubated with primary antibodies as per manufacturers 
instructions (BRCA2 – AbCam; βSNAP – BioMol International; DRP2 – courtesy of 
Calum Sutherland, Dundee University; cABL - AbCam; GDI – ProteinTech Europe; 
Tubulin - Abcam; UBE1 - AbCam; SMN1 – BD Bioscience; STI – BD Transduction 
Labs; VDAC1 – GeneTex Inc; ZPR1 – BD Bioscience; all 1:10,000). Odyssey 
secondary antibodies were added according to manufacturers instructions (Goat anti 
rabbit IRDye 680 and Goat anti mouse IRDye 800). Blots were imaged using an 
Odyssey Infrared Imaging System (Li-COR Biosciences). Scan resolution of the 
instrument ranges from 21-339µm and in this study blots were imaged at 169µm. 
Quantification was performed on single channels with the analysis software provided. 
Bands were identified according to their relative molecular and delineated using 
Odyssey software and the arbitrary fluorescence intensity calculated by the software. For 
each membrane, scans were carried out at three different intensities in order to minimise 
possible user error in determining correct scan intensities or over-saturation of the 
membrane. The average of these three separate scans (giving an N of 1 per membrane) 
was used for analysis. 
 
2.6 RNA isolation and microarray 
Whole spinal cords were removed and RNA was extracted using an RNEasy micro kit 
(Qiagen) and RNA samples were shipped to the microarray facilities in Oxford where 
subsequent procedures and analysis was conducted by Sheena Lee. Any genomic DNA 
was removed using an on column digest. The quality and integrity of RNA was assessed 
on a BioAnalyzer; all samples had a RNA Integrity Number (RIN) ≥ 9 (Agilent 
Laboratories, US). 1µg starting RNA was ribosome depleted using the Ribominus 
Human/MouseTranscriptome Isolation kit (Invitrogen). Labelled sense ssDNA for 
hybridization was generated with the Affymetrix GeneChip WT sense target labelling 
and control reagents kit (Affymetrix, UK) according to the manufacturer’s instructions.  
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
33 
Sense ssDNA was fragmented and the distribution of fragment lengths was measured on 
the BioAnalyser.  The fragmented ssDNA was labelled and hybridized to the Affymetrix 
GeneChip Mouse Gene 1.0 ST Array (Affymetrix). Chips were processed on an 
Affymetrix GeneChip Fluidics Station 450 and Scanner 3000. The core genes on the 
arrays were RMA normalized in GeneSpring GX 9 and differentially expressed genes 
were identified using an unpaired t-test with a p-value cut off of ≤0.05 and a fold change 
difference between SMNMu and WT of ≥1.5.  The genes were sorted according to their 
gene ontology using GenMAPP’s GO-Elite. Only MAPPFinder ontologies with ≥3 
genes showing changes and a permuted p-value ≤0.05 were selected.  
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Based on the hypothesis that synapses are specifically vulnerable in neurodegenerative 
disease, I have investigated synaptic pathology at the neuromuscular junction in two 
mouse models of SMA. I have used immunocytochemistry, confocal microscopy and 
electron microscopy to investigate synaptic pathology in a range of muscles (levator 
auris longus, transversus abdominis, deep lumbrical muscles) in the Smn-/-;SMN2 and 
Smn-/-;SMN2;SMNΔ7 mouse models of SMA during disease progression.   
 
Results detailed in this chapter show that: 
1. Pre-synaptic degeneration of the NMJ was an early and significant event in 
mouse models of SMA, being present at pre-symptomatic time points in the most 
severely affected muscle groups. 
2. There was significant inter-muscle heterogeneity in regards to pre-synaptic 
pathology, with postural, slow twitch muscles of the trunk being more affected 
than fast twitch muscles. 
3. Significant post synaptic shrinkage of muscle fibres and endplates was apparent 
but appears to be dissociated with pre-synaptic degeneration. 
4. Pre-synaptic pathology in Smn-/-;SMN2;Δ7 mice was reduced compared to Smn-
/-;SMN2 mice at late-symptomatic time-points, although post-synaptic pathology 
was equally severe. 
5. Selectively vulnerable pools of motor units exist within the caudal band of the 
LAL muscle and appear to belong to a developmentally distinct subtype. 
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3.1 Introduction 
As mounting evidence suggests that synaptic compartments of neurons are specifically 
vulnerable to a range of pathogenic triggers, I have investigated whether the NMJ was a 
primary pathological target in SMA. Prior to this study, a number of studies based on 
human patients (Soubourillard et al., 1996; Mishra et al., 2004, Swoboda et al., 2005) 
and animal models (Cifuentes-diaz et al., 2002;  Chan et al., 2003; Monani et al., 2003; 
Le et al., 2005) have suggested that NMJ defects are an important aspect of SMA 
pathology.  Findings include electrophysiological abnormalities associated with 
denervation (Mishra et al., 2004), vacant endplates (Cifuentes-diaz et al., 2002; Le et al., 
2005) and terminal and nodal sprouting associated with denervation-induced re-
innervation (Monani et al., 2003).  Despite this work, we still lack fundamental details 
of the morphological defects and time course of the pathological events occurring at the 
NMJ. A more detailed understanding of such pathological events could give important 
insights into the disease mechanisms underlying SMA. For example, despite evidence 
suggesting that both neuron-specific and muscle-specific events can occur during SMA 
(see introduction), no studies to date have addressed whether muscle atrophy occurs as a 
direct result of synaptic denervation at the mammalian NMJ. Teasing apart the nerve- 
and/or muscle-specific roles of SMN will be important for developing therapeutic 
strategies that target all pathological sites in SMA. Similarly, it is not known whether 
certain intrinsic characteristics of motor neurons (e.g. fast-fatigable, fast fatigue-resistant 
and slow phenotypes) can lead to modifications in their susceptibility to SMA-induced 
disease stimuli. The identification of intrinsic factors that make subpopulations of motor 
neurons particularly vulnerable or resistant to SMA is likely to highlight critical 
molecular and cellular targets for the development of new therapies and treatments. 
 
Here I have undertaken a detailed analysis of synaptic pathology at the NMJ in two 
different mouse models of SMA: the Smn-/-;SMN2 mouse model of severe SMA 
(Monani et al., 2000) and the Smn-/-;SMN2;Δ7 mouse model with a modified, less 
severe phenotype (Le et al., 2005). I have used immunocytochemistry, 
fluorescence/confocal microscopy and electron microscopy to demonstrate that 
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neuromuscular synapses are grossly disrupted in late symptomatic (P5-6) Smn-/-;SMN2 
mice, with postural muscles in the trunk being more severely affected than the fast-
twitch muscles in both the trunk and lower limbs. The morphology of synaptic 
degeneration showed correlates to a dying-back neuropathy, with gradual proximal to 
distal withdrawal and minimal axonal fragmentation.  Synaptic abnormalities were 
present in severely-affected muscles at pre-symptomatic time-points (P2) indicating 
synapse loss is an early event in disease progression. Smn-/-;SMN2;Δ7 mice also showed 
signs of synaptic disruption at early/mid-symptomatic time-points (P7), but in late 
symptomatic mice (P14) post-synaptic pathology had progressed significantly but pre-
synaptic pathology had not extended much beyond the modest levels observed at P7. 
Together these findings support the hypothesis that synapses are vulnerable in SMA.  I 
also show that shrinkage of post-synaptic motor endplates does not correlate with pre-
synaptic motor nerve terminal loss, suggesting that pre- (neuronal) and post- (muscular) 
synaptic pathology can occur independently of one another. Finally, my investigations of 
neuromuscular pathology in the LAL muscle identified selectively vulnerable 
subpopulations of motor neurons, with those conforming to a ‘Fast Synapsing’ (FaSyn) 
phenotype (Pun et al., 2002) likely to be more susceptible in SMA than those with a 
‘Delayed Synapsing’ (DeSyn) phenotype. 
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3.2 Results 
3.2.1 Motor nerve terminal loss, neurofilament accumulation and muscle fibre shrinkage 
in Smn-/-;SMN2 mice 
Neuromuscular pathology was investigated in a range of muscles from the trunk and 
hind limbs of the mouse, with each muscle allowing assessment of the entire synaptic 
innervation of the muscle in a whole-mount preparation. Synaptic pathology was 
examined at the NMJ in the transversus abdominis (TVA) a postural muscle from the 
anterior abdominal wall innervated by lower intercostal nerves, known to be affected in 
other mouse models of motor neuron degeneration (Newbery et al., 2005), levator auris 
longus (LAL), a pure fast-twitch muscle from the dorsal surface of the head innervated 
by the facial nerve (Angaut-Petit et al., 1987; Erzen et al., 2000) and deep lumbrical 
muscles, fast-twitch muscles from the hind-paw innervated by terminal branches of the 
tibial nerve. These preparations allowed us to quantify and correlate pre- and post-
synaptic pathology in muscle groups taken from several anatomical regions of the 
mouse, whilst also providing the ability to compare pathology in predominantly slow- 
(TVA) versus fast-twitch (LAL and lumbricals) muscles as well as between muscles 
innervated by nerves with long (lumbricals) and short (TVA/LAL) nerve stumps. 
 
NMJs were labelled in whole-mount TVA, LAL and lumbrical preparations from late-
symptomatic (P5-P6) Smn-/-;SMN2 mice with a severe SMA phenotype. Care was taken 
during dissection to make sure that the muscle and its nerve supply were removed in 
their entirety, especially for the LAL which has two constituent muscle bands (rostral 
and caudal; see below). Pre-synaptic axons and motor nerve terminals were labelled 
using antibodies directed against 150kDa neurofilament proteins (green; Figure 3.1 A) 
and post-synaptic acetylcholine receptors were labelled using rhodamine-conjugated α-
bungarotoxin (red; Figure 3.1A). The vast majority of NMJs in control preparations 
from wild-type littermates were, as expected, fully occupied, with a motor nerve 
terminal branching over the whole post-synaptic motor endplate. As the muscles were 
taken from animals at P5-P6, most endplates in control preparations were also contacted 
by more than one incoming motor axon (polyneuronally innervated), as the process of 
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developmental synapse elimination (establishing the adult mononeuronal innervation 
pattern of one axon innervating one muscle fibre) is not complete until approximately 
two weeks after birth.  
 
In contrast, numerous examples of partially occupied and vacant endplates (Figure 3.1A) 
were present in all muscle preparations from Smn-/-;SMN2 mice, indicative of 
denervation events occurring due to a loss of pre-synaptic motor nerve terminals. The 
numbers of fully occupied endplates were significantly reduced in all muscles compared 
to wild-type littermates, albeit with the slow-twitch, postural TVA being more affected 
(63% fully occupied at P5) than the fast-twitch LAL and lumbricals (77% and 73% 
respectively fully occupied at P5; Figure 3.1 B-D).  
 
Concurrent to nerve terminal loss, numerous examples was found of pre-synaptic nerve 
terminals with abnormal accumulations of neurofilament proteins (Figure 3.2). This data 
supports similar findings from a previous study of NMJs in a different mouse model of 
SMA, suggesting that neurofilament accumulation in motor nerve terminals is a 
pathological feature of SMA (Cifuentes-Diaz et al., 2002).  
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Figure 3.1: Synaptic pathology at the neuromuscular junction in late-symptomatic 
(P5-6) Smn-/-;SMN2 mice. A – Confocal micrograph showing three neuromuscular 
junctions in an immunohistochemically labelled TVA muscle preparation from a P5 Smn-
/-;SMN2 mouse (green = 150kDa neurofilaments; red = post-synaptic acetylcholine 
receptors labelled with TRITC-α-bungarotoxin). The white arrowhead is identifying a 
fully occupied endplate, the blue arrow a partially occupied endplate, and the white 
arrow a vacant (denervated) endplate. B-D – Quantification of synaptic pathology in 
late-symptomatic (P5-6) Smn-/-;SMN2 mice. Panels show the percentages of fully 
occupied, partially occupied and vacant endplates in the TVA (B), LAL (C) and deep 
lumbrical (D) muscles from SMA mice (white bars) compared to control littermate 
controls (black bars; mean±SEM; n=4 per muscle control, n=6 per muscle). Scale bar = 
10µm (A)). 
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Figure 3.2: Neurofilament accumulation at the neuromuscular junction in late-
symptomatic (P5-6) Smn-/-;SMN2 mice.  A,B - Confocal micrographs showing 
abnormal accumulations of neurofilament at  Smn-/-;SMN2 neuromuscular junctions (B; 
white arrows) compared to littermate controls (A) in an immunohistochemically labelled 
LAL muscle preparation from a P5 Smn-/-;SMN2 mouse (green = 150kDa 
neurofilaments; red = post-synaptic acetylcholine receptors labelled with TRITC-α-
bungarotoxin; scale bar = 10µm (A,B)). 
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As previous studies have identified shrinkage of post-synaptic motor endplates alongside 
muscle fibre atrophy in SMA (Le et al., 2005), motor endplate size and muscle fibre 
diameter were examined in the TVA and LAL of Smn-/-;SMN2 mice (Figure 3.3). 
Quantitative analysis confirmed that motor endplate areas were significantly reduced in 
the TVA and LAL of Smn-/-;SMN2 mice (Figure 3.3 B).  Measurements of muscle fibre 
diameter revealed significant shrinkage in the TVA (average muscle fibre diameter of 11 
Smn-/-;SMN2 vs 17 control, P<0.001 ANOVA with Tukeys post hoc test; Figure 3.3 
C,D), with the LAL much less affected (average muscle fibre diameter of 12µm Smn-/-






Figure 3.3 Post synaptic shrinkage in end-stage Smn-/-;SMN2 mice. A,C - 
endplates area (A) and muscle fibre diameter  (C) were measured using image 
J software as shown (pink outline (A); red line (C)).  B,D - Bar charts showing 
the mean endplate area (B) and muscle fibre diameters (D)  in the TVA and LAL 
from SMA mice (white bars) compared to control littermate controls (black bars).  
(mean±SEM; n=4 per muscle control, n=6 per muscle; ANOVA with Tukey’s 
Post Hoc test; ***P<0.001; **P<0.01; ns- non significant). 
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The data discussed above suggest that NMJs are primary pathological targets in SMA 
and also indicate that significant levels of inter-muscle variability exist within affected 
individuals, with slow-twitch postural muscles more affected than fast-twitch phasic 
muscles.  
 
The morphological correlates of nerve terminal loss appeared distinct from those 
occurring during more Wallerian-like degenerative processes (Miledi and Slater, 1970; 
Gillingwater et al., 2003), suggesting that a ‘dying-back’ process is more likely to be 
responsible for removing nerve terminals. In order to confirm this, intramuscular nerves 
and NMJs were examined in deep lumbrical muscles from late-symptomatic (P5-P6) 
Smn-/-;SMN2 mice using transmission electron microscopy. All intramuscular nerves 
examined were devoid of classical markers of Wallerian degeneration (e.g. myelin 
debris and plasma membrane breakdown; Miledi and Slater 1970; Gillingwater et al., 
2003), with intact myelin sheaths, neurofilaments and microtubules (Figure 3.4 A). 
Modest accumulations of neurofilament in some axons confirmed the occasional 
neurofilament accumulations observed using immunocytochemistry (Figure 3.4 A). At 
the qualitative level, intact myofibrils were present in all skeletal muscle fibres 
examined (Figure 3.4 B). Immature NMJs could be identified (devoid of the adult 
ultrastructural characteristics such as large post-synaptic folds), and many contained 
large accumulations of neurofilaments, presenting as neurofilament whorls within the 
body of the motor nerve terminal (Figure 3.4 C). These whorls are likely to be the 
ultrastructural equivalents of neurofilament accumulations observed using 
immunocytochemistry (c.f. Figure 3.2 B) and are similar to those previously reported in 
other mouse models of SMA (Cifuentes-Diaz et al., 2002). No evidence of membrane 
breakdown, organelle fragmentation or phagocytosis by terminal Schwann cells was 
present, suggesting the involvement of a mechanism distinct from Wallerian or 
Wallerian-like degeneration (Gillingwater and Ribchester, 2003).  This data suggests 
that the morphology of synaptic degeneration in SMA is more akin to a ‘dying-back’ 
type degeneration, as observed in other models of motor neuron degeneration (Frey et 
al., 2000; Fischer et al., 2004) 
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Figure 3.4: Ultrastructural 
correlates of synaptic 
pathology at the 
neuromuscular junction in 
late-symptomatic (P5-6) 
Smn-/-;SMN2 mice. A – 
Electron micrograph showing 
a pair of intramuscular axons 
in a lumbrical muscle from a 
P6 Smn-/-;SMN2 mouse. 
Note how the gross 
ultrastructure is retained, 
with intact myelin sheaths 
(black arrow) and 
neurofilaments/microtubules. 
Both axons have low-level 
accumulations of 
neurofilaments (white arrow). 
B – High power electron 
micrograph showing intact 
myofibrils in a lumbrical 
muscle from a P6 Smn-/-
;SMN2 mouse. C - Electron 
micrograph showing a motor 
nerve terminal at a 
neuromuscular junction in a 
lumbrical muscle from a P6 
Smn-/-;SMN2 mouse. Note 
how the nerve terminal 
bouton is filled with 
abnormally large 
accumulations of 
neurofilaments in the form of 
neurofilament whorls. Note 
that ultrastructural features 
normally associated with 
mature, adult neuromuscular 
junctions (e.g. post-synaptic 
folds, large numbers of 
clustered synaptic vesicles) 
are not present in mice of 
this age due to their 
developmental stage. (Scale 
bar = 1µm (A), 0.1µm (B), 
0.5µm (C)). 
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3.2.2 Occupancy counts underestimate levels of synaptic pathology at the NMJ in Smn-/-
;SMN2 mice 
Despite clear evidence of synaptic pathology provided by counts of fully occupied, 
partially occupied and denervated endplates (Figure 3.1), I investigated whether or not 
the presence of multiple axonal inputs converging on individual endplates - due to 
ongoing developmental synapse elimination (see above) – resulted in underestimation of 
pre-synaptic nerve terminal loss. The numbers of individual axonal inputs converging on 
fully-occupied endplates were examined (i.e. classified as ‘normal’ in previous analysis) 
in the TVA and LAL of late-symptomatic Smn-/-;SMN2 mice and control littermates 
(Figure 3.5). In the TVA, the mean number of inputs converging on endplates was 
significantly reduced (1.28 Smn-/-;SMN2 vs 1.65 control; P<0.01 Mann Whitney test). 
The same trend existed in the LAL muscle (1.75 Smn-/-;SMN2 vs 1.64 control) although 
due to high intramuscular variability (see below), this did not reach statistical 
significance. Thus, more pre-synaptic inputs were being lost than previously estimated 
from denervation counts alone. 
 
Figure 3.5: Synaptic pathology at the neuromuscular junction is 
underestimated when based on occupancy counts alone. A,B – Confocal 
micrographs showing a single polyneuronally innervated neuromuscular junction 
(A, pre-synaptic axons and nerve terminal; B, post-synaptic acetylcholine 
receptors) in an immunocytochemically labelled LAL from a P6 Smn-/-;SMN2 
mouse. Note how three axons are converging on this single endplate. C – Bar 
chart showing the average number of axonal inputs innervating individual 
neuromuscular junctions classified as fully occupied (see Figure 3.1) in the TVA 
and LAL of late-symptomatic (P5-6) Smn-/-;SMN2 mice compared to control 
littermates. (mean±SEM; Mann Whitney test, two-tailed; **P<0.01, ns non 
significant; n=6 per muscle Smn-/-;SMN2 Scale bar = 5µm). 
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It is possible, however, that reduced numbers of synaptic inputs could also result from 
defective synapse formation, leading to hypo-innervation of NMJs before the onset of 
pathology. To rule out this possibility, analysis of synaptic pathology was performed in 
the TVA and LAL of P2 Smn-/-;SMN2 mice (Figure 3.6). From a qualitative 
perspective, no discernable differences could be identified between neuromuscular 
innervation in the LAL muscle from P2 (i.e. pre-symptomatic) Smn-/-;SMN2 mice 
versus control littermates (Figure 3.6 A-B). Quantification of innervation (Figure 3.6 C) 
supported qualitative observations that the LAL was devoid of denervation pathology at 
P2. Similarly, quantification of the average number of inputs and muscle fibres 
diameters in the LAL confirmed that synapses were being formed in a similar manner to 
control littermates (Figure 3.7 B,D). By P4, synaptic pathology was evident in the LAL, 
although not to the extent observed in late-symptomatic P6 mice (Figure 3.6C).  
 
A similar analysis of TVA from P2 Smn-/-;SMN2 mice showed evidence of low levels 
of pre-symptomatic synaptic pathology (Figure 3.6 C). The average number of inputs 
per synapse were also decreased at P2, although post-synaptic muscle fibre shrinkage 
was not yet evident (Figure 3.7 A,C). As in the LAL, synaptic pathology in the TVA 
progressively worsened with time and was always more severe than in LAL at any given 
time-point (Figure 3.6 C). 
 
The above results indicate that NMJ pathology in the form of pre-synaptic degeneration, 
neurofilament accumulation and post-synaptic shrinkage, is an early and significant 
event in pathology in the Smn-/-;SMN2 mouse model. Significant inter-muscle 
heterogeneity is apparent and pathological changes can be identified in the most severely 
affected muscles prior to symptom onset.  While these changes were a clear feature 
within this severe mouse model, the extent to which they are general feature of SMA, as 
oppose to specific to this mouse model, was unclear.  
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Figure 3.6: Synapses form normally, but synaptic pathology can occur 
pre-symptomatically in severely affected muscles, in Smn-/-;SMN2 mice. 
A/B – Confocal micrographs showing neuromuscular junctions in the LAL 
muscle from control (A) and Smn-/-;SMN2 mice (B). Innervation levels were 
qualitatively indistinguishable between the two genotypes in this muscle. C – 
Graph showing the onset and progression of pre-synaptic pathology in the 
TVA and LAL muscles from Smn-/-;SMN2 mice at P2 (pre-symptomatic), P4 
(mid-symptomatic) and P6 (late-symptomatic). Note how the LAL is almost 
entirely free from synaptic pathology at P2, with pathology first appearing at 
P4. By contrast, the TVA is affected, albeit at modest levels, at P2 with more 
severe synaptic pathology present at P4 and P6). The vast majority of 
endplates (>95%) were fully occupied in the TVA and LAL from control 
littermates at the same time-points (data not shown).  (n=4/5/6 muscles per 
P2/P4/P6 time-point; scale bar = 20µm).  
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3.2.3 Motor nerve terminal loss, neurofilament accumulation and muscle fibre shrinkage 
in Smn-/-;SMN2;Δ7 mice 
In order to determine that the synaptic events detailed above were not specific to Smn-/-
;SMN2 mice, NMJ morphology was quantified in early/mid symptomatic (P7) and late-
symptomatic (P14) Smn-/-;SMN2;Δ7 mice. As in the Smn-/-;SMN2 mice, synaptic 
pathology was evident in all muscle groups examined at both P7 and P14, evidenced by 
partially occupied endplates and vacant endplates (Figure 3.8). Again the presence of 
motor nerve terminals with abnormal accumulations of neurofilaments was noted 
(Figure 3.9). Interestingly, neurofilament accumulation appeared to be even more severe 
in Smn-/-;SMN2;Δ7 mice than previously observed in Smn-/-;SMN2 mice, particularly in 
the TVA (Figure 3.9 C).  
Figure 3.7: Pathology can occur pre-symptomatically in severely 
affected muscles in Smn-/-;SMN2 mice. A-D - Bar charts showing the 
average number of inputs per synapse (A,B) and mean muscle fibre 
diameter (C,D) in the TVA (A,C) and LAL (B,D) muscles from Smn-/-
;SMN2 mice at P2 (pre-symptomatic). (Mann Whitney test, two-tailed; ** 
P<0.01, ns non significant; n=5 muscles per genotype). 
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The numbers of fully occupied endplates were significantly reduced in the TVA 
compared to control littermates in early/mid symptomatic (P7) mice (reduction in 
percentage of fully occupied endplates of 9% Smn-/-;SMN2;Δ7 vs control, P<0.01 Mann 
Whitney test; Figure 3.8 B). There was only a subtle decrease in the numbers of fully 
occupied endplates in the LAL compared to control littermates (reduction in percentage 
of fully occupied endplates of 6% Smn-/-;SMN2;Δ7 vs control, non-significant Mann 
Whitney test; Figure 3.8 B). This result confirms findings in Smn-/-;SMN2 mice 
showing that the LAL is less affected in SMA than the TVA. In line with the data on 
pre-synaptic pathology, muscle fibre shrinkage was also pronounced in TVA but not 
LAL (average muscle fibre diameter of 16/13µm Smn-/-;SMN2;Δ7 vs  21/14µm control 
in TVA/LAL respectively, P<0.001 TVA, non-significant LAL, ANOVA with Tukeys 
post hoc test;  Figure 3.10 A). 
 
Surprisingly, equivalent analysis of synaptic pathology in end-stage (P14) Smn-/-
;SMN2;Δ7 revealed synaptic degeneration had not progressed significantly in either the 
TVA or LAL muscles (reduction in the percentage of fully occupied endplates  of 7% 
and 15% Smn-/-;SMN2;Δ7 compared to controls  in TVA and LAL respectively; Figure 
3.8 C). However, post-synaptic muscle fibre shrinkage was more pronounced in both the 
TVA and LAL at P14 compared to both earlier time points and end-stage Smn-/-;SMN2 
mice (average muscle fibre diameter of 13/12µm Smn-/-;SMN2;Δ7 vs  23/18µm control 
in TVA/LAL respectively, P<0.001 ANOVA with Tukeys post hoc test;  Figure 3.10 B) 
suggesting that the attenuation of pre- and post-synaptic pathology may be differentially 
modulated by the SMNΔ7 transgene. 
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Figure 3.8: Synaptic pathology at the neuromuscular junction in early/mid-
symptomatic (P7) and late-symptomatic (P14) Smn-/-;SMN2;Δ7 mice. A – 
Confocal micrograph showing neuromuscular junctions in an immunocytochemically 
labelled LAL muscle preparation from a P14 Smn-/-;SMN2;Δ7 mouse (green = 
150kDa neurofilaments; red = post-synaptic acetylcholine receptors labelled with 
TRITC-α-bungarotoxin). The white arrowhead is identifying a vacant endplate, the 
blue arrow a fully occupied endplate, and the white arrow a partially occupied 
endplate. B,C – Quantification of synaptic pathology in early/mid-symptomatic (P7; 
B) and late-symptomatic (P14; C) Smn-/-;SMN2;Δ7 mice in the TVA (left panel) and 
LAL (right panel) (black bars = control littermate; white bars = Smn-/-;SMN2;Δ7; 
mean±SEM; Mann Whitney test, 2 tailed; *P<0.05, **P<0.00; n=6 per muscle 
control, n=10 per muscle Smn-/-;SMN2;Δ7 at P7; n=2 per muscle/genotype at P14; 
Scale bar = 15µm (A)). 
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Figure 3.9: Abnormal accumulation of neurofilaments in Smn-/-;SMN2;Δ7 mice. 
A,B – confocal micrographs showing neuromuscular junctions from P7 control (A) and 
Smn-/-;SMN2;Δ7 (B)  LAL muscles (green = 150kDa neurofilaments; red = post-
synaptic acetylcholine receptors labelled with TRITC-α-bungarotoxin).  Note the 
abnormal accumulations of neurofilament present at axon terminals (white arrows).  
C,D – bar charts show percentage of neuromuscular junctions with accumulation of 
neurofilaments in TVA (C) and LAL (D) muscles. (mean±SEM; Mann-Whitney test; *** 
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3.2.4 Post-synaptic endplate shrinkage and pre-synaptic nerve terminal loss can occur 
independently at the NMJ  
The results detailed above have described the observed pre-synaptic degeneration 
alongside post-synaptic atrophy. However it was unclear whether these changes were 
interdependent, i.e. neural pathology resulted in post-synaptic atrophy or vice versa, or 
whether pathological changes were occurring independently.  In order to examine 
whether post-synaptic changes occurred as a direct result of the loss of innervation at 
individual NMJs, the percentage occupancy of individual endplates with their area was 
analysed and compared (Figure 3.11). There was no correlation between endplate area 
and occupancy (r2=0.006018; Figure 3.11 D). As a result, endplates with any given area 
were just as likely to be fully occupied as partially occupied or vacant. Of particular 
note, an equivalent spread of endplates areas was observed in both vacant and fully 
occupied endplates, indicating endplate shrinkage does not correlate with pre-synaptic 
degeneration.  The data suggest that post-synaptic changes at motor endplates are not 
simply a reaction to pre-synaptic pathology.  
 
Figure 3.10: Post-synaptic pathology in early/mid-symptomatic (P7) and late-
symptomatic (P14) Smn-/-;SMN2;Δ7 mice. A,B – Bar charts showing muscle fibre 
diameter in P7 (A) and P14 (B) Smn-/-;SMN2;Δ7  mice. (mean ±SEM; Black bars = 
control, white bars = Smn-/-;SMN2; ANOVA with tukeys post-hoc test; *** P<0.001; 
ns non-significant; n=6 per muscle control, n=10 per muscle Smn-/-;SMN2; Δ7 at P7; 
n=2 per strain/genotype at P14). 
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Figure 3.11: Dissociation of pre- and post-synaptic pathology at the 
neuromuscular junction in late-symptomatic Smn-/-;SMN2 mice. A,B – 
Fluorescence micrographs showing a single neuromuscular junction from the TVA of a 
P6 Smn-/-;SMN2 mouse immunocytochemically labelled to show the post-synaptic 
endplate (A) and pre-synaptic axon and motor nerve terminal (B). The highlighted edges 
of the endplate and motor nerve terminal illustrate how measurements were taken to 
calculate endplate area and percentage endplate occupancy (area of motor nerve 
terminal divided by area of endplate x 100). C – Bar chart showing a significant 
reduction in the mean endplate area in P6 Smn-/-;SMN2 TVA (white column) compared 
to control littermates (black column).  (unpaired t test, two-tailed; ***P<0.001; n=4 per 
muscle control, n=6 per muscle Smn-/-;SMN2 Scale bar = 7.5mm A,B). D – Scatterplot 
showing no correlation between endplate area and endplate occupancy in P6 Smn-/-
;SMN2 TVA muscles. Occupancy levels had no effect on endplate size, showing that 
post-synaptic endplate shrinkage does not occur as a direct result of pre-synaptic 
pathology. (P=0.1802, r2=0.006018, N=6 muscles, n=300 endplates (D)). Some data 
acquired by Laura Comley during a BSc honours project 
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3.2.5 Selective vulnerability of a subpopulation of motor neurons in the LAL muscle 
Whilst quantifying synaptic pathology in LAL, it became apparent that there appeared to 
be higher levels of nerve terminal loss in the thinner, caudal band of the muscle 
compared to the neighbouring rostral band. This was the case in both strains of mouse 
and at all time-points examined (Figure 3.12). Quantification of synaptic pathology 
(using both occupancy counts and assessment of the average number of inputs) 
confirmed that neuromuscular pathology was indeed widespread in the caudal band of 
LAL, but was almost absent in the rostral band of the muscle in both Smn-/-;SMN2 
(Figure 3.12 C,D) and Smn-/-;SMN2;Δ7 mice (Figure 3.12 E,F).  
 
Correlation analysis of post-synaptic endplate areas and pre-synaptic occupancy in both 
the caudal and rostral bands of LAL again confirmed post-synaptic shrinkage was not 
associated with pre-synaptic retraction (Figure 3.13). Furthermore, comparisons of 
endplate area and muscle fibre diameter showed no significant difference between the 
rostral and caudal bands of LAL (Figure 3.14). This data further supports the hypothesis 
Figure 3.11) that pre-synaptic nerve terminal loss (which is widespread in the caudal 
band of LAL but not the rostral band) is not correlated with post-synaptic endplate 
shrinkage (which shows no difference between the two muscle bands). 
 
This observed selective vulnerability of NMJs in the caudal band of the LAL muscle 
presents a useful tool to investigate factors which influence synaptic vulnerability.  Any 
intrinsic differences between the two muscle bands are therefore of great interest.  
Previous studies have demonstrated that both rostral and caudal portions of LAL are 
composed of a homogenous population of fast-twitch muscle fibres, with predominance 
of fast twitch fibres and almost complete absence of slow-twitch fibres (Erzen et al.,  
2000). Therefore fibre type is unlikely to account for the differing vulnerabilities 
observed. 
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Figure 3.12: Selective vulnerability of synapses in the caudal band of LAL in Smn-/-
;SMN2 mice and Smn-/-;SMN2;Δ7 mice. A,B – Confocal micrographs showing 
immunocytochemically labelled neuromuscular junctions (green = 150kDa neurofilaments; 
red = post-synaptic acetylcholine receptors labelled with TRITC-α-bungarotoxin) from the 
rostral band (A) and caudal band (B) of the same LAL from a P7 Smn-/-;SMN2;Δ7 mouse. 
Note how most endplates in the rostral band are fully occupied (and often polyneuronally 
innervated) whereas endplates in the caudal band are mainly partially occupied or vacant. 
C-F – Bar charts showing quantification of synaptic pathology (assessed using occupancy 
and average number of inputs criteria) in the rostral and caudal bands of LAL from late-
symptomatic (P5-6) Smn-/-;SMN2 mice (C,D) and Smn-/-;SMN2;Δ7  (E,F) mice. Both 
assessment criteria revealed significantly more pathology in the caudal band compared to 
the rostral band (Mann Whitney test(C,E) or unpaired t-test (D,F); **P<0.01, *** P<0.001; 
n=3 muscles per assessment C,D; n= 5 muscles per assessment E,F; Scale bars = 40 µm 
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Figure 3.13: Dissociation of pre- and post-  synaptic pathology in caudal and 
rostral bands of the LAL of Smn-/-;SMN2;Δ7 mice.  Scatterplot showing no 
correlation between endplate area and endplate occupancy in either the caudal band 
(red triangles) or rostral band (green squares) from P7 Smn-/-;SMN2;Δ7 LAL muscles 
as in the Smn-/-;SMN2 TVA (see Fig 3.11), pre-synaptic occupancy levels did not 
correlate with post-synaptic endplate size. (caudal band, P=0.4457, r2=0.004314, N=5 
muscles, n=137 endplates; rostral band, P=0.1406, r2=0.01433, N=5 muscles, n=153 
endplates). Some data acquired by Laura Comley during a BSc honour project 
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In order to try and identify the nature of the selective vulnerability of motor neurons and 
neuromuscular synapses in the caudal band of LAL, innervation patterns of 
immunocytochemically labelled LAL muscles from wild-type mice were mapped 
(Figure 3.15). Every muscle of over 40 examined conformed to a consistent pattern of 
innervation as shown in Figure 3.15 C. The thin caudal band consistently had two 
clusters of NMJs (C1 and C2), located at lateral and medial ends of the muscle 
respectively. The thicker rostral band consistently had five clusters of NMJs (R1 to R5), 
which were arranged in two groups (R1 and R2 together and R3-R5 together).  
Figure 3.14: No change in post synaptic parameters in rostral and 
caudal bands of the LAL in Smn-/-;SMN2;Δ7 mice. A/B – Bar charts 
showing no difference in endplate area (A) or muscle fibre diameter (B) 
between the caudal and rostral bands of the LAL muscle in P7 Smn-/-
;SMN2;Δ7  mice (mean±SEM; unpaired students t-test; ns – non significant; 
n=10 muscles).  As pre-synaptic pathology differs between rostral and 
caudal bands, this supports data indicating that pre and post synaptic 
pathology occur independently.  
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Figure 3.15: Reconstruction of whole LAL 
muscles reveals a consistent innervation 
pattern. Montages of fluorescent micrographs 
showing an entire immunocytochemically labelled 
LAL muscle from a wild-type mouse (A,C, 
bungarotoxin only; B, bungarotoxin (red) and 
immunocytochemically labelled neurofilaments 
(green); C - endplate stain only showing the 
location of distinct innervation areas (yellow 
circles), division between rostral and caudal 
bands (blue line), and location of entry point for 
the nerve supplying LAL (blue arrow)). Every 
muscle examined (>40 in total) conformed to the 
pattern of innervation shown in panel C: two 
regions of innervation in the caudal band (C1 and 
C2) and five regions of innervation in the rostral 
band (R1 to R5). Note that the large multi-axon 
nerve bundles running over the middle of the LAL 
in panel B are not supplying the muscle. (Scale 
bar = 1mm). Some data acquired by Laura 
Comley during a BSc Hons project. 
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In order to investigate whether the rostral and caudal bands shared pools of innervating 
motor neurons, or whether they were composed of distinct and separate motor units 
individual, immunocytochemically labelled motor neuron axons were traced from the 
point at which they entered the muscle (via a single muscle entry point; arrow in Figure 
3.15 C) through to their ultimate termination in one of the NMJ clusters in LAL (Figure 
3.16).  In every muscle examined, motor units exclusively supplied either the rostral or 
the caudal band. No motor units were found that had synaptic terminals in both bands. 
To confirm this observation, 16 LAL muscles from YFP-H mice in which only a small 
number of motor neurons (usually one or two) expressed endogenous yellow fluorescent 
protein were examined (Feng et al., 2000). In each case, individually labelled motor 
units innervated either the caudal band or the rostral band, but never both (Figure 3.16 
B). These experiments show that distinct populations of motor neurons supply the rostral 
and caudal bands of LAL. The preferential loss of innervation in the caudal band of 
Smn-/-;SMN2 and Smn-/-;SMN2;Δ7 mice is therefore likely to represent innervation 
from a selectively vulnerable population of motor neurons. 
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Figure 3.16: Reconstruction of muscle innervation in the LAL reveals distinct 
subpopulations of motor neurons supplying the rostral and caudal bands of the 
muscle. A - Montages of fluorescent micrographs showing immunocytochemically labelled 
axons entering a LAL muscle from a wild-type mouse (equivalent location to the arrow in 
figure 15C). The right panel is a pseudo-coloured version of the axons shown in the left panel 
which have been manually traced to identify whether they innervate the caudal band (blue; 
some endplates in area C1 can be seen at the top of the panel) or rostral band (green). We 
never found any examples of a single axon that innervated both rostral and caudal bands of 
the muscle. B - Montage of fluorescent micrographs showing two distinct YFP-labelled motor 
neurons (one bright and one faint) innervating the LAL muscle in a thy1.1-YFP-H mouse with 
innervation regions superimposed from figure 15C. Note how the bright motor neuron only 
innervates the caudal band (synapses formed in both C1 and C2) whereas the faint motor 
neuron innervates only the rostral band (R4 only). In all of the YFP-H muscles examined 
(N=16 muscles), individually labelled motor units were only seen to innervate either the caudal 
band, or the rostral band alone. Thus, distinct subpopulations of motor neurons innervate the 
rostral and caudal bands of the LAL with no overlap in innervation. (Scale bars = 200µm (A), 
750µm (B).) Some data acquired by Laura Comely during a BSc Hons project. 
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3.2.6 Selectively vulnerable motor neurons conform to a FaSyn phenotype 
One possible explanation for the selective vulnerability of synapses in the caudal band of 
LAL was that these motor units were larger (and hence had a more severe demand on 
intrinsic resources required to maintain viability following a degenerative stimulus) than 
motor units innervating the rostral band. However, quantitative analysis of motor unit 
sizes in the rostral and caudal bands of the LAL, using YFP-H mice to label the entire 
synaptic cohort of individual motor units, showed no difference between the two muscle 
bands (average motor unit size of 18/19 in rostral/caudal band respectively, non-
significant students T test; Figure 3.17). Similarly, a previous study of motor neuron 
vulnerability in SOD1 mouse models of amyotrophic lateral sclerosis demonstrated that 
axons of fast-fatiguable motor neurons are more vulnerable than slow motor neurons 
(Pun et al., 2006). However, as the LAL muscle is composed of an entirely homogenous 
population of fast-twitch muscle fibres (see above), it is unlikely that the selective 
vulnerability of motor neurons innervating the caudal band is due to a difference in the 
fast/slow status of motor neurons between the two bands of the muscle.  
 
 
Figure 3.17: There is no difference in motor unit size 
between rostral and caudal bands of the LAL.  Bar chart 
showing the motor unit size (number of endplates innervated 
by a given motor neuron) in rostral and caudal bands of the 
LAL. (mean±SEM; unpaired students t-test; ns – non 
significant; n=10 muscles).   
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I therefore examined whether motor neurons innervating the caudal band differed from 
those innervating the rostral band with respect to their FaSyn/DeSyn characteristics (Pun 
et al., 2002; see section 1.2.2). In particular, NMJs conforming to a ‘Delayed Synapsing’ 
(DeSyn) phenotype have been shown to undergo dramatic collateral sprouting and the 
formation of ectopic endplates following prolonged paralysis with BotA, whilst ‘Fast 
Synapsing’ (FaSyn) NMJs remain largely unaffected. 
 
To test whether neuromuscular synapses in the caudal band of LAL differed from those 
in the rostral band with respect to their FaSyn/DeSyn characteristics, in wild-type the 
LAL muscle was paralysed for 1 month with repeated subcutaneous injections of BotA 
(see materials and methods). Subsequent quantitative analysis of collateral sprouting 
from nerve terminals and ectopic endplate formation in immunocytochemically stained 
LAL muscles revealed striking differences between the two bands (Figure 3.18). In the 
caudal band of the muscle, very few motor nerve terminals (<5%) showed any signs of 
collateral sprouting (Figure 3.18 E). In contrast, more than 20% of endplates in the 
rostral band showed clear evidence of terminal collateral sprouting (Figure 3.18 E). 
Similarly, there were significantly fewer ectopic endplates formed in the caudal band 
compared to the rostral band (Figure 3.18 F). In addition, the differential disruption of 
post-synaptic acetylcholine receptor clusters, previously reported in FaSyn/DeSyn 
muscles in response to BotA (Pun et al., 2002), was observed in the rostral and caudal 
bands, with the former undergoing significant post-synaptic disassembly and the latter 
less affected (Figure 3.18 C,D). These experiments reveal that motor neurons supplying 
the caudal band of the LAL are more FaSyn-like than their counterparts in the rostral 
band.  Motor neurons with FaSyn-like characteristics may therefore be more likely to be 
vulnerable to SMA-induced synapse loss than those with DeSyn characteristics. 
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Figure 3.18: Selectively vulnerable motor neurons in the caudal band of LAL 
conform to FaSyn characteristics. A/B – Confocal micrographs showing 
neuromuscular junctions in the caudal (A) and rostral (B) portions of an 
immunocytochemically labelled LAL from a wild-type mouse muscle paralysed for 1 
month with repeated injections of BotA (green = 150kDa neurofilaments; red = post-
synaptic acetylcholine receptors labelled with TRITC-α-bungarotoxin). The white 
arrow is identifying a collateral terminal sprout induced by paralysis and the white 
arrowhead is highlighting an ectopic endplate innervated by a collateral sprout. C,D - 
Fluorescent micrographs showing significant post-synaptic disassembly in the rostral 
band (C) of the LAL compared to the reduced levels observed in the caudal band (D) 
(Post-synaptic AChR’s labeled with TRITC-α-bungarotoxin) E – Bar chart showing 
significantly fewer collateral terminal sprouts in paralysed neuromuscular junctions 
from the caudal band of LAL compared to the rostral band. F - Bar chart showing 
significantly fewer ectopic endplates (expressed as a percentage of total enplates) in 
paralysed neuromuscular junctions from the caudal band of LAL compared to the 
rostral band (Mean ± SEM; Mann Whitney test, two tailed; *P<0.05, **P<0.01; n=10 
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3.3 Discussion 
The findings of this chapter confirm that NMJs are early and significant targets in SMA 
and provide novel insights into neuromuscular pathology. I first demonstrated that 
neuromuscular pathology was prominent in muscle groups taken from different locations 
throughout the body of two SMA mouse models. Consistently, the postural TVA was 
more severely affected than fast-twitch LAL and lumbrical muscles, suggesting that 
muscle fibre-type and body location are likely to be important determining factors in 
regulating synaptic vulnerability during SMA. The morphological and ultrastructural 
correlates of nerve terminal loss support the hypothesis that SMA demonstrates 
characteristics consistent with a dying-back neuropathy. Second, I showed that synapses 
form normally in SMA mouse models, but that in the most severely affected muscles 
(e.g. TVA) pre-synaptic pathology occurs early on in the disease course. Third, I 
identified differences in the time-course and severity of neuromuscular pathology 
between Smn-/-;SMN2 and Smn-/-;SMN2;Δ7 mice. Severe pre-synaptic pathology in 
late-symptomatic Smn-/-;SMN2 mice was not mirrored in late-symptomatic Smn-/-
;SMN2;Δ7 mice. Post-synaptic pathology, however, appeared to be much more severe in 
late-symptomatic Smn-/-;SMN2;Δ7 mice, suggesting that the Δ7 transgene does not 
simply delay the neuropathology observed in Smn-/-;SMN2 mice. Rather, it appears that 
the Δ7 transgene has an affect in attenuating pre-synaptic pathology. Fourth, I 
demonstrated that post-synaptic changes resulting in shrinkage of motor endplates do not 
correlate with pre-synaptic pathology (loss of nerve terminals). Thus, pre- and post-
synaptic changes can occur independently of one another at any given NMJ. And finally, 
I have identified a selectively vulnerable population of motor neurons innervating the 
caudal band of the LAL muscle. These motor neurons conform to a FaSyn phenotype 
when challenged with paralysis (Pun et al., 2002) suggesting that FaSyn motor neurons 
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3.3.1 Differences in neuromuscular pathology progression in Smn-/-;SMN2 and Smn-/-
;SMN2;Δ7 mouse models 
An important finding from this study is the difference in pre-synaptic pathology 
observed between the two mouse models investigated.  Significant and progressive pre-
synaptic denervation was observed in Smn-/-;SMN2 mice in all muscles investigated, 
albeit at varying levels, with denervation being apparent from pre-symptomatic time 
points.  This finding has since been corroborated by another group who observed 
denervated endplates in intercostal muscles at late embryonic time points (McGovern et 
al., 2008).  In contrast, in the Smn-/-;SMN2;Δ7 model, although denervation was 
observed at early symptomatic time points, degeneration was not progressive leaving 
NMJs surprisingly intact at end-stage time points.  It is unclear why such discrepancies 
exist but it is perhaps worth considering given the implications such differences could 
have.  Due to the prolonged life span of the Smn-/-;SMN2;Δ7 model, it is used by many 
groups as a model for therapeutic strategy. Therapeutic approaches that facilitate 
retrograde transport, and/or synaptic protection are perhaps more likely to be successful 
in a system in which there is minimal denervation.  Further study is therefore required to 
determine, firstly why pre-synaptic denervation is attenuated in the Smn-/-;SMN2;Δ7 
model, and secondly what level of denervation is observed in human patients.  
 
3.3.2 Pre- and post- synaptic pathology can occur independently 
The data presented above showed a clear dissociation of pre- and post-synaptic 
pathology in all muscle groups examined, and in both mouse models of SMA. These 
findings provide strong support for the hypothesis that pre- and post-synaptic pathology 
can occur independently of one another in SMA.  One possible explanation for this, 
which the current study has not been able to directly address, is that SMN gene activity 
may be required in both neuronal and muscle tissue in order to alleviate the pathological 
phenotype (Chan et al., 2003). Neuron-specific functions of SMN are well documented, 
and are supported by data in the current study, with SMN being shown to be important 
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for events including axon outgrowth, path-finding and neuronal maintenance 
(McWhorter et al., 2003; Rossoll et al., 2003; Ferri et al., 2004; Gavrilina et al., 2009). 
The muscle-specific role of SMN is rather less clear, although deletion of SMN exon 7 
in mouse muscle is known to cause severe muscular dystrophy (Cifuentes-Diaz et al., 
2001) and a study utilising another Drosophila model of SMA has identified an 
important role for SMN protein in the form and function of muscle sarcomeres 
(Rajendra et al., 2007; Walker et al., 2008). A way to address this question would be to 
repeat the current set of experiments in mouse models in which SMN levels have been 
reduced, but not completely abolished, in a tissue specific fashion in muscle or nerve 
individually. Attempts have been made to create such mouse models, and although they 
demonstrate a clear requirement for Smn in motor neurons, a concurrent increase in the 
expression levels of Smn in muscle mean that the importance on Smn in muscle cannot 
be eliminated (Gavrilina et al., 2008). Another possible explanation for the apparent 
dissociation of pre- and post-synaptic pathology could be that muscle fibre pathology 
was a consequence of pre-synaptic inactivity - resulting in deficient neuromuscular 
transmission - occurring in the absence of pre-synaptic degeneration. However, the 
finding that some nerve terminals were removed from corresponding muscle fibres 
devoid of any pathology suggests that pre-synaptic inactivity is likely to play, at most, a 
minor role in regulating post-synaptic pathology. 
 
3.3.3 Selective vulnerability of NMJ pathology in SMA 
The finding that motor neurons innervating the TVA (a predominantly slow-twitch 
muscle) appear to be more susceptible in SMA models than the LAL and lumbrical 
muscles (exclusively fast-twitch muscles) is in contrast to studies of adult onset motor 
neuron diseases and provides a potential explanation for the proximal distribution of 
muscle weakness in SMA (Farrar et al., 2009). Studies of SOD1 mouse models of adult-
onset motor neuron disease have demonstrated that phasic, fast-twitch motor neurons are 
selectively vulnerable with slow-twitch motor neurons reported to be resistant and even 
capable of initiating regenerative responses (Pun et al., 2006). This contrasting data is 
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likely to reflect the different cellular stimuli and neuronal environments (e.g. age of 
disease onset) present in SMA and ALS, but it also highlights the fact that motor 
neurons cannot be grouped into those that are generically vulnerable and those that are 
not. Motor neurons that are particularly vulnerable in one form of motor neuron disease 
may not be vulnerable in another.  
 
The surprising result that motor neurons innervating the caudal band of the LAL muscle 
are more susceptible than those innervating the rostral band supports the hypothesis that 
not all pools of motor neurons are affected in the same way and at the same time in 
different motor neuron diseases (Frey et al., 2000; Ferri et al., 2004; Schaefer et al., 
2005). Whereas differences in vulnerability based around different motor neuron 
properties (e.g. fast-fatiguable, fast-fatigue resistant) and muscle fibre types are certain 
to exist, the current study demonstrates that motor neurons within a single muscle 
consisting of a homogeneous population of muscle fibres can also be differentially 
vulnerable in motor neuron disease. The result here have identified a correlation between 
vulnerable motor units and FaSyn characteristics. Whilst these experiments do not 
directly demonstrate a causal link between FaSyn characteristics and selective 
vulnerability (genetic tools to experimentally manipulate FaSyn and DeSyn 
characteristics are unfortunately not yet available), the hypothesis is strongly supported 
by the selective vulnerability of muscle groups present in human SMA patients. For 
example, the diaphragm (a DeSyn muscle; Pun et al., 2002) is relatively spared whilst 
the intercostal muscles (FaSyn muscles; Pun et al., 2002) are severely affected 
(Dubowitz, 1999). These results might suggest that developmentally distinct motor units 
populations are specifically more vulnerable to pathology in SMA and implicate 
developmental process with SMA pathogenesis.  Alternatively, they may indicate that 
the greater degree of plasticity observed in DeSyn motor units is somehow 
neuroprotective.  This finding would be consistent with the observation that slow twitch 
fibres, which are known to retain a higher degree of plasticity than fast twitch fibres, are 
selectively less vulnerable in mouse models of ALS (Pun et al., 2006). 
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This is the first time that FaSyn and DeSyn characteristics have been identified in 
subpopulations of neurons innervating the same muscle. The data suggest that further 
studies providing insights into the mechanisms through which motor neurons and their 
synapses are specified to be, and develop into, FaSyn or DeSyn motor units may provide 
important insights into vulnerability of motor neurons in SMA. The ability to identify 
factors associated with the more resistant DeSyn synapses may provide new targets for 
therapeutic intervention. The neuroanatomical map of LAL innervation and the 
identification of its differential neuronal susceptibility provided in the current study is 
likely to provide a useful model system with which to explore the differences between 
FaSyn and DeSyn synapses, and their vulnerability in SMA, in more detail. 
 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
68 




Based on the hypothesis that Smn is required for normal neuronal development, I have 
used immunocytochemical labelling and confocal microscopy to allow analysis of pre-
symptomatic (P1) LAL and AS/AAL muscles from Smn-/-;SMN2 mice.  I have 
compared the developmental morphology of pathologically vulnerable and stable motor 
units to determine whether abnormal development of lower motor neuron connectivity 
underlies neuromuscular vulnerability. Together with pre-symptomatic micro-array 
analysis of the spinal cord, results suggest that abnormal pre-symptomatic development 
does not underlie pathogenesis in SMA. 
 
Results detailed in this chapter show that: 
1. Innervation patterns form normally in both vulnerable and stable regions of the 
LAL muscle 
2. Axon guidance and branching are unaltered in both vulnerable and stable motor 
units. 
3. Significant developmental sprouting exists in control P1 muscles but is unaltered 
in vulnerable and stable SMA motor units. 
4. Post-synaptic maturation occurs normally in both vulnerable and stable muscle 
regions. 
5. There are minimal changes in gene expression in the spinal cord of P1 Smn-/-
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4.1 Introduction 
Given the early onset of SMA in its more severe form, it has been postulated that 
abnormal pre-symptomatic development could render motor units vulnerable and pre-
empt degeneration.  This finding would be consistent with the observation that motor 
units conforming to distinct development subtypes are differentially vulnerable in SMA 
mouse models (see chapter 3).  Several studies have suggested that reduced Smn protein 
levels can have a significant influence on neuro-developmental processes in lower motor 
neurons (see section 1.4.5). Although a failure to establish the neuromuscular system 
during embryogenesis appears unlikely to contribute to any developmental phenotype 
(McGovern et al., 2008), it is possible that deficiencies in motor unit development 
(controlling factors such as motor unit branching, size, pruning and function) may play a 
major role in conferring pre-symptomatic vulnerability upon lower motor neurons.  
 
These ideas have led to the suggestion that SMA may be caused by the incorrect 
development of the neuromuscular system, which confers an intrinsic vulnerability upon 
lower motor neurons during the early stages of growth and maturation before the onset 
of neurodegenerative events. If this were the case, then attempts to rescue the 
neuromuscular system after birth (e.g. by elevating levels of Smn protein using gene 
therapy or pharmaceutical approaches; Azzouz et al., 2004; Avila et al., 2007) would 
have significant limitations. However, if pre-symptomatic developmental abnormalities 
are not a major feature of SMA, the neuromuscular system may remain intact until the 
postnatal onset of symptoms and therefore be more amenable to rescue. 
 
To directly address whether alterations in pre-symptomatic development of lower motor 
neurons and motor neuron connectivity contribute to SMA pathogenesis in vivo, I have 
undertaken a combined analysis of pre-symptomatic neuromuscular morphology and 
gene expression in the Smn-/-;SMN2 mouse model of SMA (Monani et al.,  2000). I 
have taken advantage of the novel observation that selectively vulnerable populations of 
lower motor neurons and NMJs in the caudal band of the mouse LAL muscle have 
neighbouring stable populations in the rostral band of the same muscle (see chapter 3). 
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This has allowed us to investigate and compare pre-symptomatic lower motor neuron 
development and connectivity in both vulnerable and non-vulnerable motor units 
supplying the same muscle, testing the hypothesis that pre-symptomatic developmental 
dysfunction is a pre-requisite for subsequent neuromuscular pathology.  I show that 
perturbations in pre-symptomatic developmental pathways are neither present nor 
necessary for subsequent lower motor neuron pathology in SMA in vivo.  Parallel gene 
expression analyses of pre-symptomatic spinal cord from Smn-/-;SMN2 and Smn-/-
;SMN2;Δ7 mice confirmed the absence of any disruption of developmental pathways.  
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4.2 Results  
4.2.1 Innervation patterns form normally in both vulnerable and stable motor units of 
the LAL in Smn-/-;SMN2 mice 
To establish whether pre-symptomatic developmental abnormalities are a significant 
feature of SMA in vivo morphological correlates of lower motor neuron connectivity 
were examined in the Smn-/-;SMN2 mouse model of severe SMA at pre-symptomatic 
ages (post-natal day 1; P1).  At this time point there is no evidence of pre-synaptic 
degeneration or post-synaptic atrophy within this muscle (see chapter 3).  The LAL 
muscle provided us with an excellent model system with which to study selectively 
vulnerable populations of lower motor neurons in these mice, allowing a direct 
comparison of neighbouring populations of differentially-affected motor units whilst 
eliminating variables such as nerve stump length, muscle fibre type and muscle function 
(see chapter 3). Whole mount LAL muscles from P1 Smn-/-;SMN2 and litter-mate 
control mice (Smn+/+;SMN2,) were labelled with antibodies against 150kDa 
neurofilament to reveal axonal and synaptic morphology and rhodamine-conjugated α-
bungarotoxin to label post-synaptic acetylcholine receptors at the NMJ.   
 
Fluorescent micrograph montages of the whole LAL muscle (incorporating both caudal 
and rostral bands) allowed analysis of the gross muscle innervation pattern in pre-
symptomatic P1 mice (Figure 4.1).  No differences were observed between the gross 
innervation patterns of either the rostral (non-vulnerable motor units) or caudal 
(vulnerable motor units) bands of the LAL in Smn-/-;SMN2 and litter-mate control mice 
(N=8 control muscles; N=14 Smn-/-;SMN2 muscles). Endplates were clustered into 
distinct and highly characteristic innervation bands in all muscles examined: C1 and C2 
in the caudal band and R1-5 in the rostral band (see figure 3.15). Axons consistently 
entered adjacent to region C2.  Analysis of axon branching patterns in the caudal band of 
the LAL revealed some variability in the number and distribution of branch points 
within genotypes (Figure 4.2).  Despite this, no consistent abnormality between 
genotypes was observed. Quantification of the numbers of neuromuscular synapses in 
medially situated endplate bands (regions C2 and R3-5, selected because these areas 
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were least likely to suffer damage during muscle dissection) revealed no differences in 
either caudal or rostral bands between Smn-/-;SMN2 and control mice (Figure 4.3).  This 
was in agreement with previous studies that reported no obvious discrepancy in the 
initial embryonic establishment of neuromuscular innervation patterns in SMA mice 










Figure 4.1: Gross anatomy of the LAL muscle at P1 shows normal innervation 
patterns in Smn-/-;SMN2 mice.  A,B – montaged fluorescent micrographs from 
immunocytochemically labelled LAL muscles (Black = 150kDa neurofilaments) 
showing innervation pattern in P1 control (A) and Smn-/-;SMN2 (B) LAL muscles. 
Individual fluorescent micrographs were montaged and photo-inverted in adobe 
photoshop. (Scale bar = 400µm). 
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Figure 4.2: Despite variability in axon branching patterns in the caudal band of  
the LAL, no consistent abnormality was observed. A,B – Example axon traces of 
branching patterns (blue) in the caudal band (limit shown in red) revealed significant 
variability in the number and location of axon branches in both control (A) and Smn-/-
;SMN2 muscles (B).  Most caudal bands had a intermediate level of axon branching 
(left) while examples of muscle bands with a high amount of branching (middle) or 
reduced about of branching (right) could be observed in both genotypes.  Despite this, 
no consistent abnormality could be observed between genotypes. (Scale bar = 400µm) 
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4.2.2 Axon branching and path-finding occur normally in both vulnerable and stable 
motor units in the LAL muscle of pre-symptomatic Smn-/-;SMN2 mice.  
It is possible that pre-symptomatic changes in lower motor neuron branching and path-
finding could lead to excessive demands being placed on individual lower motor 
neurons (e.g. functionally and/or energetically), thereby damaging the cell and pre-
disposing it to subsequent degeneration.  Such defects in axonal path-finding and/or 
branching would most likely manifest as alterations in the number of axons present in 
intramuscular nerve bundles.  Axon number was therefore quantified in intramuscular 
nerve bundles innervating regions C2 and R3 (two anatomically highly-consistent areas 
of the LAL muscle) in P1 Smn-/-;SMN2 and control mice. Axons were only quantified in 
areas of the muscle where the complete endplate band could be seen in order to ensure 
that no other axon branches were entering the endplate band from a different nerve 
bundle. Initial attempts to quantify the numbers of individual axons in intramuscular 
nerve bundles by undertaking analyses on raw confocal stacks and z-projections proved 
inconsistent and unreliable (Figure 4.4; Appendix 10.1). To achieve the necessary 
resolution required for accurate and robust analysis, confocal stacks were subjected to 
deconvolution analyses (Figure 4.4; Appendix 10.1). Quantification of axon numbers 
normalised to the number of endplates innervated revealed no difference in the numbers 
Figure 4.3: There is no change in the number of endplates in the LAL 
muscle from P1 Smn-/-;SMN2 mice. A,B  - Bar charts (Mean ±SEM) 
showing the number of endplates in  regions R3-5 (A) and C2 (B) in LAL 
muscles from P1 control (+/+; black bars) and Smn-/-;SMN2 (-/-; white bars) 
mice. (students T-test; ns non-significant; N=7/8 per control rostral/caudal 
band; N=14/12 per Smn-/-;SMN2  rostral/caudal band.) 
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of axons innervating either C2 or R3 regions of Smn-/-;SMN2 or control mice (Figure 
4.5).  
 
 Figure 4.4: Deconvolution as a tool to count axon number in axon bundles. 
Panels show a confocal micrograph of a neurofilament labelled axon bundles 
visualised as a z-projection (A), single slice (B) or cross-sectional slice (C).  
Images on the left  show raw images obtained from the confocal microscope. 
Images on the right are the equivalent images which have undergone 
deconvolution analysis. (Scale bar = 10µm (A,B), 5µm (C)). 
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Figure 4.5: There is no change in the number of axons  innervating 
regions R3 or C2 in LAL muscles from P1 Smn-/-;SMN2 mice. A,B - 
Deconvolved confocal micrograph Z-projections  of axons bundles innervating 
region R3 (A) and C2 (B) in muscles from control and Smn-/-;SMN2 mice C – 
Bar chart (Mean ± SEM) showing number of endplates per axon in regions R3 
and C2 from control littermate (+/+;black bars), and Smn-/-;SMN2 (-/-;white 
bars) mice.  (ANOVA; ns non significant; N=4/5 per control rostral/caudal band; 
N=10/10 per Smn-/-;SMN2 rostral/caudal band; scale bar = 8µm (A,B)). 
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Although there appears to be no change in axonal branching or pathfinding within 
intramuscular nerves, it remains possible that excessive branching distal to this point 
results in an increase in motor unit size.  Such changes may increase the energetic 
demands and thus the vulnerability status of a given motor unit. Such alterations would 
likely result in an increase in the number of axonal inputs per endplate. To address this 
possibility the number of axon collaterals converging on individual post-synaptic 
endplates at NMJs were quantified in both bands of the LAL muscle from Smn-/-;SMN2 
and control mice at P1. Note that at this age, NMJs are normally poly-neuronally 
innervated, as the process of developmental synapse elimination is ongoing. No 
significant differences were found in the average number of inputs converging on 
endplates in either rostral or caudal bands between genotypes (Figure 4.6).  There was a 
small, but noticeable, trend towards an increased number of inputs in Smn-/-;SMN2 mice 
compared to Smn+/+;SMN2 controls. However, as this small increase was present in 
both bands of the LAL, and equivalent levels were also observed in heterozygote 
controls (Smn+/-;SMN2), these small differences are unlikely to contribute to 
subsequent selective neuromuscular vulnerability in the caudal band of the LAL.  
 
Therefore no changes could be detected which would be consistent with an alteration in 
axonal pathfinding or branching.  It therefore seems unlikely that such defects could 
account for either the pre-synaptic vulnerability in SMA, or for the differential 
vulnerability observed between the caudal and rostral bands of the LAL at end-stage 
time points.   
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Figure 4.6: No significant change in the number of axonal inputs per endplate 
in Smn-/-;SMN2 mice. A – Representative confocal micrograph of an LAL muscle 
from a P1 control littermate mouse, labelled with antibodies against 150kDa 
neurofilaments (green, upper left panel) and TRITC-α-bungarotoxin (red, lower left 
panel), illustrating the type of images used for the quantification of axonal inputs. 
Note the complexity of innervation patterns at this age and high degree of poly-
neuronal innervation (i.e. multiple axons converging on a single motor endplate). B 
– Bar chart showing no significant difference in the number of inputs per endplate in 
either the rostral or caudal band of the LAL muscle between P1 Smn-/-;SMN2 mice 
(-/-;white bars) and either Smn+/-;SMN2 (+/-;grey bars) or Smn+/+;SMN2 (+/+; 
black bars) littermate controls. (mean ± SEM; ANOVA; ns non-significant; n=6/6 per 
rostral/caudal band Smn+/+;SMN2, N=3/3 per Smn+/-;SMN2 rostral/caudal band; 
n=8/8 per rostral/caudal band Smn-/-;SMN2; Scale bar = 30µm) 
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4.2.3 Exuberant terminal sprouting is present in all muscles and unchanged in Smn-/-
;SMN2 LAL muscles 
During analysis of P1 muscles, numerous axon sprouts extending from pre-synaptic 
motor nerve terminals were observed that have not been previously reported in the 
literature. These sprouts were consistently present in all bands of all muscles analysed, 
including both Smn-/-;SMN2 and litter-mate control mice. Sprouts ranged in size from 
under 5µm to over 250µm. Such sprouts could potentially put significant energy 
demands on the motor unit.   
 
To establish that this was a natural phenomenon and not occurring due to the presence of 
the SMN2 transgene, P1 muscles from wild-type CD1 mice (a completely unrelated 
genetic strain) were examined. Terminal sprouts were present in CD1 mice (Figure 4.7) 
and were indistinguishable from those observed in Smn-/-;SMN2 and control mice at the 
same age (Figure 4.8; 4.9). These observations warrant further investigation in future 
studies of normal neuromuscular development.  However, neither the numbers of small 
(<150µm; see methods) nor larger ‘super sprouts’ (those >150µm in length) were 
modified in pre-symptomatic Smn-/-;SMN2 mice (Figure 4.8; 4.9).  
 
These findings indicate that excessive axonal growth in the form of terminal sprouting is 
unlikely to contribute to synaptic vulnerability in the LAL muscle.  They further show 
that the developmental processes regulating axonal growth are unaltered in Smn-/-
;SMN2 muscles.  Taken together, the data above show that pre-symptomatic 
development of lower motor neuron connectivity occurs normally in both affected and 
non-affected motor units in severe SMA mice. 
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Figure 4.7: Nerve terminal sprouts are neither strain specific nor an aberrant 
response to the expression of SMN2.  A,B – Montaged confocal micrographs from 
an immunohistochemically labelled LAL muscle preparation from a wild-type CD1 
mouse (green = 150kDa neurofilaments; red = post-synaptic acetylcholine receptors 
labelled with TRITC-α-bungarotoxin).  Note the presence of both long ‘super-sprouts’ 
(arrow) and short sprouts (arrowhead) in both rostral (A) and caudal (B) bands. (Scale 
bar = 20µm.) 
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Figure 4.8:  Small axonal sprouts were present in both rostral and caudal 
bands of the LAL muscle at P1, but were unchanged in Smn-/-;SMN2 mice.  
A – Representative confocal micrographs from an immunohistochemically 
labelled LAL muscle preparations (green = 150kDa neurofilaments; red = post-
synaptic acetylcholine receptors labelled with TRITC-α-bungarotoxin) showing 
the presence of small sprouts projecting from nerve terminals in both rostral (left) 
and caudal (right) muscle bands in both control (upper panels) and Smn-/-
;SMN2 (lower panels) mice at P1.  Sprouts were identified as neurofilament 
positive projections not contacting AChR clusters (see white arrowheads).  B – 
Bar chart showing no change in the number of small sprouts per endplate in 
Smn-/-;SMN2 mice (-/-;white bars) compared to littermate controls (+/+; black 
bars). (mean ± SEM; ANOVA;  ns non-significant; n=6/6 per rostral/caudal band 
control, n=8/8 per rostral/caudal band Smn-/-;SMN2.  Scale bar = 30µm (A)). 
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Figure 4.9: Large ‘super sprouts’ were present in both rostral and caudal bands of the LAL 
muscle but were also unchanged in Smn-/-;SMN2 mice.  A-D – Representative confocal 
micrograph reconstructions showing large super sprouts (axonal projections exceeding 150µm in 
length; white arrowheads) in rostral (A,B) and caudal (C,D) bands from immunohistochemically 
labelled LAL muscle preparations from P1 control (A,C) and Smn-/-;SMN2 (B,D) mice (green = 
150kDa neurofilaments; red = post-synaptic acetylcholine receptors labelled with TRITC-α-
bungarotoxin; Scale bar = 20µm).  E – Bar chart showing no significant difference in the numbers 
of super sprouts (normalised to the number of endplates) present in regions R3-5 and C2 of the 
LAL muscle of Smn-/-;SMN2 mice(-/-; white bars) compared to littermate controls (+/+; black 
bars). (Mean ± SEM; ANOVA; ns non-significant; n=8/8 per rostral/caudal band control, n=15/14 
per rostral/caudal band Smn-/-;SMN2). 
 
 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
83 
4.2.4 Post-synaptic maturation was unaltered in Smn-/-;SMN2 mice 
As lower motor neuron morphology and connectivity were unaffected in Smn-/-;SMN2 
mice at pre-symptomatic stages, I next investigated whether changes in post-synaptic 
development at the NMJ were present and could account for subsequent vulnerability of 
motor units.  In agreement with previous studies, results here have already established 
that the position and relative number of post-synaptic motor endplates was normal in 
both caudal and rostral bands of the LAL muscle in Smn-/-;SMN2 mice (Figure 4.1, 4.3).  
Quantification of individual endplate areas revealed a similar, normal distribution in 
Smn-/-;SMN2 mice (Figure 4.10).  As previous work has suggested that endplate 
maturation may have an impact upon lower motor vulnerability in SMA mice (Biondi et 
al., 2008), a scale to quantify and compare endplate maturation was applied in Smn-/-
;SMN2 and control mice (Figure 4.11 A). Endplates were categorised as either 
‘uniform’, where AChR receptors were evenly distributed within the endplate area, 
‘folded’ where bright bands on the endplate had formed which were indicative of post-
synaptic fold formation (a sign of early maturation), or perforated, where holes in the 
AChR labelling was indicative of the endplate beginning to take on the adult ‘pretzel-
like’ morphology (see Marques et al., 2000).  Overall, there was no difference in the 
numbers or proportion of uniform, folded and perforated endplate morphologies between 
genotypes (Figure 4.11 B).  However, there was an observed increase in endplate 
maturation in the caudal band of the LAL in mice from both genotypes, as evidenced by 
an increase in the number of folded and perforated endplates.  This finding is consistent 
with motor units in the caudal band conforming to ‘FaSyn’ characteristics, being 
developmentally more advanced than their ‘DeSyn’ neighbours (Pun et al., 2002; see 
chapter 3).   
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Figure 4.10: There is no difference in endplate area in rostral or caudal 
bands of the LAL in Smn-/-;SMN2 mice. Box and whisker plot showing 
endplate area in regions R3-5 and C2 in LAL muscles from control (+/+; dark 
grey boxes), and Smn-/-;SMN2 (-/-;white boxes) mice.  (Kruskal-Wallis test; 
ns non significant; N=8/8 per control rostral/caudal band; N=14/14 per Smn-/-
;SMN2 rostral/caudal band). 
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Figure 4.11:  There is no difference in endplate maturation in either the rostral or 
caudal bands of the LAL in Smn-/-;SMN2 mice.  A – confocal micrographs showing 
example images of endplates in which the bungarotoxin staining is  uniformly distributed 
(left), developed post synaptic folds  (red arrowheads, middle) or become perforated (red 
arrows, right).  B – Bar chart showing the percentage of endplates which were categorised 
uniform (black bars), folded (grey bars) and perforated (white bars) in regions R3-5 and C2 
in LAL muscles from Smn-/-;SMN2 (-/-) mice compared to control littermates (+/+). (mean ± 
SEM; Kruskal-Wallis test; P>0.05; N=8/8 per control rostral/caudal band; N=15/14 per Smn-
/-;SMN2  rostral/caudal band). 
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4.2.5 There is no alternation in pre-symptomatic development between differentially 
vulnerable fast-twitch and slow-twitch muscles 
The finding that lower motor neuron development occurs normally in both the rostral 
and caudal bands of the LAL implies that abnormal pre-symptomatic neuromuscular 
development does not contribute to the increased vulnerability of motor units in the 
caudal band of the LAL.  However, these analyses compared two bands of a 
homogenous fast-twitch muscle. It therefore remained possible that abnormalities in pre-
symptomatic development may contribute to increased vulnerability of lower motor 
neurons innervating slow-twitch muscles.  To investigate this possibility, two additional 
muscles immediately deep to the LAL muscle were examined: abductor auris longus 
(AAL) and auricularis superior (AS). The AAL is a predominantly fast-twitch muscle 
whilst the AS is predominantly slow-twitch (Figure 4.12 A). These muscles were chosen 
for comparison because of their close proximity and function to one another (and the 
LAL) as well as their common innervation by the facial nerve (eliminating variables 
such as nerve stump length and body position, while still allowing whole mount analysis 
of the complete innervation pattern within a muscle). In late-symptomatic (P5) Smn-/-
;SMN2 mice, there was approximately 25% denervation in the AS muscle while the 
AAL remained relatively unaffected (Figure 4.12 B,C). The increased vulnerability of 
slow-twitch muscles at late-symptomatic stages was therefore reflected in the increased 
pathology observed in the AS muscle.  
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Figure 4.12: Selective vulnerability of motor units in the predominantly slow twitch 
auricularis superior muscle compared to the fast twitch abductor auris longus muscle 
in late-symptomatic (P5) Smn-/-;SMN2 mice.  A – Representative micrographs of AAL and 
AS muscles sectioned coronally and stained with antibodies against either slow myosin (upper 
panel) or fast myosin (lower panel). Note how the AAL muscle is composed of predominantly 
fast twitch fibres while the AS muscle is composed of predominantly slow twitch fibres (albeit 
with fast-twitch fibres also present).  B – Confocal micrographs from immunohistochemically 
labelled AAL (left) and AS (right) muscles from P5 Smn-/-;SMN2 mice (green = 150kDa 
neurofilaments; red = post-synaptic acetylcholine receptors labelled with TRITC-α-
bungarotoxin) showing large numbers of denervated endplates in the AS muscles while the 
AAL muscle remained relatively spared.  C – Bar chart (mean ± SEM) showing the percentage 
of fully occupied endplates from P5 Smn-/-;SMN2 AAL and AS muscles.   Note that only 75% 
of endplates in the AS muscle remain fully innervated at this stage of the disease whereas 
nearly 100% of connections remained in the AAL muscle. (Mann Whitney test; * P<0.01; n = 
6/6 per AAL/AS muscle and genotype; Scale bar = 100µm (A), 15µm (B)). 
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Comparable analyses of pre-symptomatic development to those detailed above for the 
LAL muscle revealed no significant differences in gross innervations patterns in either 
the AAL or AS muscle (Figure 4.13).  Quantification of endplate numbers revealed no 
difference in either muscle (Figure 4.14).  There was also no change in the levels of poly 
innervating in either muscle between Smn-/-;SMN2 mice and control littermates (Figure 
4.15).   
 
 
Figure 4.13: Gross anatomy of the AAL and AS muscles at P1 shows normal 
innervation patterns. A,B – montaged fluorescent micrographs from 
immunocytochemically labelled AAL/AS muscles (Black = 150kDa neurofilaments) 
showing innervation pattern in P1 control littermate (A) and Smn-/-;SMN2 (B) AAL 
and AS muscles. Individual fluorescent micrographs were montaged and photo-




.                                                                                                                                            . 
 
 
.                                                                                                                                            . 









Figure 4.14: There is no change in the number of endplates in  either the AS or 
AAL  muscle from P1 Smn-/-;SMN2 mice. A,B  - Bar charts (mean ±SEM) 
showing the number of endplates in  the AAL (A) or AS (B) muscle P1 Smn-/-;SMN2 
mice (-/-; white bars) compared to control littermates (+/+; black bars). (students T-
test; ns  non-significant; N=10/9 per control AAL/AS muscle; N=9/7 per Smn-/-
;SMN2 AAL/AS muscle). 
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Figure 4.15: No change in the number of axonal inputs per endplate in either 
AAL or AS muscles from Smn-/-;SMN2 mice. A,B – Representative confocal 
micrographs of AAL muscles from a P1 control littermate (A) and Smn-/-;SMN2 (B) 
mouse, labelled with antibodies against 150kDa neurofilaments (green) and TRITC-α-
bungarotoxin (red), illustrating the type of images used for the quantification of axonal 
inputs. C – Bar chart showing no significant difference in the number of inputs per 
endplate in either the AAL or AS muscles between P1 Smn-/-;SMN2 (-/-; white bars) 
and litter mate controls (+/+; Black bars).  (mean ± SEM; ANOVA; ns - non significant; 
N=10/9 per control AAL/AS muscle; N=9/7 per Smn-/-;SMN2 AAL/AS muscle;  Scale 
bar = 30µm (A,B)). 
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There was again, high variability in the levels of both small and ‘super’ terminal sprouts 
but over all there was no difference between genotypes in either muscle.  Although there 
was no significant difference in the level of sprouting between the AS or AAL muscle 
(Figure 4.16; 4.17), there did appear to be subtle differences in sprout morphology.  
Sprouts in the AAL muscle generally appear fine and minimally branched, while those 
in the AS muscle commonly contained spherical neurofilament accumulations and an 
increase in branching (Figure 4.16; 4.17).  As these differences in morphology were 
present in both Smn-/-;SMN2 mice and littermates controls, it is unlikely that they are a 
result of or contributor to pathology, however these observations do raise the possibility 
that these sprouts are dynamically distinct (see discussion).   
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Figure 4.16:  There is no difference in the number of small sprouts in either AAL or 
AS muscles P1 Smn-/-;SMN2 mice.  A – confocal micrographs of neuromuscular 
preparations (green = 150kDa neurofilaments, red = TRITC-α-bungarotoxin) showing the 
presence neuronal sprouts present in AAL and AS muscles in both litter mate controls 
and Smn-/-;SMN2 mice. B - Bar chart showing the number of sprouts per endplate in 
AAL and AS muscles from control (+/+; black bars) and Smn-/-;SMN2 (-/-; white bars) 
mice. (mean ± SEM; ANOVA; ns non significant. N=8/6 per control AAL/AS muscle; 
N=8/9 per Smn-/-;SMN2 AAL/AS muscle. Scale bar = 30µm(A)). 
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Figure 4.17:  There is no difference in the number of super sprouts in either AAL 
or AS muscles P1 Smn-/-;SMN2 mice.  A,B – montaged confocal micrographs of 
neuromuscular preparations (150kDa neurofilaments (green) and TRITC-α-
bungarotoxin (red)) showing the presence large super sprouts in both AAL (A) and AS 
(B) muscles in Smn-/-;SMN2 mice.  (C) Bar chart showing the number of super sprouts 
per endplate in AAL and AS muscles in control (+/+; black bars) and Smn-/-;SMN2 (-/-; 
white bars) mice. (mean ± SEM; ANOVA; ns non significant; N=8/6 per control AAL/AS 
muscle; N=8/9 per Smn-/-;SMN2 AAL/AS muscle. Scale bar = 20µm (A,B)).  
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Again, no difference was observed in endplate area or maturation in either AAL or AS 
muscle compared to littermate controls, although interestingly, more advanced endplate 
maturation was observed in the less vulnerable AAL muscle compared to the AS muscle 
(Figure 4.18).  This is in contrast to increased maturation being present in the more 
vulnerable caudal band of the LAL muscle.  This result implies that while there are 
different time courses of endplate maturation in distinct muscles/muscle bands, it is 
unlikely to be a direct contributor to pathology. 
 
This data therefore indicates that, at pre-symptomatic time points, development of lower 
motor neuron connectivity in differentially vulnerable fast and slow twitch muscles 
fibres proceeds normally.   These findings are therefore in agreement with results from 
the LAL muscle, suggesting that abnormal neuromuscular development cannot account 
for neuromuscular pathology in SMA. 
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Figure 4.18: There is no difference in post synaptic area of maturation in 
either the AS or AAL muscle Smn-/-;SMN2 mice. A - Box and whisker plot 
showing no change in the distribution of endplate areas between control (+/+; black 
boxes) and Smn-/-;SMN2 (-/-; white boxes) mice in either AAL or AS muscles 
(ANOVA;  P>0.05 for all comparisons, N=10/9 per control AAL/AS muscle; N=9/7 
per Smn-/-;SMN2 AAL/AS muscle).  B -Bar chart (mean ± SEM) showing the 
percentage of endplates which were categorised uniform (black bars), folded (grey 
bars) and perforated (white bars) in AAL or AS muscles from Smn-/-;SMN2 (-/-) 
mice compared to control littermates (+/+). (Kruskal-Wallis test; P>0.05; N=8/6 per 
control AAL/AS muscle; N=8/9 per Smn-/-;SMN2 AAL/AS muscle.) 
 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
96 
4.2.6 Minimal alterations in developmental gene expression at pre-symptomatic time-
points in mouse models of SMA 
The experiments detailed above indicate that lower motor neurons develop normally 
until the onset of degenerative symptoms in SMA mice. Although there was no evidence 
of abnormal pre-symptomatic morphological development in the neuromuscular system, 
it remained possible that developmental changes at the level of gene expression could 
impact on lower motor neuron vulnerability without modifying morphology.  To 
investigate this possibility, gene expression analyses was undertaken in pre-symptomatic 
(P1) Smn-/-;SMN2 mouse spinal cord compared to control littermates (Smn+/+;SMN2; 
N=4 mice per genotype, littermate matched). Affymetrix Mouse Exon ST arrays (see 
methods) were used to identify any genes showing more than 1.5 fold changes in 
expression levels.  Out of 16,755 genes examined at P1, only 3 were significantly 
changed i.e >1.5 fold (Table 4.1). The largest change observed was in expression levels 
of Smn, providing an internal control for the sensitivity of the experiment.  The other 
two genes identified fell close to the margin of the 1.5 fold cut off (1.6 fold down 
regulation and 1.7 fold up-regulation; Table 4.1) but to date neither are considered 
important for development of the neuromuscular system. Equivalent microarray analysis 
was performed in a collaboration with colleagues in Oxford on the Smn-/-;SMN2;Δ7 
mouse model of SMA.  Results implied that there were again minimal changes in gene 
expression in pre-symptomatic time points, with only small magnitude changes observed 
in a small number of genes (Table 4.2).  
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Table 4.1: Gene expression changes >1.5 fold in pre-symptomatic (P1) Smn-/-
;SMN2 mouse spinal cord compared to litter-mate controls. 
Gene Title Gene Symbol Fold change Regulation 
survival motor neuron 1 Smn1 2.7 down 
olfactory receptor 1288 Olfr1288 1.6 down 
developmental pluripotency associated 5A Dppa5a 1.7 up 
 
 
Table 4.2: Gene expression changes >1.5 fold in pre-symptomatic (P1) Smn-/-
;SMN2;Δ7 mouse spinal cord compared to litter-mate controls.  
Gene Title Gene Symbol Fold change Regulation 
survival motor neuron 1 Smn1 3.4 down 
histone cluster 1, H1c Hist1h1c 1.8 up 
histone cluster 1, H2bc et al Hist1h2bc  1.8 up 
glycoprotein 49 A /// leukocyte immunoglobulin-
like receptor, subfamily B, member 4 
Gp49a /// 
Lilrb4 1.8 up 
olfactory receptor 1393 /// olfactory receptor 
1392 
Olfr1393 /// 
Olfr1392 1.6 down 
laminin, alpha 2 Lama2 1.6 up 
olfactory receptor 978 Olfr978 1.6 down 
kallikrein 1-related peptidase b21 et al Klk1b21  1.6 up 
polymerase (RNA) II (DNA directed) polypeptide 
H Polr2h 1.6 down 




k 1.5 down 
Adrenomedullin Adm 1.5 down 
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4.3 Discussion 
The data presented in this chapter have generated two important findings. Firstly, 
reduced Smn expression does not significantly modify pre-symptomatic development of 
lower motor neuron morphology and connectivity in vivo. Abnormal pre-symptomatic 
development is therefore not a pre-requisite for subsequent lower motor neuron 
vulnerability in SMA. Secondly, lower motor neurons and their neuromuscular synaptic 
connections have no pre-existing abnormalities when degenerative changes and 
symptoms begin to occur. This suggests that there is a “therapeutic time-window” which 
extends into the postnatal period for many motor units. Significantly, during this period 
the neuromuscular system may be in a state amenable to rescue. This study therefore 
highlights a need to focus on the role of Smn protein in maintaining the neuromuscular 
system once formed, rather than its role in regulating motor neuron outgrowth and 
axonogenesis, for understanding SMA pathogenesis. 
 
The data suggest that the developmental effects of reduced Smn levels reported in vitro 
as well as in zebra fish and Xenopus models in vivo (Fan and Simmard, 2002; 
McWhorter et al., 2003, Rossoll et al., 2003; Shafey et al., 2008; Ymlahi-Ouazzani et 
al., 2009) are not mirrored in mammalian SMA models in vivo. Whilst it remains 
possible that Smn protein can influence developmental pathways including axon 
outgrowth and path-finding under some experimental conditions, the data presented here 
demonstrate that such changes are not sufficient to cause defects in motor neuron 
development in mouse models in vivo and are not a major contributing factor to SMA 
pathogenesis.  As a result, efforts to understand the role of Smn protein in the triggering 
and progression of SMA pathology would likely be better served by focussing on events 
occurring during and around the onset of motor neuron degeneration and symptom 
onset. The data also suggest that modifier genes which influence disease severity in 
SMA, such as plastin 3 (Oprea et al., 2008), are more likely to work through stabilising 
the neuromuscular system (e.g. by modifying actin dynamics) rather than by influencing 
pre-symptomatic developmental pathways such as axonogenesis (c.f. Oprea et al., 2008). 
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Whilst development of lower motor neuron connectivity is unlikely to be a contributor to 
pathology in SMA, this study has not investigated the contribution of muscle 
development.  Studies which employ human muscle cell cultures have reported that 
myoblast fusion into myotubes can be significantly delayed in cells from SMA type I 
patients and that ACh receptor clustering in response to agrin was reduced (Guettier-
Sigrist 2001; Arnold et al., 2004).  Analysis of human embryonic muscle development 
also revealed changes which are consistent with abnormal muscle growth and 
development (Martínez-Hernández et al., 2009). These studies together suggest that 
there may be intrinsic abnormalities in muscle development which may have profound 
influences on early NMJ formation.  Further studies into the contribution of muscle 
development to pathology in SMA are therefore required. 
 
4.3.1 Morphological discrepancies between distinct muscles/muscle regions 
While pre-symptomatic development of lower motor neurons was not modified by 
SMA, some subtle differences between neuromuscular development of the rostral and 
caudal bands of the LAL, and between the AS and AAL muscles were observed. The 
finding that endplate maturation was occurring faster in the caudal band of the LAL 
muscle is in agreement with previous findings that motor units in this muscle band 
belong to the developmentally more advanced fast-synapsing (‘FaSyn’) subtype (Pun et 
al., 2002; chapter 3).  Whilst this may indicate that increased maturation is linked to 
increased vulnerability, advanced endplate maturation was also seen in the relatively 
non-vulnerable AAL muscle compared to the less mature endplates in the vulnerable AS 
muscle.  These results indicate that the rate of endplate maturation does not impact upon 
motor unit vulnerability in SMA.  This is in contrast to recent published findings 
suggesting that increasing endplate maturation by exercise stabilises the NMJ and 
confers neuroprotection (Biondi et al.,  2008).  In light of the findings presented here, it 
may be appropriate to revise these conclusions to state that, while exercise can clearly be 
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neuroprotective, endplate maturation is likely to be a by-product of the exercise regime 
and is not likely to have a direct effect on lower motor neuron vulnerability.  
 
The results also indicated that, while there was overall no significant change in the level 
of sprouting between Smn-/-;SMN2 mice and control littermates, there was a tendency 
for increased numbers of ‘super sprouts’ in more affected muscles/muscle bands (i.e. 
caudal band of the LAL and AS muscle) compared to neighbouring more stable regions.  
While this is unlikely to be a pathological event as it is also seen in control littermates, it 
may indicate increased demands upon these motor neurons and increase their 
vulnerability.  There was also subtle differences in sprout morphology between the AS 
and AAL muscles. The consequence of these morphological discrepancies is currently 
unclear although it possibly reflects differences in the dynamic status of the sprouts.  
Without performing real-time imaging of sprout morphology, it is not possible to discern 
whether these sprouts are actively growing, stable or undergoing retraction.  These 
processes could have significant impacts upon the energy demands of the motor unit and 
developmental status of the motor unit.   
 
4.3.2 Minimal gene expression changes in pre-symptomatic SMA mice 
One remarkable finding of this study was that pre-symptomatic analyses of lower motor 
neuron gene expression failed to identify any major changes in either mouse model prior 
to symptom onset.  This is true even in the severe mouse model of SMA where the 
disease kills the animals by P5-P6. Although no gross changes in gene expression were 
identified, these results must be interpreted with caution as the analysis performed does 
not account for genes in which a high degree of variability caused them to be discounted 
from the results. It is also important to remember that this analysis is on whole spinal 
cord, not just motor neurons, let alone selectively vulnerable populations.  Such 
experiments would not be practically possible in such severe mouse models at such 
young ages. Despite these caveats, should there have been a disruption in the normal 
development of lower motor neurons at pre-symptomatic time points, it might be 
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reasonable to expect to observe a degree of change in gene expression.  The minimal 
changes observed here are further emphasised when results are compared to the wide 
spread gene expression changes occurring at end-stage time points (see chapter 5). 
 
Together with the morphological data, these results highlight the rapid progression of 
neuromuscular breakdown that can occur as a result of reduced Smn levels, but also 
gives great encouragement for the development of post-natally delivered treatments for 
SMA in human patients.  Had there been evidence for disrupted pre-symptomatic 
development of lower motor neurons, leading to subsequent neuronal vulnerability, it 
would be difficult to envisage how this could be fully remedied by post-natal treatment 
options alone. By contrast, the results suggest the existence of a pre-symptomatic 
therapeutic time window in which lower motor neurons and neuromuscular synaptic 
connections remain intact, extending into post-natal days even in a mouse model of 
severe SMA where death occurs by P5-P6. This work therefore provides encouragement 
for current efforts to treat SMA post-natally, using strategies such as increasing Smn 
levels in the nervous system (Azzouz et al., 2004; Foust et al., 2009) or increasing full-
length splicing from the preserved SMN2 gene (Lim and Hertel, 2001; Madocsai et al., 
2005; Baughan et al., 2006; Avila  et al., 2007; Coady et al., 2007; Ting et al., 2007; 
Hua et al., 2008; Baughan et al.,  2009). 
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Further to results suggesting that there are minimal changes in gene expression prior to 
symptom onset, I have investigated what cellular pathways are mis-regulated during 
disease progression in SMA. Microarray analysis has been performed on spinal cord 
from P5 Smn-/-;SMN2 and P14 Smn-/-;SMN2;∆7 mice and compared gene expression 
levels to littermate controls. 
 
Results detailed in this chapter show that: 
 
1. A large number genes are altered in end-stage SMA mice highlighting the 
minimal extent of changes observed at pre-symptomatic time points 
2. Pathways involved in growth factor signalling and extracellular matrix integrity 
are altered in end-stage SMA mice. 
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5.1 Introduction 
In this study, I have thus far demonstrated that neuromuscular pathology is a progressive 
event in SMA, with synaptic loss being apparent early in the disease time course.  I have 
further shown that abnormalities in pre-symptomatic lower motor neuron connectivity 
do not underlie neuromuscular pathology and that at pre-symptomatic time points there 
are minimal changes in gene expression in the spinal cord.  This result is somewhat 
striking, indicating that the neuromuscular system remains physically and functionally 
intact up to P1, at which point an unidentified trigger causes rapid and progressive 
neural muscular pathology causing death within 4 days in the Smn-/-;SMN2 model.  This 
work therefore leads to the question: what cellular and molecular pathways are 
responsible for the initiation and progression of neuromuscular breakdown?  
 
To begin to address this question, high stringency microarray analysis has been 
performed on spinal cord tissue from end-stage (P5) Smn-/-;SMN2 mice.  This analysis 
identified a large number of genes which show altered expression in end-stage Smn-/-
;SMN2 mice, further emphasising the minimal changes observed at P1.  Use of GO-Elite 
MAPPFinder software for pathways analysis revealed significant alterations in pathways 
implicated  in growth factor signalling and extracellular matrix integrity.   
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5.2 Results 
5.2.1 Significant changes in gene expression were present in late-symptomatic Smn-/-
;SMN2 mice  
In an attempt to gain insights into the pathways controlling pathological progression in 
SMA, microarray expression analysis was applied to late-symptomatic (P5) spinal cord 
from Smn-/-;SMN2 mice (N=4 mice per genotype, littermate matched).  Of the 16,755 
individual genes investigated, 160 were significantly changed greater than 1.5 fold 
(Table 5.1). The biggest single change was found for a gene in the myelination pathway, 
where there was a significant 6.5 fold decrease in expression of myelin protein zero. 
 
These results were in stark contrast to the P1 results (a 53 fold increase in the number of 
changed genes), underlining the minimal changes seen pre-symptomatically (see chapter 
4). A comparison of P1 and P5 data also clearly underlined the scale and rapid 
progression of pathological changes that occur in the neuromuscular system in this 
severe model of SMA.  
 
5.2.2 Pathway mapping software implicates pathways involved in cell extracellular 
matrix integrity and growth factor signalling in SMA pathology 
Utilisation of GO-Elite MAPPFinder software to further investigate the potential 
function of genes shown to have modified expression levels identified 35 different 
cellular pathways which were modified in late-symptomatic (P5) Smn-/-;SMN2 spinal 
cord (Table 5.2). This in silico analysis highlighted changes in pathways relating to 
extracellular matrix integrity (shown in blue) and growth factor signalling (shown in 
green) in SMA pathology. Equivalent microarray analysis has been performed 
collaboratively with colleagues in Oxford, on the Smn-/-;SMN2;∆7 mouse model 
(Baumer et al.,  under review).   Results from the Smn-/-;SMN2;∆7 mouse model reveal 
a very similar pattern of gene expression changes, with very few changes pre-
symptomatically (11 genes statistically altered) and large numbers of changes at end-
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stage time points (142 genes statistically altered).  Equivalent G0 pathway analysis on 
microarray results from P14 Smn-/-;SMN2;∆7 spinal cord revealed that gene changes did 
not coincide with known cellular pathways to the extent observed in Smn-/-;SMN2 
mice, but again pathways involved in growth factor signalling were highlighted (Table 
5.3).    
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Table 5.1: Gene expression changes >1.5 fold in late-symptomatic (P5) Smn-/-
;SMN2 mouse spinal cord compared to litter-mate controls. 
Gene Title Gene Symbol 
Fold 
change Regulation 
myelin protein zero Mpz 6.5 down 
decorin Dcn 4.2 down 
microfibrillar-associated protein 4 Mfap4 3.8 down 
peripheral myelin protein 22 Pmp22 3.7 down 
osteoglycin Ogn 3.7 down 
periostin, osteoblast specific factor Postn 3.6 down 
lumican Lum 3.5 down 
survival motor neuron 1 Smn1 3.5 down 
prostaglandin D2 synthase (brain) Ptgds 3.4 down 
collagen, type III, alpha 1 Col3a1 3.0 down 
collagen, type I, alpha 1 Col1a1 2.9 down 
histocompatibility 2, et al H2-T22  2.7 down 
procollagen C-endopeptidase enhancer protein Pcolce 2.7 down 
ATP-binding cassette, sub-family A (ABC1), member 8a Abca8a 2.6 down 
thrombomodulin Thbd 2.5 down 
fibronectin 1 Fn1 2.5 down 
reticulocalbin 3, EF-hand calcium binding domain Rcn3 2.4 down 
dipeptidylpeptidase 4 Dpp4 2.3 down 
collagen, type I, alpha 2 Col1a2 2.3 down 
asporin Aspn 2.3 down 
immunoglobulin superfamily containing leucine-rich repeat Islr 2.3 down 
dermatopontin Dpt 2.2 down 
solute carrier family 6 (neurotransmitter transporter, GABA), 
member 13 Slc6a13 2.2 down 
serine (or cysteine) peptidase inhibitor, clade G, member 1 Serping1 2.2 down 
collagen, type XII, alpha 1 Col12a1 2.2 down 
gap junction protein, beta 2 Gjb2 2.2 down 
cadherin 5 Cdh5 2.2 down 
nidogen 2 Nid2 2.1 down 
AE binding protein 1 Aebp1 2.1 down 
Rho GTPase activating protein 19 Arhgap19 2.1 down 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 11 Slc7a11 2.1 down 
histone cluster 1, H2bb Hist1h2bb 2.1 down 
solute carrier family 13 (sodium/sulfate symporters), member 4 Slc13a4 2.1 down 
vesicle-associated membrane protein 5 Vamp5 2.0 down 
vitronectin Vtn 2.0 down 
insulin-like growth factor 2 Igf2 2.0 down 
serine (or cysteine) peptidase inhibitor, clade D, member 1 Serpind1 2.0 down 
CD93 antigen Cd93 2.0 down 
laminin, alpha 2 Lama2 2.0 down 
family with sequence similarity 107, member A Fam107a 1.9 up 
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Agt 1.9 up 
lymphatic vessel endothelial hyaluronan receptor 1 Lyve1 1.9 down 
disabled homolog 2 (Drosophila) Dab2 1.9 down 
epithelial membrane protein 3 Emp3 1.9 down 
mannose receptor, C type 1 Mrc1 1.9 down 
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H19 fetal liver mRNA H19 1.9 down 
transforming growth factor, beta induced Tgfbi 1.9 down 
solute carrier family 38, member 5 Slc38a5 1.9 down 
proteoglycan 4 (megakaryocyte stimulating factor, articular 
superficial zone protein) Prg4 1.9 down 
alcohol dehydrogenase 1 (class I) Adh1 1.9 down 
laminin B1 subunit 1 Lamb1-1 1.9 down 
peptidylprolyl isomerase C Ppic 1.9 down 
endothelial-specific receptor tyrosine kinase Tek 1.9 down 
folate hydrolase Folh1 1.8 up 
RIKEN cDNA 2810417H13 gene 
2810417H13
Rik 1.8 down 
crystallin, alpha B Cryab 1.8 down 
nephroblastoma overexpressed gene Nov 1.8 down 
forkhead box C2 Foxc2 1.8 down 
laminin, alpha 4 Lama4 1.8 down 
collagen, type VI, alpha 3 Col6a3 1.8 down 
insulin-like growth factor binding protein 4 Igfbp4 1.8 down 
metallothionein 2 Mt2 1.8 up 
follistatin-like 1 Fstl1 1.8 down 
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) Cdkn2c 1.8 down 
microfibrillar associated protein 5 Mfap5 1.8 down 
fibulin 5 Fbln5 1.8 down 
apolipoprotein D Apod 1.8 down 
integrin, beta-like 1 Itgbl1 1.8 down 
angiopoietin-like 2 Angptl2 1.8 down 
periaxin Prx 1.7 down 
discoidin domain receptor family, member 2 Ddr2 1.7 down 
insulin-like growth factor binding protein 6 Igfbp6 1.7 down 
coagulation factor XIII, A1 subunit F13a1 1.7 down 
histone cluster 1, H1b Hist1h1b 1.7 down 
aldehyde dehydrogenase family 1, subfamily A1 Aldh1a1 1.7 down 
actin, alpha 2, smooth muscle, aorta Acta2 1.7 down 
coatomer protein complex, subunit zeta 2 Copz2 1.7 down 
EF hand domain containing 1 Efhd1 1.7 down 
collagen, type VI, alpha 2 Col6a2 1.7 down 
aldehyde dehydrogenase family 1, subfamily A2 Aldh1a2 1.7 down 
Nik related kinase Nrk 1.7 down 
bone morphogenetic protein 5 Bmp5 1.7 down 
fibrillin 1 Fbn1 1.7 down 
leptin receptor Lepr 1.7 down 
inter-alpha trypsin inhibitor, heavy chain 2 Itih2 1.7 down 
monooxygenase, DBH-like 1 Moxd1 1.7 down 
collagen, type VI, alpha 1 Col6a1 1.7 down 
histone cluster 1, H2ac Hist1h2ac 1.7 up 
integral membrane protein 2A Itm2a 1.7 down 
G protein-coupled receptor 182 Gpr182 1.7 down 
palmitoyl-protein thioesterase 1 Ppt1 1.7 up 
collagen, type XV, alpha 1 Col15a1 1.7 down 
annexin A2 Anxa2 1.6 down 
acyl-CoA thioesterase 11 Acot11 1.6 up 
zinc finger protein 458 /// zinc finger protein 457 Zfp458 /// 1.6 down 
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Zfp457 
pleckstrin homology-like domain, family B, member 2 /// 
phosphatidylinositol-specific phospholipase C, X domain 
containing 2 
Phldb2 /// 
Plcxd2 1.6 down 
collectin sub-family member 12 Colec12 1.6 down 
lipopolysaccharide binding protein Lbp 1.6 down 
cathepsin H Ctsh 1.6 down 
Friend leukemia integration 1 Fli1 1.6 down 
solute carrier family 22 (organic anion transporter), member 8 Slc22a8 1.6 down 
apelin receptor Aplnr 1.6 down 
platelet factor 4 Pf4 1.6 down 
carbonic anhydrase 13 Car13 1.6 down 
Rho GTPase activating protein 29 Arhgap29 1.6 down 
EH-domain containing 2 Ehd2 1.6 down 
small nuclear ribonucleoprotein polypeptide A' Snrpa1 1.6 up 
glypican 3 Gpc3 1.6 down 
RIKEN cDNA 2310046A06 gene 
2310046A06
Rik 1.6 down 
RAN binding protein 3-like Ranbp3l 1.6 down 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) Erbb3 1.6 down 
biglycan Bgn 1.6 down 
calponin 2 Cnn2 1.6 down 
inter-alpha (globulin) inhibitor H5 Itih5 1.6 down 
ATP-binding cassette, sub-family A (ABC1), member 9 Abca9 1.6 down 
cellular retinoic acid binding protein II Crabp2 1.6 down 
RIKEN cDNA 1110032E23 gene 
1110032E23
Rik 1.6 down 
claudin 5 Cldn5 1.6 down 
cysteine-rich protein 1 (intestinal) Crip1 1.6 down 
ASF1 anti-silencing function 1 homolog B (S. cerevisiae) Asf1b 1.6 down 
thrombospondin 2 Thbs2 1.6 down 
gliomedin Gldn 1.6 down 
tubulin, beta 6 Tubb6 1.6 down 
glycophorin C Gypc 1.6 down 
chemokine (C-C motif) ligand 11 Ccl11 1.6 down 
olfactomedin-like 3 Olfml3 1.6 down 
EGF-like domain 8 Egfl8 1.6 down 
SET domain containing (lysine methyltransferase) 8 Setd8 1.6 down 
early growth response 2 Egr2 1.6 down 
sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3B Sema3b 1.6 down 
perlecan (heparan sulfate proteoglycan 2) Hspg2 1.6 down 
zinc finger protein 458 /// zinc finger protein 457 
Zfp458 /// 
Zfp457 1.6 up 
epidermal growth factor-containing fibulin-like extracellular matrix 
protein 1 Efemp1 1.6 down 
PDZ binding kinase Pbk 1.6 down 
cyclin B1 Ccnb1 1.6 down 
smoothelin Smtn 1.5 down 
elastin Eln 1.5 down 
odd-skipped related 1 (Drosophila) Osr1 1.5 down 
cell division cycle associated 7 Cdca7 1.5 down 
ubiquitin-like, containing PHD and RING finger domains, 1 Uhrf1 1.5 down 
ectodysplasin A2 isoform receptor Eda2r 1.5 up 
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histone cluster 1, H1a Hist1h1a 1.5 down 
phospholipid transfer protein Pltp 1.5 down 
HtrA serine peptidase 1 Htra1 1.5 up 
histocompatibility 2, K1, K region /// histocompatibility 2, Q region 
locus 2 /// histocompatibility 2, D region /// histocompatibility 2, D 




D1 1.5 up 
stabilin 1 Stab1 1.5 down 
cyclin A2 Ccna2 1.5 down 
src homology 2 domain-containing transforming protein C1 Shc1 1.5 down 
myelin and lymphocyte protein, T-cell differentiation protein Mal 1.5 down 
collagen, type V, alpha 2 Col5a2 1.5 down 
cadherin 1 Cdh1 1.5 down 
epithelial membrane protein 1 Emp1 1.5 down 
collagen, type X, alpha 1 Col10a1 1.5 down 
protein regulator of cytokinesis 1 Prc1 1.5 down 
Fc receptor, IgG, alpha chain transporter Fcgrt 1.5 down 
aldehyde dehydrogenase family 1, subfamily A7 Aldh1a7 1.5 down 
regulator of G-protein signaling 5 Rgs5 1.5 down 
phospholipase A2, group III Pla2g3 1.5 up 
alpha 1,4-galactosyltransferase A4galt 1.5 down 
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Table 5.2: Pathway analysis of late-symptomatic (P5) microarray results. 
















ute P Adjusted P 
≥3 genes changing & ≥50% genes changing p0.05 
43256 laminin complex 3 5 7 60 71 12.7 0 0 
48407 
platelet\-derived growth factor 
binding 4 8 9 50 89 13.3 0 0 
≥3 genes changing and 20-49% genes changing p0.05 
42573 retinoic acid metabolic process 4 10 11 40 91 11.8 0 0 
5605 basal lamina 3 8 11 38 73 9.9 0 0 
46332 SMAD binding 3 8 10 38 80 9.9 0 0 
6776 vitamin A metabolic process 5 15 18 33 83 12.0 0 0 
5201 
extracellular matrix structural 
constituent 7 24 24 29 100 13.2 0 0 
1523 retinoid metabolic process 3 11 14 27 79 8.3 0 0 
16101 diterpenoid metabolic process 3 11 14 27 79 8.3 0 0 
30199 collagen fibril organization 4 15 18 27 83 9.5 0 0 
6775 
fat\-soluble vitamin metabolic 
process 5 19 25 26 76 10.6 0 0 
6721 terpenoid metabolic process 3 13 18 23 72 7.6 0 0 
5520 insulin\-like growth factor binding 4 18 20 22 90 8.6 0 0 
5581 collagen 4 18 19 22 95 8.6 0 0 
44420 extracellular matrix part 13 59 71 22 83 15.5 0 0 
≥3 genes changing and 10-19% genes changing p0.05 
6022 aminoglycan metabolic process 3 17 20 18 85 6.6 0 0 
30203 
glycosaminoglycan metabolic 
process 3 17 20 18 85 6.6 0 0 
19838 growth factor binding 8 50 56 16 89 10.1 0 0 
5604 basement membrane 7 44 54 16 81 9.5 0 0 
6817 phosphate transport 11 70 80 16 88 11.8 0 0 
30198 
extracellular matrix organization 
and biogenesis 7 49 59 14 83 8.9 0 0 
16620 
oxidoreductase activity\, acting 
on the aldehyde or oxo group of 
donors\, NAD or NADP as 
acceptor 3 22 27 14 81 5.7 0.0005 0.0645 
5578 
proteinaceous extracellular 
matrix 31 234 267 13 88 18.0 0 0 
31012 extracellular matrix 31 238 271 13 88 17.8 0 0 
1871 pattern binding 10 79 93 13 85 9.9 0 0 
5539 glycosaminoglycan binding 9 72 79 13 91 9.3 0 0 
8201 heparin binding 7 56 62 13 90 8.2 0 0 
30247 polysaccharide binding 9 76 86 12 88 9.0 0 0 
6720 isoprenoid metabolic process 3 26 35 12 74 5.1 0.0035 0.2485 
6334 nucleosome assembly 4 36 94 11 38 5.8 0.0005 0.0645 
7160 cell\-matrix adhesion 8 75 85 11 88 8.0 0 0 
16903 
oxidoreductase activity\, acting 
on the aldehyde or oxo group of 
donors 3 30 36 10 83 4.7 0.0015 0.147 
7422 
peripheral nervous system 
development 3 30 34 10 88 4.7 0.002 0.176 
1656 metanephros development 4 41 51 10 80 5.3 0.0005 0.0645 
7596 blood coagulation 5 52 59 10 88 5.9 0.0005 0.0645 
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Table 5.3: Pathway analysis of late-symptomatic (P14) Smn-/-;SMN2;Δ7 
microarray results. 



















≥3 genes changing and >10% genes changing p0.05 





5520 insulin\-like growth factor binding 3 18 20 17 90 7 0 0 
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5.3 Discussion 
In this chapter I have shown that gene expression changes correlating with SMA 
pathology progress rapidly following the onset of symptoms and the results highlight the 
involvement of specific cellular pathways, namely extracellular matrix integrity, growth 
factor signalling and myelination pathways.   
 
The finding that pre-symptomatic developmental pathways do not play a role in SMA 
pathogenesis suggests that a focus on cellular and molecular pathways active around the 
time of disease onset and lower motor neuron breakdown will be required for a full 
understanding of the disease and for the identification of novel therapeutic targets. The 
late-symptomatic (P5) gene expression data presented in this study provide some initial 
insights into these pathways. Whilst, at this point it is not possible to dissect gene 
expression changes causing pathology from those resulting from pathological changes, 
the data suggest that extracellular matrix integrity, growth factor signalling and 
myelination pathways are all significantly modified in SMA.  
 
Although microarray data presented here represent the first attempt to understand gene 
expression changes in mouse models of severe SMA, equivalent analysis has been 
performed using a mouse model of a very mild form of the disease (Balabanian et al., 
2007).  Comparison of the individual expression changes in microarray analysis of the 
mild model of SMA (Smn+/-) reveal very little overlap with results detailed here - as 
might be expected given the differing nature of pathological changes between the two 
models.  Despite this, they did observe changes in the expression of genes associated 
with the extracellular matrix (Balabanian et al., 2007). It is therefore conceivable that 
therapeutic strategies designed to preserve and support the extracellular matrix (often 
referred to as peri-neuronal nets in the nervous system; Celio et al., 1998) may help to 
sustain lower motor neuron form and function by influencing factors such as the 
maintenance of cellular relationships and adhesion, the control of synaptic plasticity and 
neurotransmitter receptor localisation, and the concentration of growth factors around 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
113 
neurons (Celio et al., 1998; Frischknecht et al., 2009). Similarly, the finding that genes 
associated with growth factor signalling are dys-regulated in late-symptomatic SMA 
spinal cord suggests that lower motor neurons may be breaking down as a result of 
abnormal trophic signalling. Trophic factors have long been considered as potential 
therapeutic agents for SMA (Swoboda et al., 2007), but a comprehensive analysis of the 
effects of different growth factors on SMA pathology has yet to be undertaken. The 
identification of changes in retinoic acid metabolic processes is also of significant 
interest. A role for retinoic acid in neuronal patterning, differentiation and maintenance 
has been well established (for review see Maden, 2007).  Additional studies have 
suggested that a dietary deficiency of retinoids can cause motor neuron disease like 
symptoms in rats, and identified disruption in the retinoid signalling pathways in rat 
models of motor neuron disease and ALS patients (Corcoran et al., 2002; Jokic et al., 
2007).   
 
A common theme occurring within the microarray results is the potential for disruption 
of myelination pathways.  The largest change in expression was observed in the myelin 
protein P0. Over 50% of the genes involved in platelet derived growth factor binding 
were altered and such pathways have been implicated in oligodendrocyte recruitment in 
the CNS (Hinks and Franklin, 2000).  Furthermore,  significant alterations were seen in 
pathways involved in the laminin complex, which has been implicated in the process of 
myelination with decreased expression being associated with axon loss and congenital 
muscular dystrophies in humans  (Masaki et al., 2000; Masaki et al., 2003; Pegoraro et 
al., 1998).  Clearly such changes in myelination could be either causative or resultant of 
pathological events, but further work is clearly required to look at the myelin 
surrounding axons, perhaps by use of the electron microscope to visualise myelin 
integrity both within intramuscular nerves and ventral roots during the disease time 
course.  
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Chapter 6: Loss of eEF1A2 distinguishes dying-back neuropathy from Wallerian 




Results from chapter 3 have suggested that synaptic degeneration in SMA mouse models 
conformed to a dying-back type morphology, as observed in other models of motor 
neuron pathology.  This morphology is quite distinct to the rapid fragmentation observed 
in Wallerian degeneration occurring, for example, in response to traumatic injury. 
Despite clear morphological discrepancies, little is known about the convergence or 
divergence of mechanisms underlying morphologically distinct types of synaptic 
degeneration, for example Wallerian degeneration and dying-back neuropathy.  I have 
therefore used the wasted mouse model of neurodegeneration to further investigate the 
retraction process in a characteristic dying-back neuropathy, and have further observed 
that the progression of Wallerian degeneration is altered in the presence of an existing 
dying-back neuropathy. 
 
Results detailed in this chapter show that: 
1. In wasted mice, functional loss at the synapse precedes structural loss, therefore 
implying degeneration is a dying-back neuropathy.  
2. Synapse loss occurs asynchronously within a motor unit, therefore implying 
degeneration is a dying-back neuropathy. 
3. Wasted and Smn-/-;SMN2 mice are united by a shared reduction in ZPR1 levels. 
4. Axotomy induced Wallerian degeneration is significantly delayed in wasted 
mice, thus indicating that morphologically distinct types of degeneration are also 
mechanistically distinct. 
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6.1 Introduction 
Work thus far has indicated that neuromuscular junctions are pathological targets in 
SMA. This synaptic degeneration does not appear to be based on developmental 
abnormalities, suggesting degeneration is caused by activation of post-natal degenerative 
pathways.  Although microarray analysis has presented some putative pathways which 
may be involved in neuromuscular pathology in SMA, the precise mechanisms 
regulating synaptic degeneration are unclear.  
 
Morphologically, synaptic degeneration in SMA conforms to a dying-back neuropathy, 
with gradual proximal to distal retraction of the pre-synaptic terminal and an absence of 
widespread fragmentation (Chapter 3) and is quite distinct when compared to the rapid 
fragmentation observed in Wallerian degeneration (see introduction, section 1.6).  Such 
dying-back degenerative morphology is consistent with observations in other motor 
neuron disease models (Frey et al., 2000; Fischer et al., 2004), however it is not clear 
whether this shared morphology extends to reflect a commonality in degenerative 
mechanism.  Furthermore, despite these clear morphological differences between dying-
back and Wallerian degeneration processes, little is known about convergence or 
divergence of their underling molecular mechanisms (Coleman, 2005; Hoopfer et al., 
2006), although evidence has been presented suggesting that morphologically distinct 
degenerative pathways can share common mechanistic links (Coleman, 2005; Mi et al., 
2005). More detailed knowledge of the cellular events in morphologically distinct types 
of degeneration and the potential overlap in mechanistic pathways would therefore be of 
significant importance for our understanding of the healthy and pathological nervous 
system and may give insight into the degenerative mechanisms in SMA. 
 
Due to the early lethality in models of SMA their use as a model to investigate and 
compare degenerative mechanisms is somewhat limited.  For this reason, I now turn to a 
different model of neurodegeneration known as the wasted mouse.  The delayed onset of 
neurodegenerative events at around P14 in this mouse model allow investigation and 
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comparison of pathways controlling dying-back neuropathy and Wallerian degeneration 
while eliminating the contribution of developmental events. 
 
Wasted mice carry a spontaneous mutation in a gene encoding the translation elongation 
factor eEF1A2, which abolishes its expression (Shultz et al., 1982; Chambers et al., 
1998).  EEF1A (of which there are two variant forms; eEF1A1 and eEF1A2) is the 
second most abundant protein in the cell, constituting 1-2% of total protein and playing 
an integral role in the elongation stages of protein synthesis during which the 
polypeptide chain is assembled (Condeelis, 1995). Alongside important roles in protein 
synthesis, eEF1A proteins have also been postulated to play non-canonical roles in 
pathways including modification of the cytoskeleton (Condeelis, 1995), the heat shock 
response (Shamovsky et al., 2006) and synaptic plasticity (Giustetto et al., 2003). 
Expression patterns of the two variant forms (eEF1A1 and eEF1A2) are mutually 
exclusive in all cells and tissues examined. The eEF1A2 variant is only expressed in 
neuronal cells and muscle (Pan et al., 2004). However, eEF1A1 is expressed in nerve 
and muscle at the time of birth, where its expression declines from the first post-natal 
week onwards until it is absent by around post-natal day 20-21 (Pan et al., 2004). During 
this period of declining expression, the role of eEF1A1 is normally replaced by 
correlated increasing expression levels of eEF1A2 (Chambers et al., 1998), with the 
latter being the sole translation elongation factor in muscle and nerve by post-natal day 
21.  
 
It has previously been shown that loss of eEF1A2 results in the degeneration of lower 
motor neurons in wasted mice, characterised by vacuolation and neurofilament 
accumulation in neuronal soma and denervation of skeletal muscle fibres (Newbery et 
al., 2005). Importantly, the onset of degeneration correlates precisely with the switch to 
reliance on eEF1A2 expression (Newbery et al., 2005) and it has been conclusively 
demonstrated that the specific loss of eEF1A2 function is solely responsible for these 
events (Newbery et al., 2007). Recent work from the Gillingwater laboratory has 
indicated that synaptic degeneration in wasted mice conforms to a dying-back pathology 
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distinct from classic Wallerian degeneration (ultimately published in Murray et al, 
2008).  Pre-synaptic terminals underwent a gradual retraction from the post-synaptic 
endplate with no apparent fragmentation of pre-synaptic or axonal compartments.  This 
morphology shares striking similarities with synaptic degeneration in SMA mouse 
models (see chapter 3).  Furthermore, ultrastructural studies in wasted mice revealed 
synaptic degeneration occurred in advance of overt axonal pathology and retracting 
terminals were devoid of structural fragmentation and organelle depletion.   
 
In this chapter I further detail the pathological changes occurring at the neuromuscular 
junction in wasted mice and use them to investigate the mechanistic commonality or 
divergence between Wallerian degeneration and dying-back neuropathy. Firstly, I have 
shown that functional loss at the NMJ precedes structural loss in wasted mice and that 
degeneration occurs asynchronously within motor units. Such changes confirm that 
neurodegeneration in wasted mice conforms to a characteristic dying-back neuropathy.  
Secondly, I have used quantitative protein expression experiments to show that dying-
back pathology in wasted and SMA mouse models share a common reduction in ZPR1 
levels, presenting a common mechanistic link between SMA and wasted pathology. 
Thirdly, I have used nerve axotomy experiments to show that Wallerian degeneration of 
distal axons and synaptic terminals in wasted mice is delayed, with synapses remaining 
up to 48 hours post nerve injury and retaining functional ability.  This demonstrates that 
eEF1A2 is required for the normal initiation and progression of Wallerian degeneration 
pathways and suggest that divergent mechanism are responsible for the instigation 
and/or progression of Wallerian degeneration and dying-back neuropathies. 
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6.2 Results 
6.2.1 Dying-back pathology was evident in the LAL muscle and shows mild correlation 
to axonal length   
Previous reports have identified synaptic pathology in wasted mice in the TVA and deep 
lumbrical muscles (Newbery et al., 2005).  I extended these observations to include the 
LAL in which there was significant NMJ loss (Figure 6.1). Closer examination of the 
distinct endplate regions within rostral and caudal bands of the LAL muscle, revealed no 
selective vulnerability betweens NMJs in the caudal and rostral band (Figure 6.1 B).  
This is in contrast to the selective vulnerability seen in SMA mouse models (see chapter 
3), suggesting this selective vulnerability of the LAL caudal band is a feature unique to 
SMA pathology. There was a slight reduction in pathology in the C1 region of the 
muscle (as evidenced by an increase in partially occupied endplates with a 
corresponding decrease in vacant endplates). This may indicate that NMJs closer to the 
point of nerve entry into the muscle are more vulnerable.  I therefore sought to 
determine whether axon length had an impact upon the vulnerability of an NMJ.   
Wasted YFP-H mice (in which only a small subset of motor neurons are labelled with 
YFP allowing reconstruction of single motor units) were therefore used to assess of the 
degree of denervation at a given NMJ with the length of the intramuscular axon.  This 
revealed a weak correlation, indicating that an increase in axon length is associated with 
increased vulnerability of a NMJ (Figure 6.1 C).  For this analysis, any endplate that is 
completely denervated cannot be included and as there is an increased number of vacant 
endplates in regions further from the point of nerve entry into the muscle, this 
correlation may be even stronger than suggested by this data.  
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Figure 6.1: Synaptic pathology in the LAL muscle is equivalent in caudal and 
rostral bands but shows modest correlation to axonal length. A – Confocal 
micrographs showing neuromuscular junctions in immunohistochemically labelled 
LAL muscle preparations from P25 wasted mice (green = 150kDa neurofilaments; 
red = post-synaptic acetylcholine receptors labelled with TRITC-α-bungarotoxin). 
Partially occupied (white arrowhead) and vacant (white arrow) endplates were 
present throughout the muscle groups, as previously observed in TVA and lumbrical 
muscles (Figure 1; Newbery et al., 2005) (Scale bars = 10µm). B – Bar chart 
showing the percentage of fully occupied, partially occupied and vacant endplates in 
LAL muscles from wasted mice at P25 in LAL regions C1,C2, R1-2 and R3-5 
(mean±SEM; Kruksal Wallis test; all non significant by except for % vacant C1 vs 
R3-5 where P<0.05; N=4 mice,). Note that there is no selective vulnerability of the 
caudal band compared to the rostral band.   C – Scatter plot showing a modest 
correlation between the degree an endplate is innervated and the distance from the 
point of nerve entry (P<0.05, r2 = 0.05970).  
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6.2.2 Functional loss at the NMJ precedes structural loss 
Previous reports of characteristic dying-back neuropathies indicate that functional loss at 
the synapse precedes structural loss (Balice-Gordon et al., 2000; Pun et al., 2006).  
Synaptic fuction was therefore investigated in wasted mice to investigate whether this 
feature of a dying-back neuropathy was also present in wasted mice. 
 
Interestingly, prior work from the Gillingwater laboratory has identified an accumulation 
of synaptic vesicles at the NMJ in wasted mice (ultimately published in Murray et al., 
2008) and such an increase in synaptic vesicle numbers may imply altered synaptic 
function. Pre-synaptic function at the NMJ in late-symptomatic (P25) homozygous 
wasted;YFP-H mice was examined.  The styrl dye FM4-64 was applied in high 
potassium ringer solution allowing the labelling of functionally active NMJs (see 
methods). Wasted;YFP-H mice allowed us to examine synaptic function at 
morphologically intact motor nerve terminals, indicated by the presence of YFP label 
(Feng et al., 2000; see below). While, as expected, all motor nerve terminals showed 
uptake of FM4-64 in wild-type littermate mice, large numbers of morphologically 
present motor nerve terminals in wasted mice showed no FM4-64 uptake (Figure 6.2). 
These data suggest that despite the presence of large numbers of synaptic vesicles in 
motor nerve terminals, the functional machinery required for exocytosis/endocytosis was 
impaired as part of the dying-back process in wasted mice. Thus, functional loss 
preceded morphological retraction, and degeneration in wasted mice is consistent with 
previous reports for other dying-back neuropathies.   
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Figure 6.2: Functional loss precedes structural loss at neuromuscular junctions undergoing 
dying-back pathology in wasted mice. Confocal micrographs (merge of all 3 channels in top panels 
with separate channels shown below) of neuromuscular junctions from a P25 YFP-H and 
wasted;YFP-H mouse LAL muscle. Motor nerve terminals were loaded with FM4-64FX using a 
depolarising high-potassium solution leading to the selective labelling of functionally-active terminals 
(i.e. with the retained ability to recycle synaptic vesicles). In control YFP-H muscles (left) FM4-64 
labelled all nerve terminals. In the wastedYFP-H preparation shown (right), two neuromuscular 
junctions with motor nerve terminals containing YFP can be seen, but only one of these motor nerve 
terminals demonstrated retained functional ability (red arrow; note the presence of strong FM4-64FX 
label in the bottom panel). The junction indicated by the white arrow was present morphologically (as 
evidenced by the YFP label) but had lost its functional capacity to recycle synaptic vesicles and hence 
had not taken up the FM4-64FX label. Thus, synaptic function was lost before morphological 
retraction occurred in wasted mice. (Scale bar = 20µm (YFP-H), 10µm (wastedYFP-H)). 
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6.2.3 Synapse loss occurs asynchronously within single motor units in wasted mice 
The pattern of synaptic loss within a motor unit can give important information about 
the factors regulating degeneration.  For example, synchronous loss within a motor unit, 
where all NMJs in a given motor unit degenerate, with all NMJs in a neighbouring 
motor unit remaining intact, might imply that pathogenic mechanisms are mediated from 
the cell body. Conversely, if degeneration within the motor unit is asynchronous, where 
some NMJs from a motor unit degenerate while other remain intact, then it is likely that 
local factors regulate synaptic vulnerability.  
 
To investigate the synchronicity of synapse loss within motor units, the patterns of 
synaptic pathology occurring within single YFP-labelled motor units of wasted;YFP-H 
mice (Feng et al., 2000) have been examined. Synaptic cohorts of single motor units 
supplying 5 different LAL muscles from late-symptomatic wasted;YFP-H mice were 
reconstructed and analysed (Figure 6.3).  Branching diagrams produced by tracing 
individual, labelled motor units revealed a homogenous response, with all motor neurons 
seemingly affected to a similar level (i.e. all motor units exhibited clear evidence of 
synaptic pathology; Figure 6.4). Moreover, each motor unit displayed a wide range of 
synaptic morphologies, including intact synapses (fully occupied) and synapses at 
various stages of dismantling (partially occupied). Comparison of the innervation states 
of neighbouring synapses, sharing a single branch point, showed that synapses were 
being lost progressively and asynchronously in wasted mice. This finding indicates that 
local mechanisms, resident at individual synapses, are likely to play an important role in 
determining an individual synapse’s response to the effects of a loss of eEF1A2.  This 
finding is consistent with results from other dying-back neuropathies (Gillingwater and 
Ribchester, 2003) which are characterised by a progressive asynchronous loss of nerve 
terminals and is in contrast to Wallerian degeneration, which is known to bring about a 
relatively synchronous and rapid (i.e. within several hours) degeneration of NMJs 
(Miledi and Slater, 1970).  The above results therefore further support the hypothesis 
that degeneration in wasted mice conforms to a highly characteristic dying-back 
neuropathy.  
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Figure 6.3: Reconstruction of individual YFP-H motor units reveals 
asynchronous loss of synapses at the NMJ in late-symptomatic wasted mice. A 
– Montage of confocal micrographs showing a single YFP-H labelled motor unit from 
a P25 wasted;YFP-H mouse (green = YFP; blue = post-synaptic acetylcholine 
receptors labelled with α-bungarotoxin). B – Higher power confocal micrograph 
showing a small region of the larger whole motor unit shown in A (position indicated 
by black arrow in A). Note how the first (far left) NMJ is fully occupied, the second 
(lower right) NMJ is partially occupied and the third (upper right) NMJ has lost its pre-
synaptic input, remnants of which are left as a retraction bulb. (Scale bars = 500µm 
(A), 50µm (B)). 
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Figure 6.4: Branch diagrams confirm asynchronous loss of synapses at the NMJ in late-
symptomatic wasted mice. Branch diagrams generated from an analysis of the single motor 
units (i.e. See figure 4), with each individual NMJ represented as a circle relative to its branch 
point position within the motor unit. The occupancy status of each NMJ is represented by the 
colour of the circle (key to colours is at bottom left). Note how synaptic retraction occurred 
asynchronously throughout the motor units, with a full spread of occupancies present. Note 
also how fully occupied (i.e. ‘normal’; red) NMJs were distributed at locations throughout the 
motor units, as were almost fully retracted NMJs (blue). NMJs represented by a question mark 
indicate a point at which it was not possible to trace the motor unit branch any further. 
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6.2.4 Molecular correlates of dying-back neuropathy: A role for ZPR1? 
The degenerative morphology in wasted mice shares striking similarities with 
degeneration in SMA mouse models, with both models displaying characteristic features 
of dying-back neuropathy.  Despite this, the extent to which there is mechanistic 
commonality between SMA and wasted mice is currently unclear. A potential link is 
created by the observation that eEF1A and Smn proteins both assemble into complexes 
with the zinc finger protein ZPR1, which has also been implicated in motor neuron 
pathology (Gangwani et al., 1998; Mishra et al., 2007).  
 
To test whether the dying-back pathology in wasted mice could simply be accounted for 
by reduced levels of Smn protein resulting from decreased eEF1A2 expression, Smn 
protein levels were quantified in the spinal cord of late-symptomatic wasted mice (P25) 
and littermate controls using fluorescent (Li-COR) western blots. Smn levels remained 
relatively stable in homozygous wasted mice, and if anything showed a trend towards 
increased rather than decreased expression levels (Figure 6.5). This was in stark contrast 
to the significant reduction in Smn levels observed in the spinal cord of late-
symptomatic Smn-/-;SMN2 mice.  Thus, the dying-back pathology observed in wasted 
mice could not be simply attributed to downstream changes in Smn protein levels. 
 
Next, a similar question was posed, but this time focussing on levels of ZPR1 protein 
expression. Interestingly, ZPR1 protein levels were found to be consistently reduced in 
wasted mice (Figure 6.5).  Equivalent analysis in Smn-/-;SMN2 mice revealed ZPR1 
levels were reduced to similar levels (Figure 6.5). As reduced ZPR1 levels have been 
previously been suggested to contribute to dying-back pathology in SMA (Gangwani et 
al., 2001; Helmken et al., 2003) a comparable reduction in wasted mice may provide 
evidence for a common regulatory role of ZPR1 in regulating dying-back pathways in 
both wasted and Smn-/-;SMN2 mice.  
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Figure 6.5: Dying-back pathology in wasted mice occurs independently of changes in Smn 
protein expression but correlates with modest reductions in ZPR1 protein levels. A - Bar 
chart (mean±SEM; upper panel) showing expression levels of Smn and ZPR1 protein in the 
mid-thoracic spinal cord of late-symptomatic wasted (Wst; left bars; P25) and Smn-/-;SMN2 
(right bars; P5) mice compared to respective control littermate mice, quantified using 
fluorescent western blots (N = 3 mice per genotype). B - Representative fluorescent western 
blots showing levels of Smn and ZPR1 protein in wasted (Wst) mice versus control littermates 
(left panel) and Smn-/-;SMN2 mice versus control littermates (right panel). Smn protein levels 
did not decrease in wasted mice (if anything showing a modest increase in expression), but as 
expected decreased by around 75% in Smn-/-;SMN2 mice. Thus, dying-back pathology 
observed in wasted mice is not simply occurring due to reduced levels of Smn protein. ZPR1 
protein levels, however, were reduced by comparable amounts in both wasted and Smn-/-
;SMN2 mice. (mean ± SEM;data reflect changes normalised to control littermate values, 
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6.2.5 eEF1A2 is required for the normal initiation and progression of axotomy-induced 
Wallerian degeneration  
If, as suggested, Wallerian degeneration and dying-back neuropathy are regulated by 
common mechanisms (Coleman et al., 2005), then one might expect Wallerian 
degeneration to be accelerated in neurons already undergoing a dying-back neuropathy. 
As results to date provide strong evidence that eEF1A2 is an important regulator of 
dying-back pathways in vivo, the progression of Wallerian degeneration in wasted mice 
was investigated by studying responses to nerve injury in homozygous wasted, 
heterozygous wasted and wild-type littermate mice. For these experiments lumbrical 
muscles were examined following a tibial nerve cut, as synaptic pathology resulting 
from dying-back pathology is significantly less in these muscles compared to more 
rostral muscle groups (Newbery et al., 2005), thus minimising the complexity of 
distinguishing disease-induced changes from those induced by nerve injury. Late-
symptomatic (P24) wasted and wasted;YFP-H mice were subjected to a unilateral tibial 
nerve cut under general anaesthesia. 24 hours later (P25), following recovery and 
resumption of normal behaviour, mice were sacrificed and their lumbrical muscles and 
tibial nerves distal to the site of lesion removed.  
 
As expected, nerve lesion in wild-type littermate mice resulted in a complete loss of 
neuromuscular innervation 24 hours after surgery, occurring via classical Wallerian 
degeneration pathways characterised by rapid breakdown and fragmentation of pre-
synaptic motor nerve terminals and distal axons (Figure 6.6 A). Surprisingly, however, 
the vast majority (~80%) of motor nerve terminals and their intramuscular axon 
collaterals remained intact in lumbrical muscles from homozygous wasted mice 24 hours 
after nerve lesion (Figure 6.6 B,C). Similarly, the tibial nerve distal to the site of nerve 
lesion showed no signs of degeneration in homozygous wasted mice assayed using YFP-
H and ultrastructural techniques (Figure 6.7). Examination of early axonal ultrastructural 
indicators of Wallerian degeneration (swelling and damage of mitochondria; Miledi & 
Slater, 1970; Winlow & Usherwood, 1975) revealed subtle but widespread changes in 
wild-type nerves (~50% of axons examined showed mitochondrial changes or disruption 
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of the myelin sheath; Figure 6.7 B), but almost complete absence of any early markers of 
Wallerian degeneration in wasted nerves (only one out of ~200 axons showed signs of 
disrupted mitochondria; Figure 6.7 C).   
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Figure 6.6: eEF1a2 expression is required for the normal initiation and progression of 
axotomy-induced synaptic WD. A,B – Confocal micrographs showing NMJs in 
immunohistochemically labelled lumbrical muscle preparations from P25 wild-type (+/+; A), 
homozygous wasted (-/-; B) mice 24 hours after a tibial nerve cut (green = 150kDa neurofilaments; 
red = post-synaptic acetylcholine receptors). As expected, axotomy resulted in almost complete WD 
of motor nerve terminals and distal axon collaterals in lumbrical muscles of wild-type mice (A). 
Surprisingly, however, axotomy-induced WD was almost completely absent from homozygous 
wasted mice at the same time-point (B). C – Bar chart showing the percentage of NMJs remaining in 
lumbrical muscles 24 hours post-axotomy. Note how less than 5% of NMJs remain intact in muscles 
from wild-type mice, whereas ~80% of NMJs remained intact in muscles from homozygous wasted 
mice. (mean±SEM; Kruskal Wallis test with Dun’s post hoc; *** P<0.001; n=57 muscles, N=19 mice 
+/+; n=36 muscles, N=12 mice +/-; n=36 muscles, N=12 mice -/-; Scale bar = 50µm (A,B)). 
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Figure 6.7: eEF1a2 expression is required for the normal initiation and progression of 
axotomy-induced axonal Wallerian degeneration. A – Montage of fluorescence micrographs 
showing YFP-labelled axons in a tibial nerve (supplying the lumbrical muscles) from a P25 
wasted;YFP-H mouse 24 hours after a tibial nerve cut. Note the complete absence of any axonal 
pathology at this time-point. B – Electron micrograph showing early ultrastructural signs of WD in +/+ 
tibial nerves 24 hours after axotomy (swollen and disrupted mitochondria; red arrows). C - Electron 
micrograph showing lack of early ultrastructural signs of WD in -/- tibial nerves 24 hours after 
axotomy (mitochondria remained intact; red arrows). (Scale bars = 200µm (A), 2µm (B,C)) 
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To investigate whether structurally preserved NMJs were also functional, 
electrophysiological recordings were made from flexor digitorum brevis (FDB) muscles 
from both operated and un-operated legs of wasted and wild-type mice.  FDB muscles 
are also innervated by the tibial nerve and show significant structural protection 24 hours 
after nerve cut in wasted mice, albeit at a lower level than that observed in lumbrical 
muscles (Figure 6.8).  While in wild-type muscles 24 hours after nerve cut, no endplates 
show any evoked or spontaneous activity endplate potential in response to a nerve 
stimulus, significant functional protection was observed in wasted mice, with around 
50% of NMJs showing spontaneous transmitter release and/or evoked activity (Figure 
6.9; 6.10).  
  
Figure 6.8: Significant delay in synaptic degeneration 24 hours after nerve cut in 
flexor digitorum brevis muscles. Bar chart showing percentage of fully occupied 
endplates in wild-type and wasted FDB muscles in un-operated control legs, and legs 24 
hours after tibial nerve cut.  Note NMJ protection still occurs in this muscle, albeit at a 
slightly lower level than in lumbrical muscles. (Mean ± SEM; Mann Whitney test; ***P<0.001; 
N = 2/3 per mouse, 6/9 per muscle  wild-type/wasted) 
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Figure 6.9: Synaptic function is retained in wasted NMJs 24 hours post 
nerve cut. A-D – example electrophysiological traces showing evoked response 
from nerve stimulation in flexor digitorum brevis muscles from wild-type (A,B) and 
wasted (C,D) mice from both operated  (B,D) and control contralateral (A,C) legs .  
Note  muscles from un-operated control legs (A,C) show robust endplate 
potentials in response to nerve stimulation while no response is seen in wild-type 
operated legs 24 hours post-nerve cut (B).  Muscles from wasted operated legs 
show endplate potentials in response to nerve stimulation (D) implying functional 
activity is retained 24 hours after nerve transection. 
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Figure 6.10: Synaptic function is retained in wasted NMJs 24 hours post nerve cut. A,B - 
Bar charts (mean ± SEM) showing the percentage of endplates in the FDB muscle showing 
spontaneous (B) and evoked (C) activity in wildtype (black bars) and wasted mice (white bars) in 
control un-operated legs and legs 24 hours following tibial nerve cut. Note an increase in the 
percentage of endplates showing evoked and spontaneous activity in muscles from operated 
legs in wasted mice compared to wild-type.  (Kruskal Wallis test with Dunns multiple comparison, 
ns non significant. N = 2/3 per mouse, 6/9 per muscle muscle wildtype/wasted) 
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In order to confirm that the significant inhibition in Wallerian degeneration found in 
homozygous wasted mice extended beyond the 24 hour period initially examined, 
synaptic degeneration was quantified morphologically in mice subjected to a unilateral 
tibial nerve cut at P23 that were sacrificed 48 hours later (P25). Even at 48 hours post-
axotomy, around 50% of motor nerve terminals and their intramuscular axon collaterals 
remained intact in lumbrical muscles from homozygous wasted mice (Figure 6.11). As 
at 24 hours, almost all motor nerve terminals (>95%) had undergone degeneration in 
wild-type and heterozygous littermates. It was not possible to extend the time-course of 
investigations much beyond this 48 hour period because the operated mice do not live 
beyond P26 (due to the severity of dying-back pathological changes in more severely 
affected rostral muscle groups).   
 
The experiments detailed above demonstrate that eEF1A2 is required for the normal 
initiation and progression of Wallerian degeneration. These data also add further support 
to the conclusion that the dying-back pathways instigated following disruption of 
eEF1A2 in wasted mice are mechanistically distinct from Wallerian degeneration, as 
Wallerian degeneration pathways are actually inhibited (rather than initiated) in wasted 
mice. 
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6.2.6 Is the delay in Wallerian degeneration due to a requirement for eEF1A2 or the 
instigation of dying-back pathways? 
In order to investigate whether this protection is a result of a requirement of eEF1A2 
during Wallerian degeneration, or due to the instigation of dying-back pathways, tibial 
nerve cuts were performed in wasted mice at P16, prior to the onset of any 
neuromuscular pathology.  Interestingly, although significant synaptic protection was 
observed in wasted mice, equivalent protection was evident in wild-type and 
heterozygote mice (Figure 6.12).  Although it was previously reported that Wallerian 
degeneration progresses quite differently in neonatal mice, with proximal degeneration 
being more apparent and distal degeneration being inhibited, it is perhaps not 
Figure 6.11: Wallerian degeneration remains significantly delayed 48 hours after 
nerve cut.  Bar chart showing the percentage of NMJs remaining in lumbrical muscles 
from wild-type and homozygous wasted mice 24 and 48 hours post-axotomy 
(mean±SEM; Unpaired students T-test between WT and wasted at 48hr; ** P<0.01  n=57 
muscles, N=19 mice wildtype 24hrs; n=36 muscles, N=12 mice wasted 24 hrs; n=6 
muscles, N=2 mice wildtype and wasted 48 hrs; N numbers are insufficient for statistical 
analysis). Note how ~50% of NMJs remained intact in muscles from homozygous wasted 
mice even at 48 hours post-axotomy. 
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appreciated that this phenomenon continues to this time point.  Although this finding 
prevents us from further addressing the original question, it does provide a potential 
explanation for the protection seen in wasted mice i.e. if a lack of eEF1A2 impairs 
neuromuscular development and the system retains an immature phenotype, normal 
adult progression of Wallerian degeneration could be significantly altered.  This finding 
may be consistent with the preliminary observation that an increase in temperature 
and/or exercise ameliorated wasted pathology and reduced the observed protection from 
Wallerian degeneration (Appendix 10.2).  This theory undoubtedly requires further 
investigation. 
 
During this study I also made some interesting observations about the progression of 
Wallerian degeneration in motor neurons labelled with YFP, indicating that either 
presence of the protein or genetic background may have modifying effects on the time 
course of NMJ breakdown in response to nerve axotomy (Appendix 10.3).  This finding 
clearly has important implications for the use of fluorescent markers to label cell types 
and again clearly warrant further investigation. 
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Figure 6.12: Preservation of neuromuscular 
junctions 24hrs post-nerve cut in wildtype, 
heterozygous and homozygous wasted P17/P18 
mice.    A-C  - Confocal micrographs of 
immunocytochemically labelled lumbrical muscles from 
P18 wildtype (A), wasted heterozygote (B) and wasted 
(C) mice 24 hours following tibial nerve cut (green = 
150KDa neurofilaments; red = post-synaptic 
acetylcholine receptors). Note all neuromuscular 
junctions in all genotypes remain fully innervated.  (Scale 
bar = 30µm) 
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The results presented in this chapter firstly support the hypothesis that degeneration in 
wasted mice conforms to highly characteristic dying-back neuropathy.  Significant NMJ 
pathology can be identified in the LAL muscle, where a mild correlation between 
synaptic vulnerability and axonal length was observed. Functional loss preceded 
structural loss and synapse loss was asynchronous, which is consistent with previous 
report from other dying-back neuropathies (Balice-Gordon et al., 2000; Pun et al., 
2006). Secondly I show that there may be a common molecular linkage between SMA 
and wasted mice, through the mutual down-regulation of ZPR1.  This finding may 
prompt further study into the pathways acting downstream of eEF1A2 and SMN and 
their regulation in a variety of neurodegenerative conditions. Thirdly, the experiments 
show that significant divergence exists in the mechanisms regulating degenerative 
pathways in axons and synapses, where dying-back pathology can be caused by 
deficiencies in eEF1A2 whereas Wallerian degeneration requires eEF1A2 expression. 
This finding contradicts, to some extent, an emerging view that many axonal and 
synaptic degenerative pathways converge onto common underlying mechanisms (c.f. 
Coleman, 2005; Kielar et al., 2009). The observation that eEF1A2 expression is required 
for the normal initiation and progression of Wallerian degeneration also adds significant 
support to previous experimental studies suggesting that Wallerian degeneration is an 
active, genetically-regulated process, rather than a simple passive consequence of 
disconnection from the parent cell body (Mack et al., 2001; Coleman and Perry, 2002). 
 
6.3.1 Can deficiencies in protein synthesis explain the neurodegenerative phenotype in 
wasted mice? 
The most parsimonious explanation for the observed dying-back pathology in wasted 
mice is that defects in protein synthesis, resulting directly from a loss of eEF1A2 
expression and function, are responsible for triggering dying-back pathways and for the 
delay in Wallerian degeneration. The fact that deficiencies in eEF1A proteins lead to 
disruption of protein synthesis is not in doubt (Shultz et al., 1982; Chambers et al., 1998; 
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Pan et al., 2004). Moreover, the protein synthesis machinery is known to influence 
axonal and synaptic form and function in neuronal cells (Piper and Holt, 2004; 
Grossman et al., 2006; McCann et al., 2007) and eEF1A is known to be important for 
local protein synthesis determining synaptic stability and function (Giusetto et al., 
2003).  This also provides mechanistic links to SMA, as the main documented function 
of Smn is in pre-mRNA slicing, a crucial step in protein translation (Burghes and 
Beattie, 2009).  However, whilst inhibition of protein synthesis has been shown to 
accelerate neurodegeneration of axons and synapses in vitro (Stavisky et al., 2003), the 
influence of protein synthesis on neurodegenerative mechanisms resident in axons and 
synapses in vivo remains unclear.  
 
It is not currently possible to directly visualise or measure de novo protein synthesis 
occurring in distal axonal and/or neuromuscular synaptic compartments of wasted mice 
in vivo with any accuracy, ruling out the possibility of definitively linking the induction 
of dying-back pathways to deficiencies in protein synthesis. Similarly, the current data 
do not allow us to directly link the inhibition of Wallerian degeneration with deficiencies 
in local protein synthesis. However, wasted mice are likely to provide an ideal model 
system within which to further investigate downstream molecular mechanisms, once 
more sensitive techniques to measure local neuronal protein synthesis become available. 
Its attractiveness as an experimental model is highlighted by the fact that eEF1A2 
deficiencies are restricted to neuronal cells and muscle and are only instigated post-
natally before progressing over a fairly rapid time-course. 
 
6.3.2 Could non-canonical roles of eEF1A2 be responsible for the neurodegenerative 
phenotype in wasted mice? 
Alternative hypotheses explaining the potential mechanisms underlying modifications in 
dying-back pathways and Wallerian degeneration in wasted mice can be raised in light 
of other known non-canonical functions of eEF1A proteins. For example, several studies 
have implicated eEF1A proteins in assembly and stability of the cytoskeleton, including 
roles in actin binding and microtubule severing (Yang et al., 1990; Yang et al., 1993; 
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Shiina et al., 1994). It is possible, therefore, that the dying-back pathways instigated in 
wasted mice occur as a direct result of perturbations in stability of the axonal and 
synaptic cytoskeleton. Moreover, a loss of ability to transport factors down the distal 
axon resulting from cytoskeletal disruption may explain the inhibition of Wallerian 
degeneration pathways. If the latter were found to be true, it would provide experimental 
support for the hypothesis that Wallerian degeneration is triggered by a signal that 
passes from the site of injury down to the nerve terminal (Miledi and Slater, 1970). 
Alternatively, it is possible that perturbations in synaptic plasticity pathways, known to 
be modulated by eEF1A levels (Giustetto et al., 2003), lead to destabilisation of the NMJ 
and induction of dying-back pathology. However, it should be noted that it has yet to be 
demonstrated that the eEF1A2 variant has the same non-canonical roles previously 
attributed to non variant-specific eEF1A protein. It therefore also remains possible that 
eEF1A2 has as yet unidentified roles that are responsible for the phenotypes described in 
the current study. 
 
It should also be noted that it is by no means certain that the same down-stream effects 
resulting from loss of eEF1A2 in wasted mice are responsible for the dual effects on 
dying-back pathways and Wallerian degeneration pathways. Further mechanistic 
experiments are required to distinguish the specific characteristics or molecular targets 
of eEF1A2 required to prevent a dying-back neuropathy and/or inhibit the initiation and 
progression of Wallerian degeneration. 
 
6.3.3 Potential implications for the stability and vulnerability of lower motor neurons in 
human motor neuron disease  
As highlighted above, although eEF1A2 mutations are not currently thought to be 
directly responsible for any human neurodegenerative conditions, eEF1A proteins are 
known to assemble into complexes with Smn and ZPR1 (Gangwani et al., 1998; Mishra 
et al., 2007). The finding that dying-back pathology occurring in wasted mice closely 
resembles lower motor neuron pathology occurring in mouse models of SMA and in 
ZPR1-deficient mice (Monani et al., 2000; Monani et al., 2003; Doran et al., 2006) 
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prompted us to examine whether the pathways modified by loss of eEF1A2 converged 
onto those involving Smn and ZPR1. Results suggest that dying-back pathology in 
wasted mice can not be attributed to corresponding reductions in Smn protein levels, 
showing that dying-back pathology in wasted and Smn-/-;SMN2 mice are not triggered 
by the same molecular cues. However, the observation that ZPR1 protein levels were 
modestly reduced in wasted mice, to a similar level found in Smn-/-;SMN2 mice, raises 
the possibility of shared mechanistic pathways focussed around ZPR1. As decreasing 
ZPR1 levels have been shown to correlate with disease severity in SMA patients 
(Helmken et al., 2003) and ZPR1 is known to be required for the normal maintenance 
and localisation of Smn protein (Gangwani et al., 2001), it is tempting to speculate that 
ZPR1 is capable of playing an important role in regulating lower motor neuron 
vulnerability in SMA and in wasted mice. Further investigations into the expression and 
function of ZPR1 in wasted and Smn-/-;SMN2 mice may therefore provide novel insights 
into cellular and molecular cascades regulating the vulnerability of motor neurons in 
SMA. Moreover, as the current data suggest that eEF1A2 is required to prevent pre-
synaptic degeneration via a dying-back neuropathy, it may also be worth investigating 
the possibility of increasing levels of eEF1A2, on its own or in combination with ZPR1, 
as a potential neuroprotective strategy in dying-back neuropathies, such as SMA. 
 
The finding that distinct rostral and caudal bands of the LAL muscle showed comparable 
levels of synaptic pathology in wasted mice is in contrast to observation in SMA mouse 
models and has potential implications for our understanding of the selective 
vulnerability of motor neuron pools and neuromuscular synapses in SMA. As similar 
selective vulnerability does not occur in wasted mice, it seems reasonable to conclude 
that the selective vulnerability observed in SMA mouse models occurs as a direct 
response to mutations in the SMN gene, rather than a more generic neurodegenerative 
stimulus. These findings also suggest that, whilst there may be potential linkages 
between eEF1A2 and proteins modulating dying-back pathology in SMA (i.e. ZPR1), 
the selective vulnerability of motor neurons and NMJ sub-types observed in SMA mice 
must be occurring via mechanisms distinct from eEF1A2.  
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In addition to using models of neurodegeneration, it is also possible to gain insight into 
mechanisms which regulate synaptic vulnerability by analysis of models of 
neuroprotection. In this chapter, I have utilised quantitative fluorescent western blotting 
to investigate whether proteomic changes occurring in tissue expressing the 
neuroprotective Wlds gene which protects axons and synapses can also be observed in 
Smn-/-;SMN2 mice. I also describe attempts to cross Smn-/-;SMN2 mice with Wlds mice 
to investigate any potential phenotypic rescue. Due to practical issues and time 
constraints, the results presented within this chapter are not intended to represent a 
complete or conclusive story, but rather reflect a ‘proof of principle’ study detailing 
work in progress. 
 
Results detailed in this chapter show that: 
1. Proteomic changes identified in Wlds mice were observed to occur in an opposite 
direction in Smn-/-;SMN2 mice and could potentially be used to identify 
important regulators of synaptic vulnerability 
2. This approach can be used to identify novel biomarkers which can act as 
indicators of the pathological status of an individual/tissue 
3. In Smn-/-;SMN2 mice with one copy of Wlds, no protection was observed, with 
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7.1 Introduction. 
Work presented so far has revealed that NMJs are early and significant targets in SMA 
and has demonstrated that abnormal development of neural connectivity is unlikely to 
underlie pathology.  While microarray analysis has hinted at some pathways which may 
be involved in the degenerative processes, the mechanisms regulating synaptic 
pathology in SMA are broadly unknown. A better understanding of the mechanisms 
regulating synaptic vulnerability will therefore be important for our understanding of 
disease pathogenesis and are likely to be key in the development of effective therapeutic 
approaches.  
 
In order to better understand the mechanisms which regulate synaptic stability, much 
work to date has been focused on the Wlds mutation.  This spontaneous mutation 
produced a novel 373 amino acid protein, termed Wallerian Degeneration Slow, or Wlds, 
and confers significant synaptic and axonal protection in response to a range of 
traumatic and pathological insults (Lunn et al., 1989; Perry et al., 1990; Glass et al., 
1993; Mack et al., 2001; Ferri et al., 2003; Samsam et al., 2003; Gillingwater et al., 
2006).  Intriguingly, the Wlds mutation does not have an influence on the process of 
developmental synapse elimination (Parson et al., 1997; Hoopfer et al., 2006) thus 
providing an in vivo tool to separate two mechanistically distinct types of synapse loss.  
Synaptic and axonal protection appears to be proportional to Wlds protein expression 
levels i.e. while significant axonal and synaptic protection is observed in homozygote 
animals, heterozygote animals only show axonal protection (Mack et al., 2001; Wong et 
al., 2009).  
 
The Wlds mutation is of clear interest due to its potential clinical application and 
mechanistic insight.  Wlds  mice have now been crossed to a range of neurodegenerative 
models including models of motor neuron diseases, with varying degrees of protection 
observed (Ferri et al., 2003; Samsam et al., 2003; Vande-Velde et al., 2004; Fischer et 
al., 2005; Mi et al., 2005; Hasbani and O’Malley, 2006; Beirowski et al., 2008; Gultner 
et al., 2009).    In SMA research, crossing Wlds mice with the Smn;SMN2;Δ7 model 
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revealed no change in motor phenotype or life span (Kariya et al., 2009; Rose et al., 
2009). However, as resultant mice were only heterozygous for the Wlds gene and 
homozygosity is required for synaptic protection, these studies does not conclusively 
demonstrate whether or not the Wlds mutation can confer protection in SMA mice.  
 
Although the precise mechanisms underlying the Wlds phenotype are currently 
controversial, several in vivo and in vitro proteomic and genomic screens have 
highlighted a number of genes and proteins which show altered expression in the 
presence of the Wlds mutation and may therefore be important regulators of synaptic 
status (Gillingwater et al., 2006b; Wishart et al., 2007b; Wishart et al., 2008).  
Furthermore, some of these expression changes have been observed to occur in an 
opposite direction in mouse models of Batten disease (an autosomal recessive childhood 
neurodegenerative disorder), and these changes occurred in proportion to the levels of 
pathology present (Kielar et al., 2009).  This work implies that the Wlds mouse model 
can be used to identify proteins which are differentially regulated in models of 
neurodegeneration.  This approach could potentially provide mechanistic insights into 
cell death pathways in axons and synapses and identify candidate biomarkers which may 
be used to assess pathological status and disease progression. 
 
In this chapter I have investigated whether mechanisms regulating synaptic and axonal 
protection in Wlds mice can offer any insight into pathological mechanisms in SMA.  
Due to practical issues and time constraints, the results presented here are not intended 
to represent a complete or conclusive story, but rather reflect a ‘proof of principle’ 
study, where this hypothesis driven approach can give insight into mechanisms 
regulating neuronal vulnerability in SMA.  I have firstly used quantitative western blots 
to assess levels of proteins altered in Wlds and have identified a number of proteins 
which are also altered in SMA.  I have also investigated whether any of these proteins 
can be used as potential biomarkers for SMA disease progression.  I finally attempt to 
cross Wlds mice with Smn-/-;SMN2 mice to investigate whether Wlds can confer any 
neuroprotection and  modify disease phenotype.  While this work is ongoing and 
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consequently currently incomplete, preliminary results imply that this approach can give 
mechanistic insight into the pathological processes in SMA and potentially yield novel 
biomarkers to measure disease progression.   
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7.2 Results 
7.2.1 Candidate proteins altered in Wlds are also differentially regulated in SMA 
Previous work using 2D gel electrophoresis to perform proteomic screens on synaptic 
compartments of Wlds striatal neurons has identified a number of candidate proteins 
which may act to regulate synaptic vulnerability (Wishart et al., 2007b). I therefore 
sought to determine whether any of these proteins were also differentially regulated in 
tissue from SMA mice.  As it is currently not technically viable to investigate protein 
expression in synaptic compartments of lower motor neurons, quantitative western 
blotting was used to investigate protein expression levels in whole spinal cord from P1 
(pre-symptomatic) and P5 (end-stage) Smn-/-;SMN2 mice compared to littermate 
controls (for quantification methodology see Appendix 10.4). A neuronal specific 
loading control (β-Tubulin) was included to ensure results were not due to the decreased 
proportion of neural cells, especially at the end-stage time point. Of the 8 proteins 
initially investigated, which have been identified as those which show some of the 
greatest changes in Wlds, apparent changes in levels compared to littermate controls 
were observed in 6 proteins (UBE1, DRP2, βSNAP, VDAC1, GDI, STI; Figure 7.1).   In 
5 of the 6 proteins a progressive increase in the magnitude of the change was observed 
from P1 to P5.  This therefore indicates that these proteins are strong candidates for 
indicators of pathological status in SMA.   
 
Of the proteins investigated, UBE1, βSNAP, VDAC1 and DRP2 were of particular 
interest as significant changes were observed to occur in the opposite direction to those 
in Wlds i.e. down regulated in SMA and up-regulated in Wlds (UBE1, βSNAP, DRP2), 
or up regulated in SMA and down regulated in Wlds (VDAC1; Figure 7.2).  This further 
indicates that these proteins could be involved in pathways regulating neuronal survival.  
Furthermore these proteins could potentially act as makers for altered neuronal 
vulnerability, and quantification of their levels could act as a ‘read-out’ for the 
pathological status of the neuromuscular system.  
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Figure 7.1: Protein level changes observed in P1 and P5 Smn-/-;SMN2 spinal cord.  
Bar chart showing the average percentage change in protein levels compared to control 
littermates as assessed by quantitative western blotting on proteins from whole spinal 
cord from P1 mice (grey bars) and P5 mice (black bars).  (mean ± SEM;data reflect 
changes normalised to control littermate values, Student unpaired T test for each 
column compared to control; *P<0.01 Smn-/-;SMN2 compared to Smn+/+;SMN2 litter 
mate controls, all other changes were not statisitically significant; N=5/4 (UBE1), 3/5 
(DRP2; βSNAP; cABL; BRCA2), 4/5 (VDAC1;GDI), 4/4 (STI1) per P1/P5 mouse  
respectively). 
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Figure 7.2: Protein changes  in Smn-/-;SMN2 spinal cord which occur in an 
opposite direction to that seen in Wlds synaptosomes. Bar chart showing the 
average percentage change in protein levels in Wlds striatal synaptosomes (black 
bars; Data courtesy of S Meridith and T Wishart) compared to protein from whole 
spinal cord from Smn-/-;SMN2 mice at P1 (grey bars) and  P5 (white bars). (mean ± 
SEM; data reflect changes normalised to control littermate values, Student unpaired T 
test for each column compared to control; * P<0.05, ** P<0.01, ***P<0.001 Wlds/Smn-
/-SMN2 mouse compared to control littermates. Non-annotated bars were not 
statistically significant; N=12/5/4 (UBE1), 9/3/5 (DRP2; βSNAP), 12/4/5 (VDAC1) per 
Wlds/P1/P5 mouse  respectively). 
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7.2.2 Identification of potential biomarkers for outcome measures in SMA 
The identification of novel proteins which are altered in SMA tissue in a manner that is 
proportional to the pathological status of the individual and/or tissue would be a great 
value to SMA research.  Such proteins could be used as biomarkers to indicate disease 
progression and be used as an outcome measure in clinical trials.  As a number of 
proteins have been identified which are altered in SMA tissue, I investigated whether 
any of these proteins might posses the profiles required of suitable biomarkers, such as 
relevant changes in clinically accessible material, minimal inter-individual variability 
and progressive changes associated with pathological status. 
 
Firstly, I have investigated whether the changes observed in the spinal cord, are also 
apparent in other tissues. For this analysis, proteins which have either shown high 
magnitude (VDAC1) or highly consistent (βSNAP, DRP2) changes in the spinal cord 
were chosen.  Quantitative western blots for these proteins in muscle and skin samples 
show that similar changes in protein levels for VDAC1, βSNAP and DRP2 in both 
tissues can be detected and the direction of these changes correlates well with what was 
observed in spinal cord (Figure 7.3).  The magnitude of change of protein level observed 
in VDAC1, βSNAP and DRP2 in skin samples was observed to increase from P1 to P5.  
This finding suggests that protein levels are associated with pathological status.    
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For clinical application, protein biomarkers would be measured over time and protein 
levels compared to previous levels observed within the individual. As the approach used 
here relies upon comparing protein levels between Smn-/-;SMN2 mice to littermates, one 
might expect that variability in this system will be higher than when levels are compared 
Figure 7.3: Protein changes observed in spinal cord  are also observed in 
muscle and skin from Smn-/-;SMN2 mice.  A – Bar chart showing percentage 
change in levels of VDAC1, βSNAP and DRP2 protein from spinal cord from P1 
(black bars) and P5 (white bars) Smn-/-;SMN2 mice.  B,C – Bar chart showing 
equivalent protein analysis in total protein extracted from the transversus abdominis 
muscle (B) and skin sample (C).  D - Example images from western blots used for 
quantification of levels of VDAC1, βSNAP and DRP2.  Tubulin (spinal cord) or 
βactin (muscle,skin) was included as a loading control.   Note how changes in 
protein expression observed in spinal cord are also observed in muscle and skin.  
(mean ±SEM, N = 4/5 (VDAC1); 3/5 (DRP2; βSNAP), per P1/P5 mouse  
respectively (A); 2/3 (VDAC1; βSNAP) per P1/P5 mouse  respectively (B); 4/2 
(VDAC1); 3/2 (βSNAP); 2/2 (DRP2), per P1/P5 mouse  respectively (C)). 
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at different time points within the same individual.  Despite this, an appropriate 
biomarker should show relatively consistent changes between individuals, with at least 
the direction of the change being reliable.  Comparison of the changes observed in 
VDAC1 reveals substantial variability in both magnitude and direction between 
individuals (Figure 7.4).  This was apparent at both P1 and P5, in both the TVA muscle 
and skin sample.  Equivalent analysis of βSNAP revealed that although there was 
significant variability in the magnitude of observed changes, particularly in skin 
samples, the direction of the change was consistent (Figure 7.5).  Furthermore, in the 
TVA, the changes appeared of greater magnitude at P5 compared to P1. Results 
therefore suggest that while VDAC1 appears to be subject to high fluctuation and 
therefore may not be appropriate for use as a biomarker, β-SNAP may be a good 
potential candidate for further study.  
 
Figure 7.4: Highly variable 
changes in VDAC1 expression 
make it an inappropriate 
candidate biomarker.  A,B – Bar 
charts showing change in 
expression of VDAC1 in the TVA 
muscle (A) and skin sample (B) 
in individual mice compared to 
control litter mates at both P1 
(black bars) and P5 (white bars).  
Note the high degree of variability 
in relative levels of this protein in 
both magnitude and direction 
observed in both tissues and 
time-points (mean ± SEM; Data 
reflect 3 different scan intensity 
settings on the same membrane 
and reflect percentage change 
compared to control littermate 
normalised to βactin loading 
control). 
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Due to the amount of protein required, sufficient tissue could not obtained for analysis 
without sacrificing the mouse, making repeated measurements within one individual 
impossible in the present study.  Therefore to determine whether these observed changes 
have a direct correlation to pathological status, relative changes in protein levels have 
been compared in differentially affected tissues within 1 individual. Analysis of protein 
levels of βSNAP and VDAC1, revealed that the greatest magnitude of change was seen 
in the TVA muscle (175% up regulation VDAC1, 25% down regulation βSNAP 
compared to control; Figure 7.6).  Smaller changes in protein level were also observed in 
the less affected diaphragm (70% up regulation VDAC1, 5% down regulation βSNAP 
Figure 7.5: Consistent changes in βSNAP expression make it a potential  candidate 
biomarker.  A,B – Bar charts showing change in expression of βSNAP in the TVA 
muscle (A) and skin sample (B) in individual mice compared to control littermates at both 
P1 (black bars) and P5 (white bars).  Note that, although there is some variability in 
magnitude, especially in skin samples, the direction of change remains consistent. (mean 
± SEM; Data reflect 3 different scan intensity settings on the same membrane and reflect 
percentage change compared to control littermate normalised to βactin loading control). 
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compared to control) and skin samples (55% up regulation VDAC1, 0% change βSNAP 
compared to control).  This finding indicates that protein changes occurred in proportion 
to the pathological state of the tissue i.e. while changes were generally still observed in 
the diaphragm (a relatively spared muscle in SMA) and skin (a tissue thought to be 
unaffected in SMA), the magnitude was consistently smaller than the changes observed 
in the TVA.  The minimal changes observed in the diaphragm and skin are to be 
expected as this analysis was performed at P1. It would therefore be interesting to see if 
this same correlation remains at later time points.    
 
 
Figure 7.6: Changes in VDAC1 and βSNAP are proportional to the 
pathological status of the tissue. Bar chart showing change in expression of 
VDAC1 (black bars)  and βSNAP  (white bars) in the TVA muscle (which is a 
vulnerable muscle in Smn-/-;SMN2 mice), diaphragm (which is relatively spared) 
and skin (which is thought to be unaffected in SMA) from a single P1 Smn-/-
;SMN2 mouse. Note the change in magnitude is generally proportional to the 
pathology observed in the associated tissue.  (mean ± SEM; Data reflect 3 
different scan intensity settings on the same membrane and reflect percentage 
change compared to control littermate normalised to βactin loading control). 
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7.2.3 SmnWlds mice 
From the protein changes described above, it would appear that there may be 
mechanistic overlap in the pathways conferring synaptic protection on Wlds mice with 
those pathways regulating synaptic vulnerability in SMA.  In order to directly test 
whether there is any mechanistic overlap, I have attempted to cross Smn-/-;SMN2 mice 
with Wlds mice.  Previous studies attempting to cross Wlds mice with Smn-/-;SMN2;Δ7 
have concluded that there is no phenotypic benefit (Kariya et al., 2009; Rose et al., 
2009), but as they only bred the mice to be heterozygous for the Wlds mutation, Wlds 
proteins levels may have been insufficient for synaptic protection (Mack et al., 2001).  
The reason that they only reached heterozygosity is perhaps immediately apparent when 
the challenges of generating this cross are considered, namely the extensive crosses and 
problematic Wlds copy number genotyping (Appendix 10.5).  For this reason breeding 
pairs of appropriate genetic combination i.e. Smn+/-;SMN2+/+;Wlds+/- have only 
recently been obtained.  Litters to date have unfortunately not contained any Smn-/-
;SMN2+/+;Wlds+/+ mice, however data has been obtained from one Smn-/-;SMN2; 
Wlds +/- mouse (herein referred to as Smn-/-:Wlds+/-) and non-Wlds control littermate 
(herein referred to as Smn-/-;Wlds-/-) and compared them to an unaffected littermate 
(Smn+/+;Wlds+/+).  Due to licensing restrictions, mice must be culled when symptoms 
become severe, making it difficult to assess any change in life span.  However, 
assessment of body weight at P5 revealed a similar reduction in Smn-/-;Wlds+/- and 
Smn-/-;Wlds-/- mice compared to Smn+/+;Wlds+/+ littermate (body weight = 1.57g 
Smn-/-;Wlds-/- and Smn-/-;Wlds+/- vs 3.52g Smn+/+;Wlds+/+). Synaptic degeneration 
in TVA and LAL muscles was assessed by quantification of the number of fully 
occupied endplates. Consistent with previous reports, pathology was more advanced in 
the TVA and LAL caudal band compared to the LAL rostral band, although similar 
levels of pathology were observed in both Smn-/- mice compared to unaffected 
littermate (Figure 7.7), indicating that the presence of one copy of Wlds has no 
protective effect on synaptic pathology in SMA mice. Subsequent analysis on Smn-/-
;Wlds+/+ mice is clearly required. 
.                                                                                                                                            . 
 
 
.                                                                                                                                            . 
    L Murray  PhD Thesis 
155 
Figure 7.7: NMJ phenotype in SmnWlds mice.  A – confocal micrographs of 
immunocytochemically labeled TVA and LAL (rostral and caudal bands) muscle 
preparations (green = 150kDa neurofilaments; red = post-synaptic acetylcholine 
receptors labelled with TRITC-α-bungarotoxin) from P5 Smn+/+;Wlds+/+, Smn-/-
;Wlds-/- and Smn-/-;Wlds+/- mice. As expected, there is no evidence of 
denervated endplates in Smn+/+;Wlds+/+ muscles, while significant synaptic 
pathology is evident in Smn-/-;Wlds-/- muscles, as evidenced by unoccupied 
endplates (white arrowhead) and pre-terminal accumulation of neurofilaments 
(white arrow).  In Smn-/-;Wlds+/- mice, there was also evidence of denervated 
endplates and accumulation of neurofilaments. B – Bar charts (mean ± SEM) 
showing the percentage of fully occupied endplates in P5 Smn+/+;Wlds+/+ (black 
bars), Smn-/-;Wlds-/- (white bars) and Smn-/-;Wlds+/- (grey bars) mice in the TVA 
muscle, LAL rostral band and LAL caudal band.  Note that there was a similar 
decrease in the number of fully occupied endplates in Smn-/-;Wlds-/- mice 
compared to Smn-/-;Wlds+/- mice, indicating that the presence of one copy of the 
neuroprotective Wlds gene does not confer any protection to SMA related NMJ 
pathology. (N=2/1 muscles/mice per genotype; N numbers are insufficient for 
statistical analysis; scale bar = 30µm (A)) 
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7.3 Discussion 
The findings presented above provide preliminary analyses showing that Wlds can 
provide mechanistic insights into the pathogenic processes in SMA.  Firstly, of a small 
screen of candidate proteins, I have identified proteins which are changed in the opposite 
direction in SMA compared to Wlds thus providing the first evidence that there may be 
convergent mechanisms regulating synaptic vulnerability in SMA and Wlds. Secondly, I 
have demonstrated that such an approach could be used to identify potential biomarkers 
which may be used to assess pathological status.  Finally, I provide preliminary analysis 
of SmnWlds mice, which show that one copy of Wlds in Smn-/-;SMN2 mice confers no 
increase in body weight or synaptic protection.  
 
7.3.1 Proteomic screen to identify biomarkers of SMA 
The identification of relevant biomarkers for SMA would be of great benefit to the field.  
Current measures of pathological progression are based upon assessment of motor 
function, electrophysiological motor unit assessment, body composition measurement 
and quantification of Smn levels (Swoboda et al., 2009;).  Such measures are generally 
accepted to be inadequate, partly due to a lack of sensitivity and, in the former case, the 
questionable relationship between motor ability and disease progression (Swoboda et al., 
2005).   Recent studies have improved the ability to detect Smn levels in blood samples 
(Tiziano et al., 2009) however it has been suggested that Smn levels in blood do not 
correlate to disease severity (Sumner et al., 2006), making this approach only of clinical 
benefit when the therapeutic approach is to increase Smn levels. 
 
An ideal biomarker which can actively report on the status of the neuromuscular system 
should have a number of specific characteristics.  It should change in a predictable way 
with the progression of pathology, be highly sensitive (evident at early stages of the 
disease and be responsive to changes to disease progression) and be evident in clinically 
accessible material (Turner et al., 2009). The approach utilized here attempts to identify 
biomarkers by comparing affected tissues in models of neuroprotection and 
neurodegeneration, and expanding these results to clinically accessible tissue.  This 
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approach has a high probability of discovering useful biomarkers as it highlights 
proteins which have a high likelihood of reflecting subtle changes in the vulnerability 
status of the neuromuscular system. From a preliminary screen of only 8 proteins, one 
was identified which showed the desirable characteristics. Changes could be detected 
which were proportional to pathological status, apparent in clinical accessible tissue and 
present at small but noticeable levels at pre-symptomatic time points. The data presented 
here therefore provide great encouragement that this approach can yield useful 
biomarkers in the future.  Further work is now required to conduct wider proteomic 
screens on pathologically relevant tissue such as spinal cord, or comparison of 
unaffected and affected muscle regions, and ultimately assessing whether equivalent 
changes can also be observed in human tissue. 
 
7.3.2 Mechanistic insight to SMA from Wlds  
Investigation and comparison of Wlds mice and disease models can provide mechanistic 
insight into the processes regulating synaptic vulnerability. By using the approach 
described in this study, e.g. mouse crosses and search for common downstream proteins, 
we can begin to identify key pathways and events which regulate synaptic vulnerability 
in a range of conditions. A popular theory regarding neurodegenerative disease is that, 
although there are distinct pathogenic triggers, there is commonality in the mechanisms 
regulating neurodegeneration, and by extension, synaptic degeneration (Coleman, 2005; 
Wishart et al. 2006). The findings presented in this chapter are very much in agreement 
with this hypothesis, as alterations in proteins in SMA tissue were observed, which have 
previously been shown to be altered in an opposite direction in Wlds.  As equivalent 
changes have also been identified in mouse models of Batten disease (Kielar et al., 
2009), this work suggests that common mechanisms exist to regulate neuronal 
vulnerability.   Results from SmnWlds mice will also provide further insight into the 
potential mechanistic overlap between Wlds and SMA mice.  Significant protection 
might further support the theory that common mechanisms regulate a range of 
neurodegenerative conditions, while a lack of protection support the idea that distinct 
pathways control distinct types of synaptic degeneration (e.g. see chapter 6).  Regardless 
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of results, further work is required to begin to tease apart the mechanisms which regulate 
and perturb synaptic vulnerability in both neuroprotective and neurodegenerative 
models.   
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Chapter 8: General discussion 
 
8.1 Overview of results 
The work presented in this study has contributed significantly to our understanding of 
NMJ pathology and disease pathogenesis in SMA.  I have shown that NMJs are early 
and significant targets in mouse models of SMA.  Analysis of pre-synaptic and post-
synaptic parameters has revealed that pathology can occur independently in both tissues. 
In depth analysis of pre-synaptic pathology has revealed selectively vulnerable 
populations of motor units in both slow twitch muscles and in muscle regions 
conforming to a developmentally distinct FaSyn subtype.  Analysis of pre-symptomatic 
motor neuron connectivity and gene expression has shown that abnormal development 
of lower motor neuron connectivity is unlikely to underlie pathology in SMA.  Micro-
array analysis has implicated pathways involved in myelination, growth factor signalling 
and extracellular matrix integrity in SMA pathology.  I have also shown that 
morphologically distinct types of synaptic degeneration (dying-back neuropathy and 
Wallerian degeneration) can be mechanistically distinct.  Finally, I have shown that 
protein changes identified in the neuroprotective Wlds model can be used to give 
mechanistic insight into molecular processes occurring in SMA and can be used to 
identify biomarkers to assess pathological status in SMA. 
 
8.2 NMJ pathology in SMA – current thoughts 
Following on from the detailed description of NMJ pathology in mouse models of SMA 
presented here, a number of unrelated papers have subsequently been published focused 
on the same topic.  A study from Umrao Monani’s lab has used the Smn-/-;SMN2;Δ7 
mouse model and the more mild SmnA2G model to conduct a study on NMJ morphology, 
development and function during disease progression and provides some preliminary 
reports on NMJ morphology from SMA patients (Kariya et al., 2008).  Biondi and 
colleagues have conducted a study looking at NMJ morphology and post-synaptic 
development in response to exercise training in the SmnΔ7/Δ7;SMN2 model (see Table 
1.1; Biondi et al., 2008). Charlotte Sumner’s group has produced a rigorous study on the 
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electrophysiological properties on NMJs in differentially affected muscles in the Smn-/-
:SMN2;Δ7 model (Kong et al., 2009).  In this section I will discuss the implications of 
these recent advances in understanding of SMA related NMJ pathology.   
 
8.2.3 Structural changes at the NMJ  
A major question raised by recent publications, is what should we consider ‘core’ 
morphological features of NMJ pathology in SMA?  Results presented in this study have 
revealed significant denervation in both Smn-/-;SMN2 and Smn-/-;SMN2;Δ7 mouse 
models, albeit to a lesser degree in the latter model.  However, a study by Kariya et al. 
on the NMJ phenotype in the Smn-/-;SMN2;Δ7 model concluded that denervation does 
not occur at any time point (Kariya et al., 2008).  Intriguingly, they did observe a 30% 
reduction in axon number in ventral roots and in the phrenic nerve, although as they 
found no evidence of compensatory sprouting or change in poly-innervation it is 
somewhat paradoxical to suggest that denervation does not occur in this model, unless of 
course axonal degeneration occurs in a proximal to distal fashion. Regardless of this 
absurdity, the question of whether denervation is or is not a feature in this model has 
created a degree of controversy within the field.  This controversy is perhaps 
unnecessary as discrepancies in reported denervation in the Smn-/-;SMN2;Δ7 model 
range from 0% (Kariya et al., 2008), 5-10% (chapter 3) to 3-15% (Kong et al., 2009) 
and are further compounded by the exclusion or inclusion of partially occupied 
endplates.  Controversy in the field therefore appears based upon the experimenter’s 
definition of ‘significant’ rather than observed results. Importantly however, given the 
lack of severe denervation observed in this model, many groups have defined synaptic 
pathology as observed abnormalities such as thick, swollen nerve terminals, poor 
terminal arborisation and pre-synaptic accumulation of neurofilaments (Biondi et al., 
2008; Kariya et al., 2008).  The observation that such morphological defects are also 
present in the diaphragm of SMA patients has led one group to conclude that this mouse 
model is an accurate model of human SMA (Kariya et al., 2008), overlooking the fact 
that the diaphragm is a relatively spared muscle (Farrar et al., 2009).  While these 
changes may be of potential interest, if they do not represent defects observed in affected 
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muscle groups from human patients, attempts to remedy them may be of limited clinical 
benefit.  Furthermore, potential therapies based upon retrograde transport from muscle 
are likely to be far less effective in models/patients in which significant denervation has 
occurred.  The fact that such changes are present in pathologically spared muscle groups 
may suggest that they are not relevant to the pathological process. While the severe 
denervation observed in other mouse models of SMA may reflect the severe reduction in 
Smn levels (Cifuentes-diaz et al., 2002; chapter 3), further work will be important to 
determine whether or not they are of clinical relevance.  
 
The work to date on incidence and prevalence of structural NMJ abnormalities in models 
of SMA therefore underlines the need for structural NMJ studies in affected muscle 
groups from SMA patients.   It will be crucial to define whether severe NMJ breakdown 
and denervation is a pathological feature of SMA in humans as it will have a significant 
impact upon the development of therapeutic strategies.  Although obtaining such post-
mortem material can be a significant challenge, the development of tissue “biobanks” 
should greatly facilitate such studies.    
 
8.2.2 Functional changes at the NMJ 
Recent papers have also indicated that there are significant functional abnormalities at 
the NMJ in SMA mouse models.  Electrophysiological recordings from the mild SmnA2G 
model (see Table 1.1) have revealed an increase in transmission failures in response to 
repeated high frequency stimulation (Kariya et al., 2008).  This observation may be 
accounted for by a decrease in synaptic vesicle numbers in the active zone. Equivalent 
studies in the Smn-/-;SMN2;Δ7 model failed to identify transmission failures but did 
observe equivalent mis-localisation of synaptic vesicles, with a patchy distribution and 
density throughout the pre-synaptic terminal, and decreased numbers within the active 
zone (Kong et al., 2009).  Electrophysiological recording implied that quantal content 
was decreased and implied that this is accounted for by a decreased probability of 
vesicle release, as opposed to changes in post-synaptic response (Kong et al., 2009). 
These studies might go some way to explaining the severe muscle weakness in the 
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absence of widespread denervation. These findings are also consistent with observations 
in wasted mice, in which functional deficits occur prior to structural loss.  Together 
these results suggest that synaptic degeneration may occur subsequent to, or in 
conjunction with functional deficits, and further work into the basis of disruption of 
synaptic function may yield important information about the initiation of synaptic 
pathology. 
 
8.2.3 Abnormal development of the NMJ  – cause or effect? 
Although the results presented here strongly suggest that abnormal pre-symptomatic 
development is not required for pathogenesis in SMA, it remains possible that abnormal 
development contributes to disease progression.  For example, pathology could 
conceivably be caused by a mis-regulation of developmental synapse elimination 
pathways. Alternatively, a failure in normal developmental processes might destabilise 
the NMJ and although initial synaptic formations establish normally, the processes 
regulating synaptic maintenance and maturation are defective.  There are now a number 
of results which might indicate that developmental processes are not occurring normally.  
There appears to be a delay in the “plaque to pretzel” process of AChR clustering and 
endplate maturation. Biondi and colleagues suggested that this delay in maturation 
correlates with motor neuron pathology (Biondi et al., 2008) and that exercise can 
accelerate the development of the neuromuscular system in mice and be neuroprotective.  
There also appears to be a delay in the switch of acetyl choline receptor subunit, with an 
increase in the embryonic γ subunit with a corresponding decrease in the adult ε subunit 
(Kariya et al., 2008), and that this delay correlates with the pathology observed in 
differentially vulnerable muscles (Kong et al., 2009). It has been suggested that this 
delay in subunit switch accounts for the electophysiological anomalies observed, such as 
an increased decay time following an endplate potential  (Kong et al., 2009).  They 
further suggest that such change in transmission properties may cause the delay in AChR 
clustering and endplate maturation.  
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The fundamental problem with investigating development of the neuromuscular system 
during disease progression is the observation that NMJ development is tightly correlated 
with synaptic activity.  In a pathological neuron, synaptic activity is likely to be affected, 
and it is therefore difficult to conclude whether abnormal development results in 
abnormal activity and thus causes synaptic vulnerability, or whether abnormal activity 
inhibits normal development.  Developmental anomalies could therefore simply be a by-
product of the pathological processes occurring.  The fact that there is a clinical 
spectrum of SMA severity depending of Smn level, with degenerative and phenotypic 
onset in milder forms of SMA occurring subsequent to the normal developmental time 
window, might suggest that developmental processes do not contribute significantly to 
pathogenesis in all types of SMA. Separating these two events remains a great challenge 
for researchers however the recent creation of ‘TET-On’ SMA mice, in which the 
expression of Smn can be turned on and off by the administration or removal of 
tetracycline, might present a good opportunity (Le, Burghes, unpublished abstract, 
Families of Spinal Muscular Atrophy, 2009).  Should Smn be turned off in adulthood, 
and the same degenerative phenotype be observed, we might conclude that SMA is not 
caused by the mis-regulation of developmental pathways.  Future studies are thus likely 
to produce insightful results relating to the contribution of abnormal development to 
pathogenesis in SMA.  
 
8.3 Convergent mechanisms of synaptic degeneration in neurodegenerative 
disease? 
This results presented here are in agreement with the hypothesis that synaptic 
compartments of neurons are vulnerable to pathological insults.  We can therefore add 
SMA to the growing list of neurodegenerative disorders which appear to be 
‘synaptopathies’.  As the list of such diseases grows, the question of mechanistic 
commonality becomes increasingly important, as this will have significant impact upon 
the scope of any therapeutics which are developed.  An emerging point of view suggests 
that despite morphological discrepancies, synaptic vulnerability and pathology is 
regulated by common mechanisms (Coleman, 2005).  Although this idea was initially 
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built upon the ability of the Wlds mouse to protect against a range of insults, recent 
reports have added significant weight to this idea, with the identification of proteomic 
changes identified in Wlds mice occurring in an opposite direction in mouse models of 
NCL disorders (Keilar et al., 2009).  The work presented in chapter 7 expands upon 
these findings, showing equivalent changes are also apparent in mouse models of SMA.    
Together these results suggest that common proteomic changes can occur in opposite 
directions to regulate synaptic pathology or protection. These findings are in contrast to 
the results presented in chapter 6, which quite clearly demonstrated that two 
morphologically distinct types of synaptic degeneration were also mechanistically 
distinct, with loss of eEF1A2 causing a dying-back neuropathy but inhibiting Wallerian 
degeneration.  This finding might suggest that a range mechanistically distinct pathways 
can regulate synaptic degeneration.  These two possibilities are perhaps not mutually 
exclusive as it remains possible that independently initiated cascades will ultimately 
converge upon common downstream mechanisms.   
 
At this stage our knowledge of the mechanisms regulating synaptic vulnerability are 
somewhat limited.  Work in this area is going to be fundamental to address the question 
not only of mechanistic commonality, but also to develop neuro-protective strategies.  
Further work investigating the initiating mechanisms of synaptic vulnerability is 
therefore likely to be crucial. Although, due to it accessibility, the NMJ remains an 
excellent model to study synaptic vulnerability, its analysis is hampered by the fact that 
there is not currently a method to study gene expression or to carry out proteomic 
analysis in specific cellular and subcellular compartments at the NMJ.  In the central 
nervous system, the ability to produce synaptosomes, where the synaptic compartment 
of the cell can be isolated from the axon and cell body, allow analysis of synaptic 
responses.  Due to the structural stability of the NMJ, no efficient method has been 
developed to isolate the pre-synaptic terminal from the surrounding muscle, Schwann 
cell and axonal compartments. The ability to do this would likely prove highly powerful, 
as it would allow synaptic function to be directly correlated to morphology and give 
great insight into the mechanisms regulating synaptic function and initiating synaptic 
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breakdown.  Current attempts to isolate the cytoplasmic contents of axonal and synaptic 
compartments using a polymer based absorption technique may provide an effective 
alternative to the traditional synaptosome (Broom, Skipp, Perry, unpublished abstract, 
Molecular and Cellular Mechanisms of Axon Degeneration, 2008).  Alternative 
approaches to physically isolate the synaptic terminal without disrupting the synaptic 
expression profile face great challenges but would undoubtedly be of great value should 
efficient methodology be developed. 
  
8.4 Mechanisms regulating neuromuscular vulnerability in SMA? 
Work within this study and the broader SMA research field has clearly demonstrated the 
occurrence and severity of neuromuscular pathology in SMA.  Despite this, very little is 
known about the underlying mechanisms.  Results from this study suggest that the pre-
symptomatic development of lower motor neurons is normal, and all additional work on 
neuro-degenerative mechanisms generally suffers from an inability to separate causative 
mechanisms from neurodegenerative by-product. For example, the identification of 
widespread splicing defects was subsequently identified to be a late stage event in SMA 
pathology (Zhang et al., 2008; Baumer et al., under review).  Furthermore the 
identification of abnormal post-synaptic development cannot be separated from the 
requirement of synaptic function for development (Biondi et al., 2008, Kong et al., 
2009).  The function of Smn protein is equally undefined as it is not clear whether SMA 
is a result of a loss of general house keeping function of Smn that neurons are for some 
reason specifically more vulnerable to, or whether there are specific axon and/or 
synaptic roles for Smn protein.  We are therefore left with a clear and fundamental 
question: what are the mechanisms regulating neuromuscular pathology in SMA? 
 
8.4.1 Muscle development 
Although results here have indicated that lower motor neuron development is normal in 
SMA mouse models, rigorous studies on the development of muscle in SMA have yet to 
be performed.  Reports from culture models and patient biopsies have suggested that 
there may be intrinsic abnormalities in muscle development (see introduction section 
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1.4.4).  As neurons and muscle are mutually dependant upon each other survival, defects 
in muscle could conceivably result in defect in motor neuron survival.  Traditional 
approaches to investigate the contribution of muscle to SMA pathology rely upon 
conditional loss or gain of Smn expression in specific tissues (Frugier et al., 2000, 
Cifuentes-diaz et al., 2001; Gavrilina et al., 2008), however such approaches do not 
account for a requirement for Smn in multiple tissues.  It may therefore be of interest to 
conduct a detailed study of muscle developmental morphology in mouse models of 
SMA prior to symptom onset.  The LAL also presents a convenient opportunity to 
investigate muscle development, for example by conducting proteomic analysis on 
affected and unaffected muscle regions at pre-symptomatic time points.  This may reveal 
subtle changes in protein levels in muscle which can be correlated to and occur prior to 
lower motor neuron breakdown.  The creation of mouse models with inducible Smn 
transgenes will also help define the contribution of abnormal development, as if an 
equivalent degenerative time course is observed when Smn is turned off in adulthood, 
the contribution of development to SMA pathogenesis is likely to minimal.  Conversely, 
if Smn can be turned on post-natally and rescue the phenotype, we might conclude that 
abnormal development does not pre-dispose the nervous system to subsequent 
pathology.   
 
8.4.2  Contribution of glial cells? 
The role of glial cells in SMA pathology has been broadly overlooked over the past 
decades despite the fact such cells are fundamental to neuronal stability (Feng et al., 
2008).  A role for glial cells in ALS is now well documented (Boillee et al., 2006) 
although it is unknown to what degree both myelinating and terminal Schwann cells 
might contribute to axonal and synaptic pathology.  Intriguingly, the largest single 
change observed from the microarray analysis on end-stage SMA mice was in the 
myelin basic protein P0.  While this could reflect loss of myelinated axons, it could also 
be indicative of a disruption in the myelination of axons which would have a significant 
impact upon their function and stability.  In addition, there is currently no data reflecting 
the accumulation and function of terminal Schwann cells at the NMJ in SMA and hence 
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further work on the morphology of such cells may be illuminating.  Such studies might 
employ both the electron microscope and fluorescence imaging of both myelinating and 
terminal Schwann cells during the disease time course and could provide crucial details 
about the integrity of myelin and the localisation of terminal Schwann cells.  
 
8.4.3 Neurotrophic support 
It is well established that growth factors and neurotrophic factors are crucial for the 
establishment, development and maintenance of motor neurons.  They regulate 
interactions between glial cells, muscle and nerve to direct growth and patterning and 
provide ongoing trophic support to maintain neuromuscular connections (for review see 
English et al., 2003; Lu and Je, 2003).   Neurotrophic factors have been extensively 
implicated in pathology in ALS, by the identification of aberrant levels in patients and 
mouse models (Ekestern 2004), single nucleotide polymorphisms associated with a risk 
of developing ALS (Orrell et al.,  1995; Lambrechts et al., 2003), and the observation 
that viral or exogenous application of growth factors can be neuroprotective (e.g. Kaspar 
et al., 2003; Azzouz et al., 2004, Pun et al, 2006).   More recently, increased levels of 
glial cell-derived growth factor have been identified in the cerebro-spinal fluid of type I 
SMA patients (Chiaretti et al., 2009), however it is currently unclear whether these 
changes represent a causative feature or protective response by the induction of nerve 
sprouting.  Result from the micro-array screen also identified a number of genes 
implicated in growth factor binding and signalling that are mis-regulated in SMA.   
 
Generally, little is known about the specific local requirement for neurotrophic and 
growth factors i.e. are they required at the NMJ or at the cell body? Therefore, clinical 
trials applying growth factors to motor neuron disease patients has produced 
disappointing results.  However, the development of viral techniques which can be 
directed to exclusively muscle, or retrogradely transported presents some excellent 
opportunities to study the local requirement for growth factors (e.g. Kaspar et al., 2003).  
Furthermore, future experiments facilitating the ability to locally introduce viruses 
delivering fluorescent proteins and growth factors, would not only allow tracing of the 
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destination of such factors, but also allow direct correlation of growth factor expression 
and NMJ pathology. 
 
8.4.4 Axon transport? 
Efficient axon transport is fundamental in delivering organelles and proteins to the 
periphery, and for the retrograde transport of trophic regulators from the periphery to the 
cell body.  Deficiencies in such processes could conceivably cause significant deficits in 
energetic and/or functional requirements at the NMJ and put synaptic function under 
significant stress and there is now significant evidence that defects in axonal transport 
are present in motor neuron diseases.  
 
Neurofilaments are the most abundant cytoskeletal proteins in motor neurons and are 
responsible for maintaining axon calibre and the frame work for intracellular transport. 
The striking accumulation of neurofilament at the NMJ is becoming a hallmark of 
pathology in SMA (Cifuentes-diaz et al., 2002, Kariya et al., 2008; chapter 3) although 
equivalent accumulations have been observed in the cell body and proximal axons in 
ALS patients and models (Mizusawa et al., 1989; Gurney et al., 1994).  Mutations in a 
number of other transport associated machinery, such as the tubulin specific chaperone 
(Schmalbruch et al.,  1991; Bommel et al., 2002; Martin et al., 2002), or molecular 
motors kinesin or dyenin (Hafezparast et al., 1999; Münch et al., 2004; Puls et al., 2005; 
Teuling et al., 2008) have also been implicated in motor neuron pathology in mouse 
models and patients.   Axon transport deficits have been noted to be an early event in 
other models of motor neuron disease (Warrita et al., 1999; Williamson and Cleveland 
1999). 
 
Despite reports that β-actin transport to distal axonal compartments and growth cones is 
disrupted by reduction of Smn levels (Rossoll et al., 2003), additional investigations into 
the efficiency of axon transport in SMA models are currently lacking.    Further work 
should therefore be dedicated to the tracing of peripherally or centrally delivered 
markers in SMA models at pre-symptomatic time points.  Due to the phenotypic severity 
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of available models, this may be technically difficult, however work is currently 
underway to produce new SMA mouse models with a milder phenotype, which may 
greatly facilitate such studies. Culture systems could also be employed to allow real time 
imaging of the transport of sub cellular organelles, such as mitochondria, in response to 
a reduction in Smn levels.   
 
8.4.5 Smn and local protein translation 
The role of Smn in pre-mRNA splicing is well established, however it is unclear how 
this ubiquitous function could result in neuromuscular specific pathology.  One 
possibility is that Smn mediates axonal/synaptic specific protein translation and this 
function is crucial to maintain synaptic function and stability.  Indeed time lapse 
imaging of Smn localisation has implied that it is transported along axons (Zhang et al., 
2003).  Mutations in the DNA/RNA binding protein FUS have recently been linked with 
ALS (Chio et al., 2009; Kwiatkowski et al., 2009; Vance et al., 2009)  and this protein 
has been implicated in the transport of RNA along to axon to peripheral locations for 
local transcription (Fujii et al., 2005).  This hypothesis would therefore create a 
mechanistic link between ALS and SMA, based upon the requirement for local 
transcription at the NMJ. The inability to isolate the pre-synaptic compartments of motor 
neurons (see section 8.3) makes it difficult to define the extent to which local 
transcription at the NMJ occurs and is required for synaptic maintenance.  Future efforts 




The work described in this study details some of the first steps to understand NMJ 
pathology in SMA and has begun to address the mechanisms underlying neuromuscular 
pathogenesis. In Summary, I have shown that  
1. NMJs are early and significant targets in mouse models of SMA  
2. Pre-symptomatic developmental abnormalities do not underlie vulnerability.  
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3. Pathways involved in myelination, growth factor signalling and extracellular 
matrix integrity are mis-regulated in SMA. 
4. Wallerian degeneration and dying back neuropathy are mechanistically distinct.   
5. Protein changes identified in the neuroprotective Wlds model can be used to give 
mechanistic insights into the processes occurring in SMA and assist in 
identifying novel biomarkers. 
 
This study will hopefully aid future work aimed at defining the mechanisms which 
regulate and perturb synaptic vulnerability, and be of significant benefit for the 
development of clinically relevant therapeutic strategies for SMA.  
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10. Appendices 
Appendix 10.1 Validation of axon counting methods 
Quantifying axon numbers in intramuscular nerves presents a significant challenge in 
order to obtain reliable results.  I have therefore dedicated some effort to determining the 
most accurate system for measuring axons in whole mount nerve/muscle preparations.  
As it was clear that axon number could not be evaluated accurately by looking down the 
standard fluorescent microscope, efforts were dedicated to using confocal images.  The 
first consideration, therefore, was as what point on the intramuscular nerve to acquire the 
image.  Regions were chosen and carefully defined in order to standardise the number of 
endplates included and to minimise the incidence of axon branching (Figure 10.1.1).   
 
Figure 10.1.1: Position of  images 
used for axon quantification.  
Images taken to quantify axon 
number in the caudal band were 
taken  at least 200µm from the 
endplate band to minimise branching 
but not more than 500µm to 
standardise the number of endplates 
included by excluding small 
branches (red arrow) (red lines show 
limits of region used).  Images taken 
to quantify axons in the rostral band 
were taken in a region in which there 
were no small collateral branches 
(blue arrows) that was at least 
200µm from the main R3/R4 
endplate band (blue lines show limits 
of region used).  (Scale bar = 
500µm). 
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Initial attempts to quantify axon number focused on counting axons from raw confocal Z 
stacks.  As it became apparent that it was commonly difficult to identify individual axon 
profiles, raw images were subject to deconvolution analysis.  The process of 
deconvolution uses an algorithm based on the intrinsic noise introduced by the imaging 
system and attempts to reverse this noise and therefore increase the image clarity.  In 
order to determine the most accurate method of axon quantification, a random sample of 
8 axon bundle images were visualised and quantified in 3 different ways: visualisation in 
grey scale and scanned up and down through the z series; pseudo-colouring images by 
signal intensity and scanning up and down through z series; pseudo-colouring images by 
signal intensity and visualisation in cross section (Figure 10.1.2).   In order to determine 
the variability in counting methods, each image was quantified at three pre-defined 
points (top, middle and bottom) and each count was compared to the average of the three 
counts (Figure 10.1.3).  To prevent experimenter bias, each image was quantified at one 
point (i.e. top) and then re-blinded before repeat counts. Results imply that the least 
variability in axon quantification is seen when axons are counted in x-y sections in grey 
scale on deconvolved images (Figure 10.1.3 B).  It was clear deconvolution decreased 
the variability seen, and that in both raw and deconvolved images, the highest variability 
was seen when axons were counted in cross section.   
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Figure 10.1.2: Methods used to visualise axon bundles.  A,B - Single z 
slices of confocal images of intramuscular axon bundle labeled with 150KDa 
neurofilaments, which reflect raw images (left) or deconvolved images (left).  
Axon were visualised in grey scale (A) or   pseudocoloured by signal intensity 
(B).  C - cross sectional pseudocoloured slices through raw images (left) or 
deconvolved images (right) of axon bundles.  (Scale bar = 10µm).  
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Figure 10.1.3: Variability in different axon counting methods.  A - example confocal 
micrograph illustrating the three points at which axon number was quantified.  Axons were 
visualized using three different methods on both deconvolved and convolved images (see 
figure 10.1.2). B - Bar chart (Mean ± SEM)  showing the average percentage variability 
between the three individual measurements taken from each image for the three different 
counting methods (grey, pseudo, coronal) on both raw images and deconvolved images.  
Data acquired from 8 randomly selected axons bundles. Note the lowest levels of variability 
is seen by counting in the grey channel on deconvolved images. (Scale bar - 15µm (A)) 
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All experimental muscles were therefore quantified using the X-Y deconvolved images 
in gray scale.  When the variability observed was compared between caudal and rostral 
bands there was a general tendency for decreased variability in the caudal band in all 
genotypes investigated (Figure 10.1.4).  Additionally there was trend for increased 
variability in Smn-/-;SMN2 muscles compared to control muscles.  While this finding 
could simply reflect natural variability, it does raise the possibility that increased 
variability could reflect an increase in axon branching.  This therefore questions whether 
it is justified to use low variability as an indication of a reliable quantification technique.  
It is possible that systems producing high variability may reflect an increase in 
sensitivity in the technique, in which new axons branches are becoming visible. Should 
this be the case, I would expect a progressive change in the number of axons when 
comparing the 3 independent counts i.e. the ‘middle’ should rarely be the highest.  In 
contrast, comparison of the 3 individual counts revealed the ‘middle’ count was the 
highest in 10/21 cases (Figure 10.1.5).  This would strongly suggest that axon branching 
does not account for the variability seen and therefore justifies using low variability as 
an indicator of a reliable counting method making the chosen method an appropriate 
choice.  
 
Results imply that variability of approximately 15-25% can be reasonably expected 
when quantifying axons in intramuscular nerves.  While this is clearly not ideal, we must 
remember that in most cases this reflects discrepancy of approximately only 1-3 axons.  
The methodology chosen here should therefore defect any changes in axon distribution 
of over 1-3 axons but will not identify more subtle changes in axon number.   
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Figure 10.1.4: Average percentage variability between three individual axons counts. 
Bar chart (mean ± SEM) showing the average percentage variability (range between three 
individual counts on the same axon bundle, divided by the average of the three values and 
multiplied by 100%) supplying regions R3 and C2 in wildtype (black bars), heterozygote (grey 
bars) and Smn-/-;SMN2 (white bars) mice.  Note the general trend for less variabilty in region 
C2 which may be accounted for by increased axon branching in region R3. (N=4/5 per 
wildtype rostral/caudal band; N=7/5 per heterozygote rostral/caudal band; N=10/10 per knock-
out rostral/caudal band.) 
 
Figure 10.1.5: Axon branching does not account for the variability seen in axon counts. 
Scatter plot showing the value for each of the three counts on  21 axon bundles counted.  The 
‘middle’ count (see figure 3) is shown in pink.  Note the middle value is the highest 10/21 times 
indicating axon branching does not account for the variability seen and we are therefore 
justified in using minimal variability as a reliable measure of a good counting technique.  
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Appendix 10.2 Maintenance of wasted mice on a heat-mat mildly ameliorates 
neuromuscular pathology and abolishes protection from Wallerian degeneration. 
10.2.1 Maintenance on a heat-mat can ameliorate pathology in wasted mice.  
During the course of these experiments, it was observed that maintaining particularly 
sick mice on a heat mat appeared to mildly ameliorate symptoms and increase expected 
life span by up to 12 hours.   For this reason, a number of litters from the wasted colony 
were maintained on a heat-mat from the point of weaning.   To investigate whether the 
heat-mat had any affect on NMJ pathology, endplate occupancy was compared in mice 
maintained on a heat-mat (wasted HM) to those maintained at normal room temperature 
(wasted).  In the LAL muscle, significant denervation was evident in muscles from both 
groups, however there was a significant increase in the number of fully occupied 
endplates in wastedHM mice (Figure 10.2).  A similar trend was evident in the TVA 
muscle although this did not reach statistical significance (Figure 10.2 B).   I also 
observed a significant increase in the body weight in wastedHM mice (Figure 10.2 C). 
 
It is currently unclear whether this apparent protection from wasted pathology is due to 
an increase in temperature or an increase in physical activity.  Maintaining mice on a 
heat mat increases their physical activity and conversely physical activity tends to 
increase body temperature.  It is therefore experimentally very difficult to separate these 
two processes to determine whether it is the warmth or activity which exerts the 
neuroprotective affect, delaying the progression of dying-back pathology.   Nonetheless, 
this finding perhaps warrants further study as if heat and/or exercise can be of 
therapeutic value, both would be relatively simply to apply and therefore be of potential 
clinical interest.  
 
10.2.2 Maintenance on a heat-mat reduces protection from Wallerian degeneration seen 
in wasted mice. 
The mice which were maintained on a heat-mat also underwent a tibial nerve cut and the 
NMJ phenotype was analysed 24 hours later.  Interestingly, in stark contrast to the 
significant protection observed in wasted mice with around 90% of endplates remaining 
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innervated, only around 15% of NMJs remained in wastedHM mice (Figure 10.2 D). 
This result suggests that maintaining mice on a heat-mat dramatically reduces the 
protection of Wallerian degeneration observed in wasted mice.  
 
As discussed above, it is unclear whether this is a result of increased activity or an 
increase in temperature. However, as all wasted  mice are maintained on a heat mat post 
operatively, this finding suggests that it is not due to altered temperature or activity 
during the course of Wallerian degeneration, and rather due to an intrinsic alteration in 
the neuromuscular system occurring prior to the nerve axotomy.  These findings may be 
in line with the suggestion that the protection from Wallerian degeneration seen in 
wasted mice is due to a delay in the maturation of the neuromuscular system and 
retention of a immature phenotype in which distal extremities are protected while 
proximal nerve stumps are subject to degeneration.  An increase in activity due to the 
heat-mat may accelerate neuromuscular development and therefore result in the normal 
adult progression of Wallerian degeneration.  Alternatively,  it is also possible that the 
heat-mat can in some way, either by direct temperature affect or via physical activity, 
increase or prolong the expression of other eEF1A isoforms which can then compensate 
for the loss of eEF1A2.  This might explain the observed reduction in neuromuscular 
pathology and indicate a requirement for eEF1A isoforms for the normal initiation and 
progression of Wallerian degeneration.  This phenomenon clearly required further 
investigation but may give important insight into the mechanisms of both wasted 
pathology and neuromuscular degeneration.   
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Figure 10.2: Mice maintained on a heat-mat show modest amelioration from NMJ 
pathology and reduced protection from Wallerian Degeneration.  A,B - Bar chart showing 
the percentage of fully occupied endplates the LAL (A) and TVA (B) muscles of  P25 wild-type 
mice, wasted mice (Wst) and wasted mice maintained on a heat mat from weaning (WstHM). 
C - Bar chart (mean ± SEM) showing body weight of wasted mice compared to wasted mice 
maintained on a heat mat from weaning (Wst HM). D - Bar chart (mean ± SEM) showing  the 
percentage of fully innervated endplates in lumbrical muscles 24 hours post nerve cut from 
Wasted mice compared to wasted mice maintained on a heatmat from weaning.  Note 
protections from denervation seen in wasted mice is significantly reduced in those time 
maintained on a  heatmat. (mean ± SEM; Mann Whitney U test (A,B,D) or Students T test (C); 
ns – non significant, *P<0.05, **P<0.01, ***P<0.001); A-C: N=6 mice/12 muscles wasted, 4 
mice/8 muscles wasted HM.  D: N=6 mice/12 muscles wasted, 3 mice/8 muscles wasted HM). 
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Appendix 10.3 Delay in Wallerian degeneration in heterozygous wasted;YFP-H 
mice. 
In order to maximise N number for this study, tibial nerve cuts were performed on 
wasted;YFP-H mice alongside mice from non-fluorescent wasted strains.   However 
during this study there was an increase in the number of fully occupied endplates after 
axotomy in heterozygous mice from the YFP-H background (Figure 10.3).  This finding 
is somewhat preliminary, and unfortunately was not corroborated by including wild-type 
YFP-H mice.  However this finding does indicate that mice on a YFP-H background 
display a delay in Wallerian degeneration.  While these mice were excluded from results 
for the current study they do raise important considerations for the study of the 
neuromuscular system.  
 
It is not clear whether this result is due to an alteration in genetic background or as a 
direct consequence of the YFP present in motor neurons. Should the effect be due to the 
presence of YFP, this would have rather major consequences for research, as ‘inert’ 
fluorescent markers are commonly used to visualise many different cell types and 
structures, including motor neurons.  It is therefore important to determine whether YFP 
can have an affect on normal neuronal homeostasis and/or degenerative pathways.  
These experiments are on going in the Gillingwater lab and could potentially yield 
important results for a wide range of research fields.  
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Figure 10.3:  A delay  in Wallerian degeneration was observed in wasted 
heterozygote mice crossed with YFP-H.  A,B - confocal micrographs from 
immunocytochemcally labelled lumbrical muscles from heterozygote wasted and 
wasted;YFP-H mice (Green = 150KDa Neurofilaments; Red = post-synaptic acetylcholine 
receptors). C – Bar chart (mean ± SEM) showing the percentage of fully occupied 
endaplates in wild-type, wasted heterozygote and wasted homozygote lumbrical muscles 
from both non-YFP strains and YFP-H strains.  Note an increase in the percentage of fully 
occupied endplates in heterozygous wasted;YFP-H mice compared to non YFP-H 
heterozygous wasted mice.  (Kruskal Wallis with Dunn’s multiple comparison test; ** 
P<0.01;  N=32/33/14 muscles WT/Het/wasted non YFP-H, N=0/9/15 WT/Het/wasted YFP-
H). 
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Appendix 10.4 Background fluorescence intensity measurement methodology in 
quantitative western blotting. 
In this study, I have used quantitative fluorescent blotting to measure protein levels as it 
is thought to give greater sensitivity than densitometry analysis on conventional western 
blots.  This system employs secondary antibodies labelled with infra-red dyes which can 
be detected using an infrared imaging system (Oddysey ®).  Laser levels can be altered 
to optimum conditions to detect faint bands while avoiding saturation of  strong bands. 
Oddysey imaging software can be used to visualise bands and by subtracting 
background fluorescence levels from fluorescence intensity of the band, it gives a 
measure of relative protein levels in neighbouring bands.  This system offers many 
advantages over traditional western blotting with densitometric analysis, including 
greater sensitivity and a wider dynamic range.    
 
Within this system, several different methods are available to calculate background 
intensity levels.  To define the area for background measurement either a ‘lane’ (which 
measures the signal intensity within the lane of the band) or a box (which measures the 
signal intensity under the box outline) can be used.  For the latter method, the 
background levels can reflect either the whole outline,  left and right or the top and 
bottom of the box, and can reflect either mean or median values. As this measurement 
will clearly have a great impact upon results, I felt it was important to determine whether 
the method of background measurement had any bearing on the reliability of results. I 
therefore measured the signal intensity on a number of blots using a variety of methods 
to calculate background: lane, box with mean intensity value, box with median from all 
4 sides or box with median from just the left and right sides. To give an indication of 
how much variability is introduced by use of a different background measurement 
method, the following formula was applied: 
 
% variability =  [(iB1L1/iB2L1) – ((iB1L1/iB2L1 + iB1L2/iB2L2 + iB1L3/iB2L3)/3)]*100% 
 
where i = fluorescence intensity; B = band (1 or 2); L = laser level settings (1, 2 or 3).  
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By making resultant values positive, the percentage that each measurement deviates from 
the average of three measurements at different laser settings can eb determined and thus 
measure the variability introduced by the quantification methodology   
 
The above analysis was applied to western blot membranes labelled for COX1, which give 
a strong signal with a high signal to noise ration.  This revealed that there was very little 
variability between different scan settings and the method of background quantification has 
little bearing upon the result (Figure 10.4 A).  I next applied this analysis to a membrane 
labelled for VDAC1, an antibody which gives a distinct, but none the less faint band, with a 
low signal to noise ratio.  In this event, method of background quantification had a 
significant impact upon the observed variability, with the lane method producing the 
highest degree of variability between laser settings, of up to 15% (Figure 10.4 B).  
Measuring background using mean background levels, as oppose to median values 
marginally decreased the variability. Due to the sensitivity of the system, some antibodies, 
such as β-Actin, label a variety of non-specific products thus producing a laddering type 
effect.  Quantification of blots labelled with β-Actin again indicated that background 
quantification method has a significant bearing on the reliability of results, with the method 
using the box outline to measure the mean signal intensity  producing significantly less 
variability than the other three methods (Figure 10.4 C). 
 
From this analysis, I conclude that the method used to quantify background fluorescence 
levels has little affect on result reliability when measuring a strong band with a high signal 
to noise ratio but can have significant effects when measuring blots with a low signal to 
noise ratio or multiple bands.  The consistently most reliable method of background 
measurement was using the box outline to measure the mean signal intensity and I have 
therefore employed this method for the western blot quantification for thus study. 
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Figure 10.4 – Variability in signal intensity levels by different measuring methods. A – 
Example image from a COX1 antibody showing a high signal to noise ratio (left).  Scatter plot 
showing that quantification of these bands at different scan settings by use of any of the 4 methods 
available to calculate background intensity (lane, average box outline, the median of all sides or 
median of left and right sides) gives relatively similar variability. B,C quantification of bands from 
blots which have either a low signal to noise ratio (B left) or multiple bands present (C left) reveals 
different methods of background calculation produce significantly different levels of variability (B,C 
right).  Use of the average box outline to calculate background gives consistently lower variability. 
(Data for scatterplots acquired by subtracting the average percentage difference in band intensity 
between 2  bands across 3 different scan intensity settings, from the percentage change seen at a 
single scan intensity setting. Data was obtained from 3 different scan settings from 2(A), 3(B) or 
4(C) separate blots.  
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Appendix 10.5 SmnWlds breeding strategy and genotyping 
Although relatively simple in concept, obtaining homozygous SmnWlds (Smn-/-
;SMN2;Wlds+/+) mice, along with relevant littermate controls, has become a significant 
challenge.   The breeding strategy firstly involved a cross between a Smn+/-;SMN2 
mouse and a homozygous Wlds mouse (Wlds+/+; Figure 10.5.1).  Interbreeding 
offspring from this initial cross which were which were heterozygous for Smn (Smn+/-
;SMN2+/-;Wlds+/-) could then potentially produce 27 genetic combinations (Figure 
10.5.1, stage 2).  Smn heterozygotes could be readily identified by conventional PCR 
protocols.  Conventional PCR could also be used to identify mice carrying the SMN2 
transgene and as the insertion site of the SMN2 transgene had not yet been mapped, 
quantitative real-time PCR was required to determine SMN2 copy number to distinguish 
between SMN2+/- and SMN2+/+ mice (Figure 10.5.2; protocol courtesy of Nick 
Parkinson).  At this point, the preferable breeding strategy would have been to interbreed 
Smn+/-;SMN2+/+;Wlds+/- mice to produce litters which contain both Smn-/-
;SMN2+/+;Wlds+/+ mice along with Smn-/-;SMN2+/+;Wlds-/- littermate controls.  
Unfortunately at this point, problematic Wlds genotyping made it difficult to accurately 
distinguish between genotypes, making heterozygotes particularly difficult to identify 
(Figure 10.5.3 A).  This protocol relies on simultaneous amplification of the NMNAT 
portion of the Wlds gene and tubulin in a single well with different fluorophores 
indicating relative levels of NMNAT compared to endogenous tubulin control (Wishart 
et al., 2007b).  Although amplification was successful, and all controls generally 
grouped by cycle number, a slight overlap at the boundaries of each genotype meant I 
could not confidently genotype animals of unknown Wlds status.  After many 
unsuccessful attempts at protocol optimisation, I decided to back cross mice which 
consistently had a high cycle number difference, and were therefore likely to be Wlds 
homozygotes, with Smn-/-;SMN2 mice.  All resultant mice should therefore be Wlds 
heterozygotes.  This step had the added benefit of increasing genetic similarity to the 
original Smn-/-;SMN2 strain thereby minimising effects of genetic modifiers. 
Concurrently with this, new attempts were made to genotype for Wlds copy number by 
using real-time PCR protocol used for SMN2 genotyping (Figure 10.5.3 B). This method 
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uses amplification of Wlds and endogenous control uses the same fluorophore in 
separate wells and has thus far given much better separation between genotypes, 
allowing identification of Wlds homozygote, heterozygote and wild-type mice.  
Unfortunately, due to the time consuming nature of these problems, appropriate genetic 
mice have only very recently become available and I are therefore at the very early 
stages of phenotypic analysis.   
 
Figure 10.5.1: Breeding strategy to produce experimental SmnWlds mice.  To obtain Smn-/-
;SMN2;Wlds mice, the above breeding plan was employed.  Number in blue denote the number of 
additional undesirable  genetic combinations produced at each breeding stage. Due to problems with Wlds 
genotyping, resulting in homozygous mice being easiest to identify, stage 3 was employed to ensure the 
production of Wlds heterozygous mice until genotyping issues could be resolved. 
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Figure 10.5.2: Conventional and quantitative methods of PCR genotyping 
for SMN2.  A – Conventional PCR and gel electrophoresis allowed 
identification of mice which carried the SMN2 transgene by presence of 
absence of a product at 530bp however this method does not distinguish 
between 1 or 2 copies of the transgene.  B – Box and whisker plot showing the 
expected cycle number differences produced from analysis of real-time 
quantitative PCR curves.  Note SMN2 homozygotes and hetoerozygotes can be 
easily distinguished. 
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Figure 10.4.3: Real-time quantitative PCR results for assessing Wlds copy 
number.  A - Box and whisker plot showing the difference in cycle number 
produced when using the original real-time PCR protocol.  Note that although, in 
general, genotypes separate by difference cycle number, there is modest overlap at 
the boundary between genotypes. This makes it difficult to definitively genotype 
animals of unknown genotype. B - Box and whisker plot showing the difference in 
cycle number produced when using the modified real-time PCR protocol, with 
different primer sets in different wells. Note genotypes group by cycle number with 
significant separation between each genotype. 
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Appendix 10.6 Publications  
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10.6.2 Conference abstracts 
Edinburgh neuroscience day  - 2007 - Poster 
“Synaptic Pathology in Childhood Motor Neuron Disease (Spinal Muscular Atrophy).” 
 
Anatomical Society of Great Britain and Northern Ireland, 2007, Durham - Poster 
“Synaptic Pathology in Childhood Motor Neuron Disease (Spinal Muscular Atrophy).” 
 
Society for Neuroscience, 2007, San Diego - Poster 
“Synaptic Pathology at the Neuromuscular Junction in Childhood Motor Neuron Disease.” 
 
UK SMA, 2007, Oxford - Poster 
“Synaptic Pathology at the Neuromuscular Junction in a Mouse Model of Childhood Motor 
Neuron Disease.” 
 
Edinburgh Neuroscience Day, 2008 - Poster 
“Synaptic pathology at the neuromuscular junction in childhood motor neuron disease (Spinal 
Muscular Atrophy; SMA)” 
 
Anatomical Society of Great Britain and Northern Ireland, 2008, Nottingham - Poster 
“Loss of translation elongation factor eEF1A2 differentially affects pathways responsible for 
dying-back neuropathy and Wallerian degeneration in vivo.” 
 
UK SMA, 2008, Sheffield – Poster and Talk 
“Loss of translation elongation factor eEF1A2 differentially affects pathways responsible for 
dying-back neuropathy and Wallerian degeneration in vivo.” 
 
Anatomical Society of Great Britain and Northern Ireland, 2009, Oxford - Talk  
“Synaptic Vulnerability in Spinal Muscular Atrophy.” 
 
Families of Spinal Muscular Atrophy, 2009, Cincinnati – Poster and Talk 
“Does abnormal neuromuscular development underlie selective vulnerability of motor units in 
mouse models of Spinal Muscular Atrophy?”  
